Clinical trial NCT02289898
Conditions: Pancreatic Cancer
Keywords: 1st-line metastatic pancreatic ductal adenocarcinoma
Sponsor: OncoMed Pharmaceuticals, Inc.
Start date: 2015-04-20; Completion date: 2017-09-01
Enrollment: 207 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma.

The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Detailed description:

Arms: arm 1: Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression arm 2: Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression arm 3: Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
Interventions: intervention 1: Demcizumab intervention 2: Abraxane® intervention 3: gemcitabine intervention 4: Placebo
Intervention descriptions: intervention 1: administered intravenously intervention 2: administered intravenously intervention 3: administered intravenously intervention 4: None

Protocol documents:
SAP_000.pdf: 









2QFR0HG3KDUPDFHXWLFDOV,QF

0

$$UP3KDVH'RXEOH%OLQG5DQGRPL]HG6WXG\RI*HPFLWDELQH
$EUD[DQH3OXV3ODFHERYHUVXV*HPFLWDELQH$EUD[DQHSOXVRU
7UXQFDWHG&RXUVHVRI'HPFL]XPDELQ6XEMHFWVZLWKVW/LQH0HWDVWDWLF
3DQFUHDWLF'XFWDO$GHQRFDUFLQRPD

0$5

6WDWLVWLFDO$QDO\VLV3ODQ

9HUVLRQ

3UHSDUHGE\

33'





&RQILGHQWLDO
,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5

7$%/(2)&217(176
7$%/(2)&217(176,, 
/,672)$%%5(9,$7,216,9 
 
,1752'8&7,21 
 
75($70(176 
 
2%-(&7,9(6 
 
,19(67,*$7,21$/3/$1 
 
29(5$//678'<'(6,*1$1'3/$1 
 
678'<(1'32,176 
 
75($70(1702',),&$7,216 
 
*(1(5$/67$7,67,&$/&216,'(5$7,216 
 
6$03/(6,=( 
 
5$1'20,=$7,21675$7,),&$7,21$1'%/,1',1* 
 
68%-(&73238/$7,216)25$1$/<6,6 
 
68%-(&7',6326,7,21 
 
',6326,7,21 
 
35272&2/'(9,$7,216 
 
'(02*5$3+,&6$1'0(',&$/+,6725< 
 
'(02*5$3+,&6$1'%$6(/,1(&+$5$&7(5,67,&6 
 
0(',&$/+,6725< 
 
*HQHUDO0HGLFDO+LVWRU\ 
 
&DQFHU'LDJQRVLV+LVWRU\ 
 
3ULRUDQGGXULQJ)ROORZXS3HULRG&DQFHU7UHDWPHQWVDQG7KHUDSLHV 
 
,1&/86,21$1'(;&/86,21&5,7(5,$ 
 
75($70(176$1'0(',&$7,216 
 
35,25$1'&21&20,7$170(',&$7,216 
 
678'<75($70(176 
 
([WHQWRI([SRVXUH 
 
()),&$&<$1$/<6,6 
 
35,0$5<()),&$&<(1'32,17 
 
%(6729(5$//5(63216(%25 
 
&217,182869$5,$%/($66(660(172)78025/(1*7+ 
 
'85$7,212)5(63216( 
 
29(5$//6859,9$/ 
 
78025$66(660(17 
 
(;3/25$725<(1'32,176 
 
))3(7,668(6$03/($1'780250$5.(5&$ 
 
6(16,7,9,7<$1$/<6,6 



,,
,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5

 
6$)(7<$1$/<6,6 
 
$'9(56((9(176 
 
'HDWK 
 
&/,1,&$//$%25$725<(9$/8$7,216 
 
9,7$/6,*160($685(0(176 
 
(&2* 
 
3+<6,&$/(;$0,1$7,21 
 
(/(&752&$5',2*5$0(&* 
 
&2/2126&23<$1'833(5*$6752,17(67,1$/(1'26&23< 
 
+($'&705,6&$1 
 
6(58035(*1$1&<7(67 
 
3+$50$&2.,1(7,&6 
 
,00812*(1,&,7< 
 
'$7$6$)(7<021,725,1*%2$5'5(9,(: 
 
,17(5,0$1$/<6,6 
 
5()(5(1&(6 
 
$33(1',&(6 
$33(1',;$/,67,1*62)7$%/(6/,67,1*6$1'),*85(6 
/,67,1*2)7$%/(6 
/,67,1*2)/,67,1*6 
/,67,1*2)),*85(6 
$33(1',;%,0387$7,21$/*25,7+0)253$57,$/250,66,1*'$7(6 
$33(1',;&'(7$,/62)&$/&8/$7,216,17$%/( 

/,672)7$%/(6
7$%/( 
&(1625,1*&219(17,216)253)6 
7$%/( 
&(1625,1*&219(17,216)25'25 
7$%/( 
&(1625,1*&219(17,216)2526 
7$%/( 
6800$5<2)32:(5$1'7<3((5525)253+$6(678'< 
7$%/( 
6800$5<2)32:(5$1'7<3((5525)253+$6($1'
(;7(1'('3+$6(678',(6 




,,,
,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5

/,672)$%%5(9,$7,216
$EEUHYLDWLRQRU
7HUP
'HILQLWLRQ([SODQDWLRQ
$&(
$QJLRWHQVLQ&RQYHUWLQJ(Q]\PH
$(
$GYHUVH(YHQW
$/76*37
$ODQLQH$PLQRWUDQVIHUDVH6HUXP*OXWDPLF3\UXYLF7UDQVDPLQDVH
D377
$FWLYDWHG3DUWLDO7KURPERSODVWLQ7LPH
$676*27
$VSDUWDWH$PLQRWUDQVIHUDVH6HUXP*OXWDPLF2[DORDFHWLF7UDQVDPLQDVH
%13
%W\SH1DWULXUHWLF3HSWLGH
%25
%HVW2YHUDOO5HVSRQVH
%3
%ORRG3UHVVXUH
%81
%ORRG8UHD1LWURJHQ
&%&
&RPSOHWH%ORRG&RXQW
&%5
&OLQLFDO%HQHILW5DWH
&5
&RPSOHWH5HVSRQVH
&5)
&DVH5HSRUW)RUP
&7
&RPSXWHG7RPRJUDSK\6FDQ
&7&$(
&RPPRQ7R[LFLW\&ULWHULDIRU$GYHUVH(YHQWV1DWLRQDO&DQFHU,QVWLWXWH
'25
'XUDWLRQRI5HVSRQVH
'60%
'DWD6DIHW\0RQLWRULQJ%RDUG
(&*
(OHFWURFDUGLRJUDP
(&2*
(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS
,15
,QWHUQDWLRQDO1RUPDOL]HG5DWLR
,5)
,QGHSHQGHQW5HYLHZ)DFLOLW\
,77
,QWHQW7R7UHDW3RSXODWLRQ
,9
,QWUDYHQRXV
,:56,956
,QWHUDFWLYH:HE5DQGRPL]DWLRQ6\VWHP,QWHUDFWLYH9RLFH5DQGRPL]DWLRQ6\VWHP
NJ
.LORJUDP6
/'+
/DFWLF'HK\GURJHQDVH
/9()
/HIW9HQWULFXODU(MHFWLRQ)UDFWLRQ
0HG'5$
0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
PJ
0LOOLJUDPV
P/
0LOOLOLWHUV
05,
0DJQHWLF5HVRQDQFH,PDJLQJ
1&,
1DWLRQDO&DQFHU,QVWLWXWH
1(
1RW(YDOXDEOH
26
2YHUDOO6XUYLYDO



,9
,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5

$EEUHYLDWLRQRU
7HUP
'HILQLWLRQ([SODQDWLRQ
3'
3URJUHVVLYH'LVHDVH2U3KDUPDFRG\QDPLF
3)6
3URJUHVVLRQIUHH6XUYLYDO
3.
3KDUPDFRNLQHWLF
33
3HU3URWRFROSRSXODWLRQ
35
3DUWLDO5HVSRQVH
37
3UHIHUUHG7HUP
5(&,67
5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG7XPRUV
55
5HVSRQVH5DWH
6$(
6HULRXV$GYHUVH(YHQW
6'
6WDEOH'LVHDVHRU6WDQGDUG'HYLDWLRQ
6/'
6XPRIWKH/RQJHVW'LDPHWHUV
62&
6\VWHP2UJDQ&ODVV
8/1
8SSHU/LPLWRI1RUPDO



9
,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
 ,QWURGXFWLRQ
7KLVLVDDUPSKDVHGRXEOHEOLQGUDQGRPL]HGVWXG\RI*HPFLWDELQH$EUD[DQH3OXV3ODFHER
YHUVXV*HPFLWDELQH$EUD[DQHSOXVRU7UXQFDWHG&RXUVHVRI'HPFL]XPDELQ6XEMHFWVZLWK
VW/LQH0HWDVWDWLF3DQFUHDWLF'XFWDO$GHQRFDUFLQRPD7KHFXUUHQWVWXG\LVEHLQJFRQGXFWHG
XQGHUWKHVSRQVRUVKLSRI2QFR0HG3KDUPDFHXWLFDOV,QF7KLVGRFXPHQWGHVFULEHVWKHSODQQHG
VWDWLVWLFDODQDO\VHVZKLFKLVEDVHGRQ3URWRFRO0DPHQGPHQW(IIHFWLYH'DWH
0DUFK
 7UHDWPHQWV
7KHUHDUHWKUHHDUPVLQWKLVVWXG\DQGWKH\DUHGHILQHGDVIROORZLQJ
$UP3ODFHER3ODFHER$EUD[DQHDQGJHPFLWDELQHSOXVSODFHERF\FOHV$EUD[DQHDQG
JHPFLWDELQHF\FOHV$EUD[DQHDQGJHPFLWDELQHSOXVSODFHERF\FOHVDQGWKHQ$EUD[DQHDQG
JHPFLWDELQHXQWLOGLVHDVHSURJUHVVLRQ
$UP'HPFL]XPDE3ODFHER$EUD[DQHDQGJHPFLWDELQHSOXVGHPFL]XPDEF\FOHV
$EUD[DQHDQGJHPFLWDELQHF\FOHV$EUD[DQHDQGJHPFLWDELQHSOXVSODFHERF\FOHVDQG
WKHQ$EUD[DQHDQGJHPFLWDELQHXQWLOGLVHDVHSURJUHVVLRQ
$UP'HPFL]XPDE'HFL]XPDE$EUD[DQHDQGJHPFLWDELQHSOXVGHPFL]XPDEF\FOHV
$EUD[DQHDQGJHPFLWDELQHF\FOHV$EUD[DQHDQGJHPFLWDELQHSOXVGHPFL]XPDEF\FOHV
DQGWKHQ$EUD[DQHDQGJHPFLWDELQHXQWLOGLVHDVHSURJUHVVLRQ
 2EMHFWLYHV
3ULPDU\2EMHFWLYH
 7RFRPSDUHWKHHIILFDF\RI$UPWRWKHSRROHGGHFL]XPDEDUPVLH$UPWR$UPV
DQGLQVXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
6HFRQGDU\2EMHFWLYHV
 7RFRPSDUHWKHHIILFDF\RI$UPWR$UPDQG$UPWR$UPLQVXEMHFWVZLWKVWOLQH
PHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
 7RFRPSDUHWKHVDIHW\RI$UPWR$UP$UPWRDQG$UPWR$UPVDQGSRROHG
LQVXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
 7RGHWHUPLQHWKHUDWHRILPPXQRJHQLFLW\DJDLQVWGHPFL]XPDEZKHQFRPELQHGZLWK
$EUD[DQHDQGJHPFLWDELQHLQVXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDO
DGHQRFDUFLQRPD




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
 7RGHWHUPLQHSRSXODWLRQSKDUPDFRNLQHWLFVRIGHPFL]XPDELQVXEMHFWVUHFHLYLQJ
GHPFL]XPDEDQG$EUD[DQHDQGJHPFLWDELQHLQVXEMHFWVZLWKVWOLQHPHWDVWDWLF
SDQFUHDWLFGXFWDODGHQRFDUFLQRPD
([SORUDWRU\2EMHFWLYHV
 7RFRPSDUHWKHVDIHW\DQGHIILFDF\RI$UPWR$UPLQVXEMHFWVZLWKVWOLQHPHWDVWDWLF
SDQFUHDWLFGXFWDODGHQRFDUFLQRPD
 7RFRPSDUHWKHH[SORUDWRU\ELRPDUNHUVRI$UPWR$UP$UPWRDQG$UPWR
$UPVDQGSRROHGLQVXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDO
DGHQRFDUFLQRPD
 ,QYHVWLJDWLRQDO3ODQ
2YHUDOO6WXG\'HVLJQDQG3ODQ
7KLVLVDUDQGRPL]HGGRXEOHEOLQGDUPVWXG\LQVXEMHFWVZLWKVWOLQHPHWDVWDWLF
SDQFUHDWLFGXFWDODGHQRFDUFLQRPD3ULRUWRUDQGRPL]DWLRQVXEMHFWVZLOOXQGHUJRVFUHHQLQJWR
GHWHUPLQHVWXG\HOLJLELOLW\7ZRKXQGUHGDQGRQHHYDOXDEOHVXEMHFWVZLOOEHUDQGRPL]HGYLDDQ
,QWHUDFWLYHZHEUDQGRPL]DWLRQV\VWHP,QWHUDFWLYHYRLFHUDQGRPL]DWLRQV\VWHP,:56,956
V\VWHP
'HPFL]XPDEPJNJRUSODFHERZLOOEHDGPLQLVWHUHGE\LQWUDYHQRXV,9LQIXVLRQSULRUWR
WKHDGPLQLVWUDWLRQRI$EUD[DQHDQG*HPFLWDELQHRQFHHYHU\ZHHNVIRUHLWKHURQHVWFRXUVH
WKURXJK6WXG\'D\RUWZRQGFRXUVHEHJXQRQ6WXG\'D\DQGFRQWLQXHGWKURXJK6WXG\
'D\GD\FRXUVHV
$EUD[DQHPXVWEHDGPLQLVWHUHGDIWHUWKHGHPFL]XPDEEXWEHIRUHJHPFLWDELQHDGPLQLVWUDWLRQRQ
GD\VZKHQWKUHHGUXJVDUHJLYHQ$EUD[DQHVKRXOGEHDGPLQLVWHUHGE\,9LQIXVLRQDWDVWDUWLQJ
GRVHRIPJPRYHUPLQXWHVRQ'D\VDQGRIHYHU\GD\F\FOH7KHGRVHRI
$EUD[DQHPD\EHUHGXFHGRYHUWLPHLIQHFHVVDU\WRUHGXFHWR[LFLW\
*HPFLWDELQHPXVWEHDGPLQLVWHUHGDIWHUWKHDGPLQLVWUDWLRQRIGHPFL]XPDEDQG$EUD[DQH
*HPFLWDELQHVKRXOGEHDGPLQLVWHUHGE\,9LQIXVLRQDWDVWDUWLQJGRVHRIPJP
RYHU
PLQXWHVRQFHZHHNO\IRUZHHNVRUXQWLOWR[LFLW\QHFHVVLWDWHVUHGXFLQJRUKROGLQJDGRVH
IROORZHGE\DZHHNRIUHVWHYHU\GD\V7KHGRVHRIJHPFLWDELQHPD\EHUHGXFHGRYHUWLPHLI
QHFHVVDU\WRUHGXFHWR[LFLW\




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
6WXG\(QGSRLQWV
3ULPDU\(QGSRLQW
x 7RFRPSDUHWKHKD]DUGRISURJUHVVLRQXVLQJWKH,QYHVWLJDWRUDVVHVVHGSURJUHVVLRQIUHH
VXUYLYDOWLPHEHWZHHQVXEMHFWVLQ$UPDQGWKHSRROHGGHPFL]XPDEDUPV
LH$UPVLQVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
6HFRQGDU\(QGSRLQWV
x 7RFRPSDUHWKHKD]DUGRISURJUHVVLRQXVLQJWKH,QYHVWLJDWRUDVVHVVHGSURJUHVVLRQIUHH
VXUYLYDOWLPHEHWZHHQVXEMHFWVLQ$UPDQG$UPDQG$UPDQG$UPLQVWOLQH
PHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
x 7RFRPSDUHWKH,QYHVWLJDWRUDVVHVVHG5(&,67UHVSRQVHUDWHWKHUDWHRIFRPSOHWH
UHVSRQVHSDUWLDOUHVSRQVHLQ$UPWR$UP$UPWRDQG$UPWR$UPVDQG
SRROHGLQVXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFFDQFHU
x 7RFRPSDUHWKH,QYHVWLJDWRUDVVHVVHG5(&,67FOLQLFDOEHQHILWUDWHLHWKHUDWHRI
FRPSOHWHUHVSRQVHSDUWLDOUHVSRQVHVWDEOHGLVHDVHLQ$UPWR$UP$UPWR
DQG$UPWR$UPVDQGSRROHGLQVXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDO
DGHQRFDUFLQRPD
x 7RFRPSDUHWKH,QYHVWLJDWRUDVVHVVHGSURJUHVVLRQIUHHVXUYLYDODWPRQWKVLQ$UPWR
$UP$UPWRDQG$UPWR$UPVDQGSRROHGLQVXEMHFWVZLWKVWOLQH
PHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
x 7RGHWHUPLQHWKHKDOIOLIHYROXPHRIGLVWULEXWLRQDQGFOHDUDQFHRIGHPFL]XPDEZKHQ
FRPELQHGZLWK$EUD[DQHDQGJHPFLWDELQHLQZLWKVXEMHFWVZLWKVWOLQHPHWDVWDWLF
SDQFUHDWLFGXFWDODGHQRFDUFLQRPD
x 7RFRPSDUHWKHVDIHW\SURILOHWKURXJKDGYHUVHHYHQWPRQLWRULQJLQFOXGLQJDWWULEXWLRQRI
DGYHUVHHYHQWVDQGVHULRXVDGYHUVHHYHQWV>6$(V@SK\VLFDOH[DPLQDWLRQYLWDOVLJQVDQG
FOLQLFDOODERUDWRU\WHVWLQJDVRXWOLQHGLQWKH6FKHGXOHRI$VVHVVPHQWVVHH$SSHQGL[%RI
3URWRFROEHWZHHQ$UPWR$UP$UPWRDQG$UPWR$UPVDQGSRROHGLQ
VXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD7RFRPSDUHWKH
LQFLGHQFHRIDQWLGHPFL]XPDEDQWLERG\GHYHORSPHQWDQGQHXWUDOL]LQJDQWLERG\
GHYHORSPHQWLQVXEMHFWVZLWKVWOLQHORFDOO\DGYDQFHGRUPHWDVWDWLFSDQFUHDWLFGXFWDO
DGHQRFDUFLQRPDEHLQJWUHDWHGZLWK$EUD[DQHDQGJHPFLWDELQHSOXVGHPFL]XPDELQ$UP
WR$UP$UPWRDQG$UPVWR$UPVDQGSRROHG
x 7RFRPSDUHWKHPHGLDQVXUYLYDOLQ$UPWR$UP$UPWRDQG$UPWR$UPV
DQGSRROHGLQVXEMHFWVZLWKVWOLQHPHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
x 7KHFRPSDUHWKH.DSODQ0HLHUHVWLPDWHVRIVXUYLYDODWDQGPRQWKVLQ$UP
WR$UP$UPWRDQG$UPWR$UPVDQGSRROHGLQVXEMHFWVZLWKVWOLQH
PHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
([SORUDWRU\(QGSRLQWV
x 7RFRPSDUHWKHSKDUPDFRG\QDPLFDQGSUHGLFWLYHELRPDUNHUVIRUGHPFL]XPDEDQG
GHWHUPLQHWKHLUFRUUHODWLRQZLWKUHVSRQVHLQ$UPWR$UP$UPWRDQG$UPWR
$UPVDQGSRROHGVHH6HFWLRQRI3URWRFRO
x 7RFRPSDUHWKH&$UHVSRQVHUDWHLHDWOHDVWDGHFOLQHIURPEDVHOLQH
EHWZHHQ$UPWR$UP$UPWRDQG$UPWR$UPVDQGSRROHGLQVXEMHFWVZLWK
VWPHWDVWDWLFSDQFUHDWLFGXFWDODGHQRFDUFLQRPD
7UHDWPHQW0RGLILFDWLRQV
$Q\VXEMHFWZKRKDVWZRFRQVHFXWLYH%13YDOXHV!SJP/RURQHYDOXH!SJP/ZLOOEH
XQEOLQGHGE\WKH,QYHVWLJDWRUWKURXJKWKH,:56,956V\VWHP,IWKHVXEMHFWLVUHFHLYLQJ
GHPFL]XPDEWKH\ZLOOVWDUWRQDFDUGLRSURWHFWLYHDJHQWVXFKDVDQ$&(LQKLELWRURUFDUYHGLORO
XQOHVVWKH%13HOHYDWLRQRFFXUUHGPRUHWKDQGD\VDIWHUWKHGLVFRQWLQXDWLRQRIGHPFL]XPDE
RUWKHUHLVDFRQWUDLQGLFDWLRQWRWKHXVHRIWKHVHDJHQWVDQGLIDSSURSULDWHUHIHUUHGWRD
FDUGLRORJLVW,IWKH\DUHQRWRQGHPFL]XPDEWKH\VKRXOGEHFDUHGIRUDFFRUGLQJWRVWDQGDUG
PHGLFDOSUDFWLFH7KHVHOHFWLRQDQGGRVHRIWKH$&(LQKLELWRUWREHDGPLQLVWHUHGRUWKHGRVHRI
FDUYHGLOROWREHDGPLQLVWHUHGVKRXOGEHEDVHGRQWKHUHFRPPHQGDWLRQVLQVWDQGDUGJXLGHOLQHVIRU
WUHDWLQJKHDUWIDLOXUH5HI,IWKHUHLVDFRQWUDLQGLFDWLRQWRDGPLQLVWHULQJERWKRIWKHVHDJHQWV
WKHSDWLHQW¶VWUHDWPHQWVKRXOGEHGLVFXVVHGZLWKWKH2QFR0HG0HGLFDO0RQLWRU
,QDGGLWLRQVXEMHFWVPXVWKDYHWKHLUGRVHRIGHPFL]XPDERUSODFHERKHOGIRUDQ\RIWKH
IROORZLQJILQGLQJV

%13RISJP/

/9()GHFOLQHIURPEDVHOLQHDQGD/9()YDOXHWKDWLV

&OLQLFDOO\VLJQLILFDQWSXOPRQDU\K\SHUWHQVLRQLHWKHVXEMHFWKDVDSHDNWULFXVSLG
YHORFLW\!PVRQ'RSSOHUHFKRFDUGLRJUDPKDVEHHQVHHQE\DFDUGLRORJLVWDQGZDV
GLDJQRVHGZLWKFOLQLFDOO\VLJQLILFDQWSXOPRQDU\K\SHUWHQVLRQ

6LJQVDQGV\PSWRPVRIKHDUWIDLOXUH
$GPLQLVWUDWLRQRIWKHVXEMHFW¶VFKHPRWKHUDS\VKRXOGEHFRQWLQXHGZKLOHGHPFL]XPDERUSODFHER
LVEHLQJKHOG




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
'RVLQJRIGHPFL]XPDERUSODFHERPXVWFRQWLQXHWREHKHOGXQWLOWKHVXEMHFWVKDV

%13SJP/

/9()YDOXHWKDWLV!

1RFOLQLFDOO\VLJQLILFDQWSXOPRQDU\K\SHUWHQVLRQDQG

1RVLJQVRUV\PSWRPVRIKHDUWIDLOXUH
$Q\VXEMHFWZKRKDVD%13RI!SJP/WKDWLVFRQVLGHUHGWREHUHODWHGWRGHPFL]XPDE
GHFOLQHLQOHIWYHQWULFXODUHMHFWLRQIUDFWLRQDQGD/9()YDOXHWKDWLVVLJQVDQG
V\PSWRPVRIKHDUWIDLOXUHRUFOLQLFDOO\VLJQLILFDQWSXOPRQDU\K\SHUWHQVLRQLHWKHVXEMHFWKDVD
SHDNWULFXVSLGYHORFLW\!PVRQGRSSOHUHFKRFDUGLRJUDPDQGKDVEHHQVHHQE\DFDUGLRORJLVW
DQGGLDJQRVHGZLWKFOLQLFDOVLJQLILFDQWSXOPRQDU\K\SHUWHQVLRQWKDWSHUVLVWVEH\RQG'D\RU
RFFXUVEH\RQG'D\PXVWKDYHWKHLUGHPFL]XPDESHUPDQHQWO\GLVFRQWLQXHG
'HPFL]XPDESODFHERPXVWDOVREHGLVFRQWLQXHGIRUDQ\RIWKHIROORZLQJ

%13RISJP/

*UDGHSXOPRQDU\K\SHUWHQVLRQ

(YLGHQFHRI*UDGHEOHHGLQJH[FHSWIRUUHDGLO\PDQDJHDEOHORFDOEOHHGLQJVXFKDV
KHPRUUKRLGDOEOHHGLQJ

+\SHUWHQVLYHFULVLV

+\SHUWHQVLYHHQFHSKDORSDWK\

%ORRGSUHVVXUHRItPP+J

1HHGIRUWKHUDSHXWLFDQWLFRDJXODWLRQ

,IWKHUDSHXWLFDQWLFRDJXODWLRQLVQRORQJHUUHTXLUHGWKHVXEMHFWPD\UHFHLYHDQ\
UHPDLQLQJGHPFL]XPDESODFHERDGPLQLVWUDWLRQV
,IWKHGHPFL]XPDESODFHERQHHGVWREHKHOGRUGLVFRQWLQXHGWKHDGPLQLVWUDWLRQRIWKH
FKHPRWKHUDS\VKRXOGFRQWLQXHXQWLOGLVHDVHSURJUHVVLRQXQOHVVFRQWUDLQGLFDWHG
 *HQHUDO6WDWLVWLFDO&RQVLGHUDWLRQV
6DPSOH6L]H
7\SHHUURULVFRQWUROOHGDWWKHRQHVLGHGOHYHO7ZRKXQGUHGDQGRQHVXEMHFWVIROORZHG
XQWLO3)6HYHQWVKDYHEHHQREVHUYHGZLOOSURYLGHSHUFHQWSRZHUWRGHWHFWDKD]DUGUDWLR
RIZKLFKFRUUHVSRQGVWRDQLQFUHDVHLQPHGLDQ3)6IURPPRQWKVWRPRQWKV
5DQGRPL]DWLRQ6WUDWLILFDWLRQDQG%OLQGLQJ
(OLJLEOHVXEMHFWVZLOOEHUDQGRPO\DVVLJQHGWRWUHDWPHQWLQDDOORFDWLRQUDWLRWRUHFHLYH
DUP3ODFHER3ODFHERDUP'HPFL]XPDE3ODFHERDQGDUP'HPFL]XPDE'HPFL]XPDE
XVLQJGRXEOHEOLQGPHWKRG6XEMHFWVZLOOEHVWUDWLILHGE\(DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
(&2*SHUIRUPDQFHVWDWXVRUUHJLRQ8QLWHG6WDWHV&DQDGDRU(XURSH$XVWUDOLDDQG
&$±8/1!8/1±8/1!8/1$WOHDVWWZRKXQGUHGDQGRQHVXEMHFWVZLOOEH
UDQGRPL]HGYLDDQ,:56,956V\VWHPWRRQHRIWKHWKUHHDUPV
)RUWKHILQDORYHUDOOVXUYLYDODQDO\VLVXQEOLQGLQJZLOOEHGRQHDWWKHVWXG\OHYHODVZHOODVWKH
LQGLYLGXDOSDWLHQWOHYHO)RUHDUOLHULQWHULPDQDO\VHVRIRYHUDOOVXUYLYDODVZHOODVRWKHUGDWD
XQEOLQGLQJZLOOEHGRQHDWWKHRYHUDOOVWXG\UHVXOWVOHYHOEXWXQEOLQGLQJZLOOQRWEHGRQHDWWKH
LQGLYLGXDOSDWLHQWOHYHOLH2QFR0HGZLOOUHFHLYHGXQEOLQGHGWDEOHVDQGILJXUHVEXWWKHSDWLHQW
OLVWLQJVZLOOEHEOLQGHG
6XEMHFW3RSXODWLRQVIRU$QDO\VLV
7KHUHZLOOEHVXEMHFWVUDQGRPL]HGLQWKHWULDO
7KH,QWHQWWR7UHDW,773RSXODWLRQFRPSULVHVDOOVXEMHFWVZKRUHFHLYHDWOHDVWRQHSDUWLDORU
FRPSOHWHGRVHRIGHPFL]XPDERUSODFHER$OOEDVHOLQHFKDUDFWHULVWLFVDQGGHPRJUDSKLF
HIILFDF\LPPXQRJHQLFLW\DQGELRPDUNHUGDWDZLOOEHDQDO\]HGXVLQJWKH,773RSXODWLRQ
7KH3HU3URWRFRO3RSXODWLRQ33LVFRPSULVHGRIDOOUDQGRPL]HGVXEMHFWVZKRUHFHLYHGDWOHDVW
RQHGRVHRIGHPFL]XPDERUSODFHERDQGKDGDWOHDVWRQHSRVWEDVHOLQHWXPRUDVVHVVPHQW$OO
HIILFDF\GDWDZLOOEHDQDO\]HGXVLQJWKH33SRSXODWLRQDVZHOODVWKH,773RSXODWLRQ
7KH6DIHW\3RSXODWLRQFRPSULVHVDOOVXEMHFWVZKRUHFHLYHDWOHDVWRQHSDUWLDORUFRPSOHWHGRVHRI
GHPFL]XPDERUSODFHERDQGZKRKDYHDWOHDVWRQHSRVWGRVLQJVDIHW\HYDOXDWLRQ$OOVDIHW\
HQGSRLQWVZLOOEHVXPPDUL]HGXVLQJWKH6DIHW\3RSXODWLRQ
7KH3KDUPDFRNLQHWLF3.3RSXODWLRQFRPSULVHVDOOVXEMHFWVZKRUHFHLYHDWOHDVWRQHSDUWLDORU
FRPSOHWHGRVHRIGHPFL]XPDERUSODFHERDQGZKRSURYLGHDGHTXDWH3.VDPSOHVDVGHILQHGE\
WKH3.VSHFLDOLVWWRFDOFXODWHWKH3.SDUDPHWHUV6XEMHFWVZLWKSURWRFROYLRODWLRQVZLOOEH
DVVHVVHGRQDVXEMHFWE\VXEMHFWEDVLVIRULQFOXVLRQLQWKH3.3RSXODWLRQ3.DQDO\VLVZLOOEH
FRQGXFWHGXVLQJWKH3KDUPDFRNLQHWLF3RSXODWLRQ
7KH5HVSRQVH(YDOXDEOH3RSXODWLRQFRPSULVHVDOOVXEMHFWVZKRUHFHLYHDWOHDVWRQHGRVHRIVWXG\
GUXJDQGZKRKDYHDWOHDVWRQHSRVWEDVHOLQHGLVHDVHUHVSRQVH&5RU35'XUDWLRQRIUHVSRQVH
ZLOOEHDQDO\]HGXVLQJ5HVSRQVH(YDOXDEOH3RSXODWLRQ

 6XEMHFW'LVSRVLWLRQ
'LVSRVLWLRQ
6XEMHFWGLVSRVLWLRQZLOOEHVXPPDUL]HGIRUWKH,773RSXODWLRQ$GLVSRVLWLRQRIVXEMHFWV
LQFOXGHVWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVIRUWKHIROORZLQJFDWHJRULHVVXEMHFWVZKRZHUH




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
UDQGRPL]HGVXEMHFWVZKRDUHLQVWXG\VXEMHFWVZKRGLVFRQWLQXHGIURPWKHVWXG\DQGVXEMHFWV
ZKRHQGHGRIIROORZXS$OOSHUFHQWDJHVZLOOEHEDVHGRQWKHQXPEHURISDWLHQWVUDQGRPL]HG
7KHUHDVRQVIRUGLVFRQWLQXDWLRQRIVWXG\DQGHQGRIIROORZXSZLOODOVREHVXPPDUL]HGLQWKLV
WDEOH$QDO\VLVSRSXODWLRQZLOOEHVXPPDUL]HGIRUDOOVXEMHFWV
6XEMHFWGLVSRVLWLRQGDWDZLOOEHDOVRSUHVHQWHGLQDOLVWLQJ
3URWRFRO'HYLDWLRQV
7KHIROORZLQJSURWRFROGHYLDWLRQVZLOOEHUHFRUGHGDQGVXPPDUL]HGIRUWKH,QWHQWWR7UHDW
SRSXODWLRQLQWKHILQDOUHSRUWUDQGRPL]DWLRQYLRODWLRQVGRVLQJYLRODWLRQVFRQFRPLWDQW
WKHUDS\YLRODWLRQVDQGFRQWLQXDWLRQRIWKHUDS\ZKHQWUHDWPHQWVKRXOGKDYHEHHQ
GLVFRQWLQXHG$OLVWRISDWLHQWVZLWKSURWRFROGHYLDWLRQZLOOEHDOVRSUHVHQWHG
 'HPRJUDSKLFVDQG0HGLFDO+LVWRU\
'HPRJUDSKLFDQGPHGLFDOKLVWRU\ZLOOEHDQDO\]HGXVLQJWKH,773RSXODWLRQ
4XDQWLWDWLYHDQGRUFDWHJRULFDOVXPPDULHVZLOOEHSUHVHQWHGIRUGHPRJUDSKLFVPHGLFDOKLVWRU\
PHWDVWDVLVLQIRUPDWLRQDQGRWKHUEDVHOLQHFKDUDFWHULVWLFV)RUFRQWLQXRXVYDULDEOHVGDWDZLOOEH
VXPPDUL]HGE\FRXQWRIQRQPLVVLQJYDOXHVPHDQVWDQGDUGGHYLDWLRQPHGLDQPLQLPXPDQG
PD[LPXP)RUFDWHJRULFDOYDULDEOHVGDWDZLOOEHVXPPDUL]HGDVIUHTXHQF\FRXQWVDQG
SHUFHQWDJHV
'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV
$JHZLOOEHFDOFXODWHGDVWKHLQWHJHUSDUWRI,QIRUPHG&RQVHQW'DWH±%LUWK'DWH
7KHGHPRJUDSKLFFKDUDFWHULVWLFVFRQVLVWRIDJHVH[HWKQLFLW\DQGUDFH7KHEDVHOLQH
FKDUDFWHULVWLFVDOVRFRQVLVWRIEDVHOLQHKHLJKWFPEDVHOLQHZHLJKWNJPHWDVWDWLFVLWHV
QXPEHURIPHWDVWDWLFVLWHVKHSDWLFPHWDVWDVLVDQG1/5QHXWURSKLOWRO\PSKRF\WHUDWLR
'HPRJUDSKLFDQGEDVHOLQHFKDUDFWHULVWLFVZLOOEHVXPPDUL]HGDVIUHTXHQF\FRXQWVDQG
SHUFHQWDJHV
0HWDVWDVLVGLDJQRVLVGDWHVVLWHVDQGKHSDWLFPHWDVWDVLVVWDWXVZLOOEHOLVWHG
0HGLFDO+LVWRU\
 *HQHUDO0HGLFDO+LVWRU\
7KHQXPEHUDQGSHUFHQWDJHRISDWLHQWVZLWKDQ\PHGLFDOKLVWRU\ZLOOEHVXPPDUL]HGRYHUDOODQG
IRUHDFKERG\V\VWHPDQGSUHIHUUHGWHUP
6XEMHFWPHGLFDOKLVWRU\GDWDLQFOXGLQJVSHFLILFGHWDLOVZLOOEHSUHVHQWHGLQDOLVWLQJ




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
 &DQFHU'LDJQRVLV+LVWRU\
&DQFHUGLDJQRVLVKLVWRU\LQFOXGLQJ6WDJHDWLQLWLDOGLDJQRVLVZKHWKHURUQRWWKHVXEMHFWKDV
PHDVXUHDEOHGLVHDVHSHU5(&,67ZLOOEHWDEXODWHG6WUDWLILFDWLRQIDFWRUVZLOOEHDOVR
VXPPDUL]HGDQGOLVWHG
$OLVWLQJRIFDQFHUGLDJQRVLVKLVWRU\ZLOOEHSUHVHQWHG
 3ULRUDQGGXULQJ)ROORZXS3HULRG&DQFHU7UHDWPHQWVDQG7KHUDSLHV
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZKRKDYHUHFHLYHGSULRUFDQFHUWUHDWPHQWVLQFOXGLQJ
SULRUV\VWHPLFWUHDWPHQWSULRUVXUJHU\WRWUHDWWKHLUFDQFHUDQGSULRUUDGLRWKHUDS\ZLOOEH
VXPPDUL]HGE\WUHDWPHQWDUPZKLFKZLOODOVRLQFOXGHIUHTXHQF\FRXQWVDQGSHUFHQWDJHVRI
GUXJVRISULRUV\VWHPLFWUHDWPHQWSURFHGXUHVRISULRUVXUJHU\
3ULRUFDQFHUWUHDWPHQWVLQFOXGLQJSULRUV\VWHPLFWUHDWPHQWSULRUVXUJLFDOWUHDWPHQWDQGSULRU
UDGLRWKHUDS\WUHDWPHQWZLOOEHSUHVHQWHGDVGDWDOLVWLQJV
6\VWHPLFWKHUDS\IRUSDQFUHDWLFFDQFHUGXULQJIROORZXSSHULRGZLOOEHWDEXODWHGDQGOLVWHG
6XUJHU\DQGUDGLRWKHUDS\ZLOODOVREHOLVWHG
,QFOXVLRQDQG([FOXVLRQ&ULWHULD
6HH6HFWLRQDQGLQVWXG\SURWRFROIRUGHWDLOVRQLQFOXVLRQDQGH[FOXVLRQFULWHULD
,QFOXVLRQDQGH[FOXVLRQFULWHULDZLOOEHSUHVHQWHGLQDOLVWLQJIRUDOOVXEMHFWV
 7UHDWPHQWVDQG0HGLFDWLRQV
3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV
3ULRUDQGFRQFRPLWDQWPHGLFDWLRQVZLOOEHSUHVHQWHGE\,773RSXODWLRQ
3ULRUPHGLFDWLRQVDUHGHILQHGDVPHGLFDWLRQVZLWKDVWRSGDWHRFFXUULQJEHIRUHUDQGRPL]DWLRQ
GDWH&RQFRPLWDQWPHGLFDWLRQVDUHGHILQHGDVPHGLFDWLRQVZLWKDVWRSGDWHRFFXUULQJRQRUDIWHU
UDQGRPL]DWLRQGDWH0HGLFDWLRQVIRUZKLFKWKHVWDUWDQGHQGGDWHVDUHPLVVLQJZLOOEHFODVVLILHG
DVSULRUDQGFRQFRPLWDQW0HGLFDWLRQVZLOOEHFRGHGXVLQJ:RUOG+HDOWK2UJDQL]DWLRQ:+2
'UXJYHUVLRQ6HS&RQFRPLWDQWSURFHGXUHVZLOOQRWEHFRGHG7KHQXPEHUDQG
SHUFHQWDJHRISDWLHQWVWDNLQJFRQFRPLWDQWPHGLFDWLRQVDQWLK\SHUWHQVLYHFRQFRPLWDQW
PHGLFDWLRQVDQG$&(LQKLELWRURUFDUYHGLOROIRU%13LQFUHDVHZLOOEHWDEXODWHGE\:+2GUXJ
JHQHULFWHUP
0LVVLQJGDWHRISULRUDQGFRQFRPLWDQWPHGLFDWLRQZLOOEHLPSXWHGDVLQ$SSHQGL[%
3ULRUDQGFRQFRPLWDQWPHGLFDWLRQVDQGSURFHGXUHVZLOOEHDOVRSUHVHQWHGLQE\SDWLHQWOLVWLQJV




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
$QWLK\SHUWHQVLYHFRQFRPLWDQWPHGLFDWLRQDQG$&(LQKLELWRURUFDUYHGLOROIRU%13LQFUHDVH
ZLOOEHDOVRVXPPDUL]HGVHSDUDWHO\DVDWVFUHHQLQJDQGRQVWXG\LQWDEOHVDQGOLVWHG
6WXG\7UHDWPHQWV
6WXG\WUHDWPHQWZLOOEHDQDO\]HGE\6DIHW\3RSXODWLRQ
 ([WHQWRI([SRVXUH
7UHDWPHQWH[SRVXUHZLOOEHVXPPDUL]HGDVGXUDWLRQRQWUHDWPHQWDQGH[WHQWRIH[SRVXUHWR
GHPFL]XPDESODFHERDEUD[DQHDQGJHPFLWDELQHLQ$UPVDQG'XUDWLRQRIH[SRVXUH
ZKLFKLVGHILQHGDVODVWGRVHGDWH±GDWHRIILUVWGRVHZLOOEHVXPPDUL]HGTXDQWLWDWLYHO\LQ
GD\VXVLQJFRXQWRIQRQPLVVLQJGDWDPHDQVWDQGDUGGHYLDWLRQPHGLDQPLQLPXPDQG
PD[LPXP7RWDOQXPEHURIGRVHWDNHQFXPXODWLYHGRVHGRVHLQWHQVLW\DQGLQIXVLRQLQWHUUXSWHG
ZLOOEHDOVRVXPPDUL]HG
'RVHLQWHQVLW\LVGHILQHGDVFXPXODWLYHGRVHWRWDOSODQQHGGRVH7KHWRWDOSODQQHGGRVHLVWKH
VXPRIWKHSODQQHGGRVHVWDNHQWKURXJKRXWWKHVWXG\)RUGHPFL]XPDESODQQHGGRVHSHUF\FOH 
PJNJEDVHOLQHZHLJKW)RUDEUD[DQHDQGJHPFLWDELQHSODQQHGGRVHSHUYLVLW 
DGPLQLVWHUHGGRVHPJPAEDVHOLQHZHLJKWAEDVHOLQHKHLJKWA
%DVHOLQHZHLJKWDQGKHLJKWDUHWKH'D\ZHLJKWDQGKHLJKWWKURXJKRXWWKHVWXG\
'HPFL]XPDEPJNJRUSODFHERZLOOEHDGPLQLVWHUHGE\,9LQIXVLRQSULRUWRWKH
DGPLQLVWUDWLRQRI$EUD[DQHDQGJHPFLWDELQHRQFHHYHU\ZHHNVIRUHLWKHURQHVWFRXUVH
WKURXJK6WXG\'D\RUWZRQGFRXUVHEHJXQRQ6WXG\'D\DQGFRQWLQXHGWKURXJK6WXG\
'D\GD\FRXUVHV6XEMHFWVZLOORQO\UHFHLYHWKHLUVHFRQGGD\FRXUVHRISODFHERRU
GHPFL]XPDELIWKHVXEMHFW¶V'D\
%13LVSJP/
SHDNWULFXVSLGYHORFLW\LVPV
/9()LV
7KHVXEMHFWGLGQRWGHYHORSSXOPRQDU\K\SHUWHQVLRQRUKHDUWIDLOXUHZKLOHRQVWXG\
7UHDWPHQWH[SRVXUHLQFOXGLQJWKHGDWHRILQIXVLRQDFWXDOGRVHDPRXQWUHDVRQRILQWHUUXSWLRQ
ZLOOEHSUHVHQWHGLQDOLVWLQJ
 (IILFDF\$QDO\VLV
(IILFDF\HQGSRLQWVLQFOXGH3URJUHVVLRQ)UHH6XUYLYDO3)6EHVWRYHUDOOUHVSRQVHGXUDWLRQRI
UHVSRQVHDQGRYHUDOOVXUYLYDO26'XUDWLRQRIUHVSRQVHZLOOEHDQDO\]HGXVLQJWKH5HVSRQVH
(YDOXDEOH3RSXODWLRQDQGRWKHUHIILFDF\HQGSRLQWVZLOOEHDQDO\]HGXVLQJWKH,773RSXODWLRQDQG
333RSXODWLRQ3RROHGGHPFL]XPDEDUPVDUHSRROHG$UPDQG$UP




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5

3ULPDU\(IILFDF\(QGSRLQW
3)6LVWKHSULPDU\HIILFDF\HQGSRLQW,WLVGHILQHGDVWKHQXPEHURIGD\VIURPUDQGRPL]DWLRQ
XQWLOGHDWKRUGLVHDVHSURJUHVVLRQDVGHILQHGE\WKH5HVSRQVH(YDOXDWLRQ&ULWHULDLQ6ROLG
7XPRUV5(&,67YFULWHULD6XUYLYDOWLPHLQGD\VGZLOOEHFRQYHUWHGWRPRQWKVPXVLQJ
P G
$VXEMHFWLVFRQVLGHUHGWRKDYHSURJUHVVHGLIWKH\KDYHD5(&,67UHVSRQVHRISURJUHVVLRQRQRU
SULRUWRWKHLUODVWRQVWXG\WXPRUDVVHVVPHQWRULIWKH\KDYHGLHGZLWKLQGD\V7XPRU
DVVHVVPHQWVDUHZHHNVDSDUWRIWKHLUODVWRQVWXG\WXPRUDVVHVVPHQW+HUHWKHODVWRQVWXG\
WXPRUDVVHVVPHQWLVWKHODVWWXPRUDVVHVVPHQWZLWKDQRQPLVVLQJ5(&,67UHVSRQVHZLWKRXWD
JDSRIGD\VWXPRUDVVHVVPHQWVRFFXUHYHU\ZHHNVRUPRUHEHWZHHQWKHFXUUHQW
DQGRUSUHYLRXVWXPRUDVVHVVPHQWV:KHQDVXEMHFWKDVSURJUHVVHGFHQVRU WKHLUWLPHWR
SURJUHVVLRQLVWKHGDWHRISURJUHVVLRQGDWHRI5(&,67UHVSRQVHDVVHVVPHQWRUGDWHRIGHDWK
PLQXVVWDUWGDWH:KHQDVXEMHFWKDVQRWSURJUHVVHGFHQVRU WKHLUWLPHWRSURJUHVVLRQLV
WKHODVWRQVWXG\5(&,67WXPRUDVVHVVPHQWGDWHVWDUWGDWH+HUHWKHVWDUWGDWHLVWKH
UDQGRPL]DWLRQGDWH
,IDVXEMHFWUHFHLYHGQRQSURWRFROWKHUDS\137SULRUWRGLVHDVHSURJUHVVLRQRUUHFHLYHG137
DQGLVQRWSURJUHVVHGWKHQWKHVXEMHFWZLOOEHFHQVRUHGRQWKHODVWDGHTXDWHDVVHVVPHQWSULRUWR
1371RQSURWRFROWKHUDS\ZLOOEHGHWHUPLQHGIURPDFOLQLFDOUHYLHZRIWKHUHOHYDQWOLVWLQJV
5DGLRWKHUDS\DQGVXUJHU\GLUHFWHGDWDGLVHDVHVLWHZLOOEHFRQVLGHUHGQRQSURWRFROWKHUDS\
%LVSKRVSKRQDWHVDQGKRUPRQHVZLOOQRWEHFRQVLGHUHGQRQSURWRFROWKHUDS\
)RUVXEMHFWVZKRGRQRWH[SHULHQFHGLVHDVHSURJUHVVLRQDQGGRQRWKDYHDQ\DGHTXDWHSRVW
EDVHOLQHWXPRUDVVHVVPHQWV3)6ZLOOEHULJKWFHQVRUHGDW'D\3)6LQPRQWKV 'DWHRI
HYHQWFHQVRULQJGDWHRIILUVWGRVH7KHFHQVRULQJUXOHVIRU3)6DUHLQFOXGHGLQ
7DEOHEHORZ





,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
&HQVRULQJ&RQYHQWLRQVIRU3)6
6LWXDWLRQ
'DWHRI3URJUHVVLRQRU&HQVRULQJ
2XWFRPH
1REDVHOLQHDQGRUSRVWEDVHOLQH
WXPRUDVVHVVPHQWDQGQRSRVW
EDVHOLQHHYHQW
5DQGRPL]DWLRQGDWH
&HQVRUHG
3URJUHVVLRQGRFXPHQWHGDWRU
EHWZHHQVFKHGXOHGYLVLWV
'DWHRIVFDQRUFOLQLFDODVVHVVPHQWRI
SURJUHVVLRQ
(YHQW
1R3URJUHVVLRQ
'DWHRIODVWDGHTXDWHRQVWXG\
DVVHVVPHQW
&HQVRUHG
'HDWKGXHWRDQ\FDXVHEHIRUHILUVW
VFKHGXOHGSRVWEDVHOLQHDVVHVVPHQW
'DWHRI'HDWK
(YHQW
'HDWKOHVVWKDQGD\VIURPWKH
ODVWWXPRUDVVHVVPHQWZLWKRXWSULRU
SURJUHVVLRQ
'DWHRI'HDWK
(YHQW
'HDWKJUHDWHUWKDQGD\VIURP
WKHODVWWXPRUDVVHVVPHQWZLWKRXW
SULRUSURJUHVVLRQ
'DWHRIODVWDGHTXDWHWXPRU
DVVHVVPHQW
&HQVRUHG
5HFHLYHG137SULRUWRGLVHDVH
SURJUHVVLRQ
'DWHRIODVWDGHTXDWHDVVHVVPHQWSULRU
WR137
&HQVRUHG

7KH.DSODQ0HLHUPHWKRGZLOOEHXVHGWRHVWLPDWHWKHSURSRUWLRQRIVXEMHFWVZLWKRXW
SURJUHVVLRQRUGHDWKRYHUWLPHDQGWKHPHGLDQSURJUHVVLRQIUHHVXUYLYDOWLPHLQWKHSRROHG
GHPFL]XPDEDUPVDVZHOODVHDFKLQGLYLGXDODUPRIWKHWULDO7KHFRQILGHQFHLQWHUYDOVIRU
PHGLDQSURJUHVVLRQIUHHVXUYLYDOWLPHZLOODOVREHFDOFXODWHGIRUWKHSRROHGGHPFL]XPDEDUPVDV
ZHOODVHDFKWUHDWPHQWDUP7KH.DSODQ0HLHUHVWLPDWHVDQGWKH&,ZLOOEHSURYLGHGDW
DQGPRQWKV7KHSYDOXHVIRUWKHGHPFL]XPDEWUHDWPHQWHIIHFWVSRROHGYHUVXVFRQWURODV
ZHOODVHDFKLQGLYLGXDOGHPFL]XPDEDUPYHUVXVFRQWUROZLOOEHJHQHUDWHGXVLQJDVWUDWLILHGORJ
UDQNWHVW$VWUDWLILHG&R[SURSRUWLRQDOKD]DUGVUHJUHVVLRQPRGHOZLOOEHXVHGWRHVWLPDWHWKH
KD]DUGUDWLRDQGLWVFRQILGHQFHLQWHUYDOV7KHVWUDWLILFDWLRQIDFWRUVZLOOEHSHUIRUPDQFH
VWDWXVRUDQGUHJLRQ8QLWHG6WDWHV&DQDGDRU(XURSH$XVWUDOLDDQG&$±8/1
!8/1±8/1!8/1,QDGGLWLRQWRWKHORJUDQNWHVWWKH:LOFR[RQWHVWZLOODOVREHXVHG
DVDVHQVLWLYLW\DQDO\VLVWRHYDOXDWHWKHLPSDFWRIWUHDWPHQWRQ3)6
7RHYDOXDWHWKHLPSDFWRIWKHVHFRQGFRXUVHRIGHPFL]XPDEWKHUDS\DFR[UHJUHVVLRQDQDO\VLV
ZLOOEHXVHGE\SRROLQJ$UPDQG$UPDQGFRPSDUHGZLWK$UP7KHPRGHOZLOOLQFOXGHD




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
WLPHGHSHQGHQWFRYDULDWHWRLGHQWLI\ZKRVWDUWHGDVHFRQGFRXUVHRI'HPFL]XPDE7KH
FRHIILFLHQWIRUWKLVWHUPZLOOEHXVHGWRDVVHVVWKHLPSDFWRIWKHVHFRQGFRXUVHRI'HPFL]XPDE
WUHDWPHQW
.DSODQ0HLHUFXUYHVRI3)6ZLOOEHSORWWHGIRUHDFKLQGLYLGXDODUP$UPDQGE\
VWUDWLILFDWLRQIDFWRUVDQGRYHUDOO)RUWKHSRROHGDQDO\VLV.DSODQ0HLHUFXUYHVRI3)6IRU
SRROHGGHPFL]XPDEDUPSRROHG$UPDQG$UPDQG$UPZLOOEHSORWWHGE\VWUDWLILFDWLRQ
IDFWRUVDQGRYHUDOO
%HVW2YHUDOO5HVSRQVH%25
7KHEHVWRYHUDOOUHVSRQVH%25LVGHILQHGDVWKHEHVWUHVSRQVHGHWHUPLQHGE\5(&,67Y
UHFRUGHGIURPWKHVWDUWRIWKHWUHDWPHQWXQWLOGLVHDVHSURJUHVVLRQLQWKHIROORZLQJRUGHURI
LPSRUWDQFH&5356'3'1(0LVVLQJ5HVSRQVHRXWFRPHVIURPDUHVSRQVHDVVHVVPHQW
GRQHDQ\WLPHOHVVWKDQ6WXG\'D\ZLOOEHFRQVLGHUHGDVQRWHYDOXDEOHXQOHVVWKHUHVSRQVH
DVVHVVPHQWLV3'
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFKGLVHDVHUHVSRQVHFDWHJRU\&5356'3'1(
DQG0LVVLQJZLOOEHVXPPDUL]HGE\WUHDWPHQWDUPDQGIRUWKHSRROHGGHPFL]XPDEDUPV
7KHUHVSRQVHUDWHLVWKHQXPEHURIVXEMHFWVSHUWUHDWPHQWDUPZKRKDYHHLWKHUD&5RUD35
GLYLGHGE\WKHQXPEHURIVXEMHFWVUDQGRPL]HGWRWKHUHVSHFWLYHDUPV&OLQLFDOEHQHILWUDWHLVWKH
QXPEHURIVXEMHFWVSHUWUHDWPHQWDUPZKRKDYHHLWKHUD&5RUD35RU6'GLYLGHGE\WKH
QXPEHURIVXEMHFWVUDQGRPL]HGWRWKHUHVSHFWLYHDUPV%RWKUHVSRQVHUDWHDQGFOLQLFDOEHQHILW
UDWHDQGWKHLUFRQILGHQFHLQWHUYDOVE\([DFW%LQRPLDOPHWKRGZLOOEHGLVSOD\HG7KHRGGV
UDWLRVDQGSYDOXHIRUHTXDOLW\RIWKHUHVSRQVHUDWHEHWZHHQWKHSRROHGGHPFL]XPDEWUHDWPHQW
DUPDQGFRQWUROZLOOEHFDOFXODWHGIRUWKHWZRJURXSVXVLQJDORJLVWLFUHJUHVVLRQPRGHOZLWK
SHUIRUPDQFHVWDWXVUHJLRQDQG&$DVIDFWRUVLQWKHPRGHO$VLPLODUFRPSDULVRQZLOOEH
PDGHEHWZHHQHDFKLQGLYLGXDOGHPFL]XPDEDUPDQGFRQWURO
&RQWLQXRXV9DULDEOH$VVHVVPHQWRI7XPRU/HQJWK
7KHWXPRUOHQJWKZLOOEHFDOFXODWHGDVWKHVXPRIWKHORQJHVWGLDPHWHUV6/'IRUWKHWDUJHW
OHVLRQVDVGHILQHGE\5(&,67YFULWHULDDQGGHWHUPLQHGE\WKH,QYHVWLJDWRU7KHGDWDZLOO
EHGLVSOD\HGJUDSKLFDOO\ZLWKZDWHUIDOOSORWV6XPPDU\VWDWLVWLFVLQFOXGLQJPHDQVWDQGDUG
GHYLDWLRQPHGLDQPLQLPXPDQGPD[LPXPIRUWXPRUOHQJWKZLOOEHSUHVHQWHGIRUEDVHOLQH
ZHHNVSRVWEDVHOLQHDQGZHHNVSRVWEDVHOLQH7KHVHVXPPDU\VWDWLVWLFVZLOODOVREH
SUHVHQWHGIRUGLIIHUHQFHVIURPEDVHOLQHDWDQGZHHNVSRVWEDVHOLQH$ORQJZLWKWKH
VXPPDU\VWDWLVWLFVWKHFRQILGHQFHLQWHUYDOVRIWKHPHDQWXPRUOHQJWKIRUHDFKWUHDWPHQW
DUPDQGWKHSRROHGGHPFL]XPDEDUPVDWHDFKRIWKHWKUHHWLPHSRLQWVZLOODOVREHSUHVHQWHG$Q
$1&29$PRGHOZLOOEHXVHGWRWHVWWKHK\SRWKHVLVWKDWWKHUHLVQRGLIIHUHQFHEHWZHHQWUHDWPHQW
DUPV$UPYHUVXV$UPDQG$UPYHUVXV$UPDVZHOODVQRGLIIHUHQFHEHWZHHQWKH
SRROHGGHPFL]XPDEDUPVDQGFRQWUROZLWKUHJDUGWRFKDQJHVIURPEDVHOLQHWXPRUOHQJWKDW




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
VFKHGXOHGWXPRUDVVHVVPHQWV7UHDWPHQWDQG(&2*36DQGUHJLRQZLOOEHIDFWRUVLQWKHPRGHO
DQGEDVHOLQHWXPRUOHQJWKZLOOEHXVHGDVDFRYDULDWH0LVVLQJYDOXHVZLOOQRWEHLPSXWHG
,QDGGLWLRQIRUWDUJHWOHVLRQWKHSHUFHQWUDWHRIFKDQJHLQWXPRUYROXPHSHUGD\IRUWDUJHWOHVLRQ
DWSURJUHVVLRQLVî6/'DWSURJUHVVLRQ±6/'DWQDGLU6/'DWQDGLUîGD\VEHWZHHQ
1DGLUDQG3URJUHVVLRQDVGHWHUPLQHGE\WKH,QYHVWLJDWRUZLOOEHVXPPDUL]HGGHVFULSWLYHO\E\
WUHDWPHQWDUPV7KHUDWHRIFKDQJHLQWXPRUEXUGHQDWSURJUHVVLRQKDVEHHQDVVRFLDWHGZLWK
VXUYLYDO7KHUDWHRIFKDQJHLQWXPRUYROXPHIRUWKHWDUJHWOHVLRQDWSURJUHVVLRQZLOOEH
VXPPDUL]HGIRUWKH,77SRSXODWLRQDQGWKH33SRSXODWLRQUHVSHFWLYHO\
'XUDWLRQRI5HVSRQVH
7KH,QYHVWLJDWRUDVVHVVHGGXUDWLRQRIUHVSRQVH'25LVGHILQHGDVWKHWLPHIURPWKHILUVWSDUWLDO
RUFRPSOHWHUHVSRQVHWRWKHWLPHRIGHDWKRUGLVHDVHSURJUHVVLRQIRUVXEMHFWV'25ZLOOEHXVLQJ
5HVSRQVH(YDOXDEOH3RSXODWLRQ6XEMHFWVZKRKDYHQRWH[SHULHQFHGGHDWKRUSURJUHVVLRQE\
WKHLUODVWFRQWDFWZLOOEHFHQVRUHGDWWKHWLPHRIWKHLUODVWRQVWXG\UDGLRJUDSKLFUHVSRQVH
DVVHVVPHQW'25LQPRQWKV 'DWHRIHYHQWFHQVRULQJGDWHRIILUVWUHVSRQVH
7KHFHQVRULQJUXOHVIRU'25DUHLQFOXGHGLQ7DEOHEHORZ
7DEOH
&HQVRULQJ&RQYHQWLRQVIRU'25
6LWXDWLRQ
'DWHRI3URJUHVVLRQRU&HQVRULQJ
2XWFRPH
1RDVVHVVPHQWDIWHUILUVWUHVSRQVH
)LUVWUHVSRQVHGDWH
&HQVRUHG
3URJUHVVLRQGRFXPHQWHGDWRUEHWZHHQ
VFKHGXOHGYLVLWV
'DWHRIVFDQRUFOLQLFDODVVHVVPHQWRI
SURJUHVVLRQ
(YHQW
1R3URJUHVVLRQRUGHDWK
'DWHRIODVWDGHTXDWHDVVHVVPHQWDIWHU
ILUVWUHVSRQVH
&HQVRUHG
'HDWKGXHWRDQ\FDXVHEHIRUHILUVW
VFKHGXOHGSRVWEDVHOLQHDVVHVVPHQW
'DWHRI'HDWK
(YHQW
'HDWKOHVVWKDQGD\VIURPWKHODVW
WXPRUDVVHVVPHQWZLWKRXWSULRU
SURJUHVVLRQ
'DWHRI'HDWK
(YHQW
'HDWKJUHDWHUWKDQGD\VIURPWKH
ODVWWXPRUDVVHVVPHQWZLWKRXWSULRU
SURJUHVVLRQ
'DWHRIODVWDGHTXDWHWXPRUDVVHVVPHQW
&HQVRUHG
5HFHLYHG137SULRUWRGLVHDVH
SURJUHVVLRQ
'DWHRIODVWDGHTXDWHDVVHVVPHQWSULRU
WR137
&HQVRUHG




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7KH.DSODQ0HLHUPHWKRGZLOOEHXVHGWRHVWLPDWHWKHGXUDWLRQRIUHVSRQVH7KH
FRQILGHQFHLQWHUYDOVIRUGXUDWLRQRIUHVSRQVHZLOODOVREHFDOFXODWHGIRUWKHSRROHGGHPFL]XPDE
DUPVDVZHOODVHDFKWUHDWPHQWDUP7KHSYDOXHIRUWUHDWPHQWHIIHFWSRROHGYHUVXVFRQWURODQG
HDFKGHPFL]XPDEDUPVYHUVXVFRQWUROZLOOEHJHQHUDWHGXVLQJDVWUDWLILHGORJUDQNWHVW$
VWUDWLILHG&R[SURSRUWLRQDOKD]DUGVUHJUHVVLRQPRGHOZLOOEHXVHGWRHVWLPDWHWKHKD]DUGUDWLRDQG
LWVFRQILGHQFHLQWHUYDOV7KHVWUDWLILFDWLRQIDFWRUVZLOOEHSHUIRUPDQFHVWDWXVRUDQG
UHJLRQ8QLWHG6WDWHV&DQDGDRU(XURSH$XVWUDOLDDQG&$±8/1!8/1±8/1
!8/1
2YHUDOO6XUYLYDO
$FRPSDULVRQRIWKHRYHUDOOVXUYLYDO26EHWZHHQWKHSRROHGGHPFL]XPDEDUPVDQGFRQWURODV
ZHOODVHDFKLQGLYLGXDOGHPFL]XPDEDUPYHUVXVFRQWUROZLOOEHSHUIRUPHG
7KHIROORZLQJDOJRULWKPZLOOEHDSSOLHGIRUWKHILQDOGHOLYHU\7KHGDWDFXWRIIGDWHLVWKHGDWH
ZKHQWKH7K3)6HYHQWKDSSHQV2YHUDOOVXUYLYDOLVGHILQHGDVWKHQXPEHURIGD\VIURP
UDQGRPL]DWLRQXQWLOGHDWKRFFXUVLIWKHGHDWKGDWHLVEHIRUHWKHGDWDFXWRIIGDWH6XEMHFWVZKR
GLHDIWHUWKHGDWDFXWRIIGDWHZLOOEHFHQVRUHGDWFXWRIIGDWH:KHQDVXEMHFWKDVDWOHDVWRQH
VXUYLYDOIROORZXSVKRZLQJDOLYHDIWHUGDWDFXWRIIGDWHWKLVVXEMHFWZLOOEHFHQVRUHGRQWKHGDWD
FXWRIIGDWH2WKHUZLVHWKHVXEMHFWZLOOEHFHQVRUHGDWWKHODVWDYDLODEOHYLVLWPHDVXUHPHQW
LQFOXGLQJVXUYLYDOIROORZXSZKLFKLVSULRUWRWKHFXWRIIGDWHDQGVKRZVWKHVXEMHFWLVDOLYH1R
WUHDWPHQWFURVVRYHULVSHUPLWWHGLQWKHVWXG\7KHFHQVRULQJUXOHVIRU26DUHLQFOXGHGLQ
7DEOH
7DEOH
&HQVRULQJ&RQYHQWLRQVIRU26
6LWXDWLRQ
'DWHRI3URJUHVVLRQRU&HQVRULQJ
2XWFRPH
'HDWKGXHWRDQ\FDXVHEHIRUHWKHGDWD
FXWRIIGDWH
'HDWK'DWH
(YHQW
'HDWKGXHWRDQ\FDXVHDIWHUWKHGDWD
FXWRIIGDWH
'DWDFXWRIIGDWH
&HQVRUHG
+DYHDWOHDVWRQHVXUYLYDOIROORZXS
VKRZLQJDOLYHDIWHUGDWDFXWRIIGDWH
'DWDFXWRIIGDWH
&HQVRUHG
1RQHRIWKHDERYHDSSO\
/DVWGDWHIURPRQVWXG\DQGVXUYLYDO
IROORZXSSHULRGVSULRUWRWKHGDWDFXWRII
WKDWVKRZVWKHVXEMHFWVLVDOLYH
&HQVRUHG
,QWKH26IROORZXSDQDO\VLVWKHFHQVRULQJUXOHVZLOOEHWKHVDPHH[FHSWWKDWWKHGDWDFXWRIIZLOO
EHDVVSHFLILHGLQWKHSURWRFRO




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7KH.DSODQ0HLHUPHWKRGZLOOEHXVHGWRHVWLPDWHERWKWKHVXUYLYDOFXUYHVDQGWKHPHGLDQ
VXUYLYDOWLPH7KHFRQILGHQFHLQWHUYDOIRUWKHPHGLDQVXUYLYDOWLPHZLOOEHFDOFXODWHG$
SYDOXHIRUWUHDWPHQWHIIHFWZLOODOVREHJHQHUDWHGXVLQJDVWUDWLILHGORJUDQNWHVW$VWUDWLILHG
&R[SURSRUWLRQDOKD]DUGVUHJUHVVLRQPRGHOZLOOEHXVHGWRHVWLPDWHWKHKD]DUGUDWLRDQGLWV
FRQILGHQFHLQWHUYDOV7KHVWUDWLILFDWLRQIDFWRUVZLOOEHSHUIRUPDQFHVWDWXVRUUHJLRQ
8QLWHG6WDWHV&DQDGDRU(XURSH$XVWUDOLDDQG&$±8/1!8/1±8/1
!8/17KHQXPEHUDQGSHUFHQWDJHRIWKHVHVXEMHFWVZKRDUHWUHDWHGDVDQHYHQWDQGDVD
FHQVRUZLOOEHGLVSOD\HG
7KH.DSODQ0HLHUHVWLPDWHVRIRYHUDOOVXUYLYDODWDQGPRQWKVZLOOEHFRPSDUHG
EHWZHHQWKHGHPFL]XPDEDUPV$UP$UPDQGFRQWURO$UPXVLQJDVLPSOH=WHVW
*UHHQZRRG¶VIRUPXODIRUWKHYDULDQFHRIWKHVXUYLYDOHVWLPDWHZLOOEHXVHGWRFRQVWUXFWWKH=
WHVW
.DSODQ0HLHUFXUYHVRI26ZLOOEHSORWWHGIRUHDFKLQGLYLGXDODUP$UPDQGE\
VWUDWLILFDWLRQIDFWRUVDQGRYHUDOO)RUWKHSRROHGDQDO\VLV.DSODQ0HLHUFXUYHVRI26IRUSRROHG
GHPFL]XPDEDUPSRROHG$UPDQG$UPDQG$UPZLOOEHSORWWHGE\VWUDWLILFDWLRQIDFWRUV
DQGRYHUDOO
3KDVH&RQWLQJHQF\3ODQ
7KLV3KDVHVWXG\KDVEHHQGHVLJQHGZLWKWKHDLPRIDVVLVWLQJWKHJRQRJRGHFLVLRQRIZKHWKHU
WRWDNHGHPFL]XPDELQWR3KDVHGHYHORSPHQW7DEOHSUHVHQWVWKHVWDWLVWLFDOSODQIRUWKLV
3KDVHWULDO7KLVWDEOHGLIIHUVVRPHZKDWIURPWKHSRZHUWDEOHSUHVHQWHGLQWKHSURWRFRO7KH
UHDVRQIRUWKLVLVWKDWWKHSURWRFROXVHGWKH2¶%ULHQ)OHPLQJVWRSSLQJERXQGDU\ZKLOH7DEOH
XVHVWKH2¶%ULHQ)OHPLQJVSHQGLQJIXQFWLRQWRFUHDWHWKHVWRSSLQJERXQGDU\8VLQJWKH2¶%ULHQ
)OHPLQJVSHQGLQJIXQFWLRQDVEHORZSURYLGHVIOH[LELOLW\LQWKHWLPLQJDQGLQWKHQXPEHURI
LQWHULPDQDO\VHVWKDWDUHFRQGXFWHG7DEOHEHORZVXSHUVHGHVWKHFRUUHVSRQGLQJWDEOHLQWKH
SURWRFRO
7DEOH
6XPPDU\RI3RZHUDQG7\SH(UURUIRU3KDVH6WXG\

,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV



=6WDWLVWLFUHMHFWWKHQXOO



=VWDWLVWLFUHMHFWWKH$OW



+D]DUG5DWLRUHMHFWWKHQXOO



+D]DUG5DWLRUHMHFWWKHDOW



&XPXODWLYH3RZHU



&XPXODWLYH7\SH(UURUVLGHG



&XPXODWLYH3URERI6WRSSLQJIRU)XWLOLW\$OW



&XPXODWLYH3URERI6WRSSLQJIRU)XWLOLW\1XOO







,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
,IWKHUHVXOWVIURPWKHDERYHSODQQHGDQDO\VHVRIRYHUDOOVXUYLYDODUHSURPLVLQJLQWKDWWKH\DUH
HLWKHUKLJKO\VWDWLVWLFDOO\VLJQLILFDQWRUWKH3KDVHHIILFDF\ERXQGDU\GHVFULEHGDERYHLVFURVVHG
7DEOHSUHVHQWVDQDSULRULGHWHUPLQHGFRQWLQJHQF\SODQZKLFKGHVFULEHVKRZWKHVH3KDVH
UHVXOWVZLOOEHFRQVLGHUHGIRUWKHSXUSRVHVRIDVVHPEOLQJ3KDVHHYLGHQFHRIHIIHFWLYHQHVV6HH
$SSHQGL[&IRUGHWDLOVRIWKHFDOFXODWLRQV
,QWKLVFRQWLQJHQF\SODQWKH3KDVHWULDOGHVFULEHGDERYHLVHPEHGGHGLQWRD3KDVHWULDORI
DSSUR[LPDWHO\VXEMHFWV7KH263KDVHHIILFDF\ERXQGDU\SUHVHQWHGLQ7DEOHDVVXPHV
WKHUROHRIDQH[SDQVLRQJDWHLQWKH3KDVHWULDOLQWKDWWKH3KDVHWULDOZLOOQRWEHH[WHQGHGWRD
3KDVHVL]HGWULDOXQOHVVWKH263KDVHHIILFDF\ERXQGDU\LQ7DEOHLVFURVVHG7KH263KDVH
HIILFDF\ERXQGDU\DSSHDUVLQ7DEOHLQWKHURZWLWOHG=6WDWLVWLFH[SDQGWKHWULDOZKHUHWKH=
VWDWLVWLFVDW,QWHULPVDQGDUHWKHVDPHDVWKH263KDVHHIILFDF\ERXQGDU\LQ7DEOH
6LQFHWKHHIILFDF\ERXQGDU\LQ7DEOHLVDVVXPLQJWKHUROHRIDQH[SDQVLRQJDWHLQ7DEOHWKH
WHVWLQJDVVRFLDWHGZLWKWKH3KDVH26HIILFDF\ERXQGDU\GRHVQRWFRQWULEXWHWRW\SHHUURUIRU
WKHSXUSRVHRIDVVHVVLQJWKHHIILFDF\RIGHPFL]XPDERQRYHUDOOVXUYLYDOZLWK3KDVHVWULQJHQF\
DWWKHRQHVLGHGOHYHORIVLJQLILFDQFH
,IDWLQWHULPWKH=VWDWLVWLFIRUFRPSDULQJWKHKD]DUGRIGHDWKRQGHPFL]XPDEYHUVXVFRQWURO
H[FHHGVKU WKHQWKHUHVXOWZLOOVXSSRUWWKHFODLPWKDWGHPFL]XPDESURORQJV
VXUYLYDO6LPLODUO\LIWKH=VWDWLVWLFH[FHHGKU RUKU UHVSHFWLYHO\DW
,QWHULPRU,QWHULPWKHQWKHUHVXOWZLOOVXSSRUWWKHFODLPWKDWGHPFL]XPDESURORQJVVXUYLYDO
,IDW,QWHULPRUWKH=VWDWLVWLFH[FHHGVRUUHVSHFWLYHO\EXWGRHVQRW
H[FHHGDQGWKHQWKHWULDOZLOOEHH[WHQGHGWRKDYHWKUHHPRUHDQDO\VHVDW
DQGHYHQWVDQGWKHILQDODQDO\VLVDWHYHQWV7KHILUVWDGGLWLRQDODQDO\VLVEH\RQGZKDWLV
SODQQHGIRULQWKH3KDVHWULDODWGHDWKVPD\EHDFFRPSOLVKHGE\VLPSO\FRQWLQXLQJWR
IROORZSDWLHQWVZKRKDYHDOUHDG\EHHQHQUROOHGLQWKH3KDVHWULDO,IWKHKULVOHVVWKDQDW
WKHIRXUWKDQDO\VLVRIVXUYLYDOWKHQWKHUHVXOWVZLOOVXSSRUWDFODLPRI26HIIHFWLYHQHVV7KH
UHPDLQLQJDQDO\VHVZLOOQHFHVVDULO\LQYROYHHQUROOLQJPRUHSDWLHQWV,IDWLQWHULPWKH=VWDWLVWLF
LVJUHDWHUWKDQKU RUWKH=VWDWLVWLFDWWKHILQDODQDO\VLVLVJUHDWHUWKDQ
KU WKHQWKHUHVXOWZLOODOVRVXSSRUWWKHFODLPWKDWGHPFL]XPDESURORQJVVXUYLYDO
1RWHWKDWRQFHWKH3KDVHHIILFDF\ERXQGDU\LVFURVVHGDQGHQUROOPHQWLQWKHWULDOKDVUHVWDUWHG
WKHUHPDLQLQJDQDO\VHVIURP,QWHULPWKURXJK,QWHULPPD\RUPD\QRWEHFRQGXFWHG7KH
FRQWURORIW\SHHUURUIRUWKH3KDVHHIILFDF\ERXQGDU\XVLQJWKHUKRIDPLO\RIVSHQGLQJ
IXQFWLRQVZLWKSDUDPHWHU SHUPLWVIOH[LELOLW\LQWKHQXPEHUDQGWLPLQJRILQWHULPDQDO\VHVLQ
WKLVWULDO
8QGHUWKLVFRQWLQJHQF\SODQWKHUHLVSHUFHQWSRZHUWRGHWHFWDKD]DUGUDWLRRI1RWHWKDW
WKHILQDODQDO\VLVRIWKHH[WHQGHGWULDOZRXOGQRUPDOO\EHODUJHHQRXJKWRGHWHFWDKD]DUGUDWLRRI
ZLWKSHUFHQWSRZHUDQGW\SHHUURU7KHGLIIHUHQFHLVGXHWRWKHHIILFDF\
ERXQGDU\H[SDQVLRQERXQGDU\IURPWKH3KDVHWULDO&RUUHVSRQGLQJZLWKWKHUHGXFHGSRZHULV
DUHGXFWLRQLQWKHW\SHHUURU7KHWUXHW\SHHUURULQWKLVFRQWLQJHQF\GHVLJQLVRQH
VLGHGLQVWHDGRIWKHQRPLQDO




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
6XPPDU\RI3RZHUDQG7\SH(UURUIRU3KDVHDQG([WHQGHG3KDVH6WXGLHV

&XUUHQWO\3ODQQHG3KDVH26$QDO\VHV
$GGLWLRQDO
26$QDO\VLV
WR6XSSRUW
([WHQGHG
)ROORZXSRI
3KDVH
3DWLHQWV
26$QDO\VHVLQWKH3KDVH
([SDQVLRQ

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO
$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFH[SDQGWKHWULDO






=VWDWLVWLFIXWLOLW\






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRH[SDQGWKHWULDO






+D]DUG5DWLRIXWLOLW\






1RQ%LQGLQJ([SDQVLRQDQG)XWLOLW\
%RXQGDULHV

&XPXODWLYH3RZHU+5 

H
H
H


&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






%LQGLQJ([SDQVLRQDQG)XWLOLW\
%RXQGDULHV

&XPXODWLYH3RZHU+5 

H
H



&XPXODWLYH3RZHU+5 











,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
6XPPDU\RI3RZHUDQG7\SH(UURUIRU3KDVHDQG([WHQGHG3KDVH6WXGLHV&RQ¶W

&XUUHQWO\3ODQQHG3KDVH26$QDO\VHV
$GGLWLRQDO
26$QDO\VLV
WR6XSSRUW
([WHQGHG
)ROORZXSRI
3KDVH
3DWLHQWV
26$QDO\VHVLQWKH3KDVH
([SDQVLRQ

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






 ,QWHULPZLOORFFXUZKHQWKHWK3)6HYHQWRFFXUVLQWHULPVDQGZLOORFFXUEDVHGRQDGDWDFXWRIIGDWHRI-XQHVWDQG1RYHPEHUVW
UHVSHFWLYHO\,QWHULPVDQGDQGWKHILQDODQDO\VLVZLOORFFXUZKHQDQG26HYHQWVKDYHRFFXUUHGUHVSHFWLYHO\ 
 7KHHIILFDF\ERXQGDU\WKDWPXVWEHFURVVHGWRDVVHUWWKDWWKHQXOOK\SRWKHVLVRIQRWUHDWPHQWHIIHFWKDVEHHQUHMHFWHGDWWKHRQHVLGHGOHYHORI
VLJQLILFDQFH7KHERXQGDU\LVGHWHUPLQHGIURPWKHUKRIDPLO\RIVSHQGLQJIXQFWLRQVZLWKSDUDPHWHUHTXDOWR
 7KHHIILFDF\ERXQGDU\WKDWPXVWEHFURVVHGLQRUGHUIRUWKHQXOOK\SRWKHVLVRIQRWUHDWPHQWHIIHFWWREHUHMHFWHGDWWKHRQHVLGHGOHYHORI
VLJQLILFDQFHDQGIRUWKHWULDOWREHH[SDQGHGDVUHSUHVHQWHGLQLQWHULPLQWHULPDQGWKHILQDODQDO\VLV7KLVERXQGDU\ZDVVSHFLILHGLQWKH3KDVH
<RVHPLWHSURWRFRO0EDVHGRQDQ2¶%ULHQ)OHPLQJJURXSVHTXHQWLDOERXQGDU\DQGKDVEHHQDGMXVWHGKHUHWRUHIOHFWDQ2¶%ULHQ)OHPLQJ
VSHQGLQJIXQFWLRQ7KHSUHVHQWDWLRQRIWKH3KDVHHIILFDF\ERXQGDU\KHUHDVEDVHGRQWKH2¶%ULHQ)OHPLQJVSHQGLQJIXQFWLRQVXSHUVHGHVWKH
GHVFULSWLRQRIWKHERXQGDU\LQWKHSURWRFRO
 7KHERXQGDU\ZKLFKLIFURVVHGZLOOUHVXOWLQWKHWULDOEHLQJVWRSSHGIRUIXWLOLW\





,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
3DJHRI
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5

7XPRU$VVHVVPHQW
5DGLRJUDSKLFHYDOXDWLRQIRUWDUJHWOHVLRQVQRQWDUJHWOHVLRQVQHZOHVLRQVDQGQRWWDUJHWOHVLRQ
WUHDWPHQWGDWDZLOOEHSUHVHQWHGLQOLVWLQJV
2WKHUWKDQWKHHIILFDF\WDEOHVIRU3)6RYHUDOOVXUYLYDODQGWXPRUDVVHVVPHQWZLOOEHDOVR
SUHVHQWHGLQDOLVWLQJ
([SORUDWRU\(QGSRLQWV
%LRPDUNHUDQGSKDUPDFRJHQRPLFVEORRGVDPSOHVZLOOEHSUHVHQWHGDVDOLVWLQJ
))3(7LVVXH6DPSOHDQG7XPRU0DUNHU&$
))3(WLVVXHVDPSOHZLOOEHWDEXODWHGE\DUFKLYDOWLVVXHVXPPLWVWDWXVDUFKLYDOWLVVXHVWDJHRIWKH
GLVHDVHDQGDQDWRPLFDOORFDWLRQ
7XPRU0DUNHU&$ZLOOEHVXPPDUL]HGE\WUHDWPHQWDUPDQGYLVLWXVLQJGHVFULSWLYH
VWDWLVWLFVRIWKHUHSRUWHGYDOXHVDQGFKDQJHIURPEDVHOLQHYDOXHV%R[SORWRI7XPRU0DUNHU&$
RYHUWLPHZLOOEHDOVRSUHVHQWHG
%RWK))3(WLVVXHVDPSOHDQG7XPRU0DUNHU&$ZLOOEHSUHVHQWHGLQOLVWLQJV
6HQVLWLYLW\$QDO\VLV

6HQVLWLYLW\DQDO\VHVZLOOEHSHUIRUPHGWRDVVHVVWKHLPSDFWRI137IRU3)6EHWZHHQWUHDWPHQW
DUPV$UPWR$UPDQG$UPWR$UP7KHFHQVRULQJUXOHLVWKHVDPHDVWKHSULPDU\
HQGSRLQWDQDO\VLVGHVFULEHGLQ6HFWLRQH[FHSWIRUWKHFRQVLGHUDWLRQRI137,QWKLV
VHQVLWLYLW\DQDO\VLVZHGRQRWFRQVLGHU137DWDOO,QRWKHUZRUGV3'VWKDWKDSSHQHGDIWHU137
ZLOOVWLOOEHFRXQWHGDVHYHQWV
6DIHW\$QDO\VLV
6DIHW\HQGSRLQWVZLOOEHDQDO\]HGE\WUHDWPHQWDUPXVLQJWKH6DIHW\3RSXODWLRQ
 $GYHUVH(YHQWV
$(VZLOOEHFRGHGLQDFFRUGDQFHZLWKWKH0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
0HG'5$7R[LFLW\JUDGHZLOOEHGHILQHGDFFRUGLQJWRWKH1DWLRQDO&DQFHU,QVWLWXWH
1&,&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(Y
$QDGYHUVHHYHQW$(LVDQ\XQWRZDUGRUXQIDYRUDEOHPHGLFDORFFXUUHQFHLQDKXPDQVXEMHFW
LQFOXGLQJDQ\DEQRUPDOVLJQIRUH[DPSOHDEQRUPDOSK\VLFDOH[DPRUODERUDWRU\ILQGLQJ
V\PSWRPRUGLVHDVHWHPSRUDOO\DVVRFLDWHGZLWKWKHVXEMHFW¶VSDUWLFLSDWLRQLQWKHUHVHDUFK




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
3DJHRI
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
ZKHWKHURUQRWFRQVLGHUHGUHODWHGWRWKHVXEMHFW¶VSDUWLFLSDWLRQLQWKHUHVHDUFK$Q\PHGLFDO
FRQGLWLRQRUFOLQLFDOO\VLJQLILFDQWODERUDWRU\DEQRUPDOLW\ZLWKDQRQVHWGDWHEHIRUH
UDQGRPL]DWLRQLVDSUHH[LVWLQJFRQGLWLRQWKDWPXVWEHOLVWHGRQWKH0HGLFDO+LVWRU\&DVH5HSRUW
)RUP&5)DQGVKRXOGQRWEHFRQVLGHUHGDQ$(XQOHVVWKHFRQGLWLRQZRUVHQVLQLQWHQVLW\RU
IUHTXHQF\DIWHUILUVWVWXG\GUXJLQIXVLRQ$WUHDWPHQWHPHUJHQW$(7($(LVGHILQHGDVDQ\
HYHQWSUHVHQWIURPWKHWLPHRIUDQGRPL]DWLRQWKURXJKGD\VDIWHUWKHWHUPLQDWLRQYLVLWZKLFK
PXVWEHGRFXPHQWHGLQWKHPHGLFDOUHFRUGDQGUHSRUWHGRQWKH$(&5)
$GUXJUHODWHG$(LVDQHYHQWZKHUHWKHLQYHVWLJDWRULQGLFDWHGWKDWWKHUHODWLRQVKLSWRVWXG\GUXJ
ZDV³UHODWHG´RU³1RWUHODWHG´)RUVXPPDULHVE\UHODWLRQVKLSDGYHUVHHYHQWVZLWKPLVVLQJ
UHODWLRQVKLSDUHFRXQWHGDV³5HODWHG´)RUVXPPDULHVE\&7&$(JUDGHDGYHUVHHYHQWVZLWK
PLVVLQJ&7&$(JUDGHDUHFRXQWHGDV&7&$(JUDGH±6HYHUH
$OOUHSRUWHG$(VZLOOEHPDSSHGWRVWDQGDUG0HG'5$FRGLQJWHUPVJURXSHGE\V\VWHPRUJDQ
FODVV62&DQGSUHIHUUHGWHUP37DQGWDEXODWHGE\WUHDWPHQWDUP7KHLQFLGHQFHRI$(VLQ
HDFKWUHDWPHQWDUPZLOOEHWDEXODWHGE\VHULRXVQHVVVHYHULW\DQGUHODWLRQVKLSWRVWXG\GUXJ
2YHUDOOVXPPDU\RI7($(VIRUQXPEHURIVXEMHFWVZLWKDQ\7($(VVHULRXV7($(V
'HPFL]XPDE3ODFHERUHODWHG7($(V$EUD[DQHUHODWHG7($(V*HPFLWDELQHUHODWHG7($(V
7($(VOHDGLQJWRVWXG\WUHDWPHQWGLVFRQWLQXDWLRQ7($(VOHDGLQJWRGHDWK7($(VZLWK
&7&$(JUDGHRUKLJKHUDQG'HPFL]XPDE3ODFHERUHODWHG7($(VZLWK&7&$(JUDGHRU
KLJKHUZLOOEHWDEXODWHGE\WUHDWPHQWDUP6XPPDU\RISXOPRQDU\K\SHUWHQVLRQKHDUWIDLOXUH
DQGEOHHGLQJHYHQWVZLOOEHWDEXODWHGLQFOXGLQJ&7&$(JUDGHVDQGUHODWLRQVKLSWRWKHGUXJV
7KHIUHTXHQF\DQGSHUFHQWDJHRISDWLHQWVZLWK7($(VZLOOEHWDEXODWHGE\RYHUDOOLQFLGHQFH
%\62&DQG37
%\62&DQG37IRUGUXJUHODWHG7($(V
%\62&DQG37ZLWK&7&$(JUDGHRUKLJKHU
%\62&DQG37IRUGUXJUHODWHG7($(VZLWK&7&$(JUDGHRUKLJKHU
%\62&DQG37IRUVHULRXV7($(V
%\62&DQG37IRUGUXJUHODWHGVHULRXV7($(V
%\62&DQG37IRU7($(VUHVXOWLQJLQVWXG\GLVFRQWLQXDWLRQ
%\62&DQG37IRUGUXJUHODWHG7($(VUHVXOWLQJLQ'HDWK
%\GHVFHQGLQJRUGHURIIUHTXHQF\IRU37DQGRYHUDOO
%\GHVFHQGLQJRUGHURIIUHTXHQF\IRU37DQGRYHUDOOIRUUHODWHG7($(V




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5

$E\SDWLHQWOLVWLQJRIWUHDWPHQWHPHUJHQW$(VUHVXOWLQJLQGLVFRQWLQXDWLRQRIVWXG\GUXJZLOOEH
SUHVHQWHG$(VDQG6$(VZLOOEHDOVROLVWHG

&7&$(*UDGHRUKLJKHUKHDUWIDLOXUHSXOPRQDU\K\SHUWHQVLRQRUEOHHGLQJHYHQWV$(VZLOOEH
DOVROLVWHG
)RUWKHSXUSRVHRIFDOFXODWLQJWUHDWPHQWHPHUJHQFHDQGLQFOXVLRQLQVXPPDU\WDEOHVLQFRPSOHWH
RQVHWGDWHVZLOOEHLPSXWHGDVGHWDLOHGLQ$SSHQGL[%
'HDWK
7RWDOQXPEHURIGHDWKVDQGUHDVRQVRIGHDWKVZLOOEHVXPPDUL]HGLQDWDEOHXVLQJWKHVDIHW\
SRSXODWLRQ)XUWKHUPRUHDOOVXEMHFWGHDWKVGXULQJWKLVVWXG\ZLOOEHSUHVHQWHGLQDOLVWLQJ7KH
OLVWLQJZLOOSURYLGHDOOUHOHYDQW&5)GDWDSHUWDLQLQJWRHDFKVXEMHFWGHDWK
&OLQLFDO/DERUDWRU\(YDOXDWLRQV
$OOFOLQLFDOODERUDWRU\DVVHVVPHQWVZLOOEHSHUIRUPHGXVLQJWKHVLWH¶VORFDOODERUDWRU\ZLWKWKH
H[FHSWLRQRI%13ZKLFKZLOOEHDVVHVVHGXVLQJWKH$OHUH%13PHWHU,IXQLWLVPLVVLQJIRU
ODERUDWRU\DVVHVVPHQWVWKHQWKHDVVHVVPHQWVZLOOQRWEHVXPPDUL]HGLQWDEOHV
+HPDWRORJ\
$FRPSOHWHEORRGFRXQW&%&LQFOXGHVKHPRJORELQKHPDWRFULWUHGEORRGFHOOZKLWHEORRG
FHOOQHXWURSKLOVO\PSKRF\WHVHRVLQRSKLOVPRQRF\WHVEDVRSKLOVZLWKGLIIHUHQWLDODQGSODWHOHW
FRXQWZLOOEHREWDLQHGDWHDFKSURWRFROVSHFLILHGYLVLWDQGDQ,QWHUQDWLRQDO1RUPDOL]HG5DWLR
,15DQG$FWLYDWHGSDUWLDOWKURPESODVWLQWLPHD377ZLOOEHREWDLQHGDWEDVHOLQH
6HUXP&KHPLVWU\
6HUXPFKHPLVWULHVLQFOXGLQJDOEXPLQDONDOLQHSKRVSKDWDVHWRWDOELOLUXELQELFDUERQDWHEORRG
XUHDQLWURJHQ>%81@FDOFLXPFKORULGHFUHDWLQLQHJOXFRVHODFWLFGHK\GURJHQDVH>/'+@
SKRVSKRUXVSRWDVVLXPWRWDOSURWHLQDVSDUWDWHDPLQRWUDQVIHUDVHVHUXPJOXWDPLFR[DORDFHWLF
WUDQVDPLQDVH$67>6*27@DODQLQHDPLQRWUDQVIHUDVHVHUXPJOXWDPLFS\UXYLFWUDQVDPLQDVH
$/7>6*37@VRGLXPZLOOEHREWDLQHGDWHDFKSURWRFROVSHFLILHGYLVLW
8ULQDO\VLV
8ULQDO\VLVZLWKPLFURVFRSLFDQDO\VLVZLOOEHREWDLQHGGXULQJVFUHHQLQJDQGDWWKHWLPHRIWKH
WHUPLQDWLRQYLVLW
%13$VVHVVPHQW




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
%13ZLOOEHDVVHVVHGGXULQJ6FUHHQLQJDQGWKHQHYHU\GD\VZKLOHRQWUHDWPHQWDQGDWWKH
WLPHRIWKHWHUPLQDWLRQYLVLW
&OLQLFDOODERUDWRU\GDWDKHPDWRORJ\VHUXPFKHPLVWU\DQGXULQDO\VLVZLOOEHVXPPDUL]HGE\
WUHDWPHQWDUPXVLQJGHVFULSWLYHVWDWLVWLFVRIWKHUHSRUWHGYDOXHV&KDQJHIURPEDVHOLQHYDOXHV
IRUQXPHULFDVVHVVPHQWVDWWKHSRLQWRIHDFKVXEMHFW¶VPLQLPXPSRVWEDVHOLQHPD[LPXPSRVW
EDVHOLQHDQGWKHODVWDYDLODEOHPHDVXUHPHQWLQVHUXPFKHPLVWU\DQGKHPDWRORJ\GDWDZLOOEH
WDEXODWHG$OOODERUDWRU\WHVWVZKLFKKDYHDVVRFLDWHG&7&$(JUDGHVZLOOEHVXPPDUL]HGDVVKLIW
WDEOHVRIWKHFKDQJHLQ1&,&7&IURPEDVHOLQHWDEOHVWRWKHSRVWEDVHOLQHZRUVW&7&JUDGH
7ZRVLGHG&7&$(JUDGDEOHWHVWVLQFOXGLQJ&DOFLXP*OXFRVH3RWDVVLXPDQG6RGLXPZLOOEH
VXPPDUL]HGLQWKHSRVWEDVHOLQHZRUVWKLJKDQGORZ&7&JUDGH
+LJKRQHVLGHG&7&$(JUDGDEOHWHVWVLQFOXGLQJ$ONDOLQHSKRVSKDWDVH$ODQLQH
$PLQRWUDQVIHUDVH$VSDUWDWH$PLQRWUDQVIHUDVH%LOLUXELQ&UHDWLQLQHZLOOEHVXPPDUL]HGLQWKH
SRVWEDVHOLQHZRUVWKLJK&7&JUDGH
/RZRQHVLGHG&7&$(JUDGDEOHWHVWVLQFOXGLQJ$OEXPLQ1HXWURSKLOV3KRVSKRUXV3ODWHOHWV
:KLWH%ORRG&HOO/\PSKRF\WHVDQG+HPRJORELQZLOOEHVXPPDUL]HGLQWKHSRVWEDVHOLQHZRUVW
ORZ&7&JUDGH
%13$VVHVVPHQWZLOOEHVXPPDUL]HGE\WUHDWPHQWDUPDQGYLVLW$OOODERUDWRU\WHVWVLQ
FKHPLVWU\KHPDWRORJ\XULQDO\VLVFRDJXODWLRQDQG%13DVVHVVPHQWZLOOEHSUHVHQWHGLQIRXU
GDWDOLVWLQJVUHVSHFWLYHO\/LVWLQJIRU$&(,QKLELWRURU&DUYHGLOROIRU%13,QFUHDVHZLOOEHDOVR
SUHVHQWHG
%R[SORWVIRUFKHPLVWU\KHPDWRORJ\DQG%13ZLOOEHSUHVHQWHG0HDQZKLOHVFDWWHUSORWRI
EDVHOLQHYHUVXVZRUVWSRVWEDVHOLQHLQFKHPLVWU\DQGKHPDWRORJ\GDWDZLOOEHDOVRJUDSKHG
9LWDO6LJQV0HDVXUHPHQWV
%ORRGSUHVVXUHVKRXOGEHPHDVXUHGZLWKWKHVXEMHFWLQWKHVDPHSRVLWLRQDWHDFKVWXG\YLVLW7KH
VDPHFXIIPHWKRGVKRXOGEHXVHGWRPHDVXUHEORRGSUHVVXUH%3WKURXJKRXWWKHVWXG\
9LWDOVLJQVGLDVWROLFEORRGSUHVVXUHPP+JDQGV\VWROLFEORRGSUHVVXUHPP+JZLOOEH
VXPPDUL]HGE\WUHDWPHQWDUPXVLQJGHVFULSWLYHVWDWLVWLFVRIWKHUHSRUWHGYDOXHVDWHDFKYLVLW
3XOVHUDWHEHDWVPLQUHVSLUDWRU\UDWHEUHDWKVPLQDQGWHPSHUDWXUHZLOOEHVXPPDUL]HGDWWKH
SRLQWRIHDFKVXEMHFW¶VPLQLPXPSRVWEDVHOLQHPD[LPXPSRVWEDVHOLQHDQGWKHODVWDYDLODEOH
PHDVXUHPHQWLQ6DIHW\3RSXODWLRQ
7KHYLWDOVLJQGDWDZLOOEHSUHVHQWHGLQDOLVWLQJ




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
(&2*
(&2*SHUIRUPDQFHVWDWXVZLOOEHOLVWHGDQGVXPPDUL]HGIRUHDFKWUHDWPHQWDUP(&2*
SHUIRUPDQFHVWDWXVVFRUHVVKLIWIURPEDVHOLQHWRZRUVWDQGVKLIWIURPEDVHOLQHWRODVWZLOOEH
VXPPDUL]HGE\WUHDWPHQWJURXSDWVHOHFWHGVFKHGXOHGWLPHSRLQWV
3K\VLFDO([DPLQDWLRQ
$IXOOSK\VLFDOH[DPLQDWLRQZLOOEHGRQHDWVFUHHQLQJ6XEVHTXHQWO\DQDEEUHYLDWHGSK\VLFDO
H[DPLQDWLRQZLOOSHUIRUPHGDW'D\HYHU\ZHHNVZKLOHRQWUHDWPHQWDQGDWWKHWHUPLQDWLRQ
YLVLW
$VXPPDU\RISK\VLFDOH[DPLQDWLRQUHVXOWVDWVFUHHQLQJDQGRQVWXG\ZLOOEHSURYLGHGLQWZR
VHSDUDWHGWDEOHV,QGLYLGXDOUHVXOWVZLOOEHSUHVHQWHGLQDOLVWLQJ
(OHFWURFDUGLRJUDP(&*
6XPPDULHVRIGHVFULSWLYHVWDWLVWLFVRIWKHUHSRUWHGYDOXHVDQGFKDQJHIURPEDVHOLQHYDOXHVZLOO
EHFDOFXODWHGIRUOHDG(&*VSDUDPHWHUV35LQWHUYDO456GXUDWLRQDQG47FLQWHUYDOLQ
6DIHW\3RSXODWLRQ7KHVHVXPPDULHVZLOOEHSUHVHQWHGE\YLVLWDQGWUHDWPHQWDUP7UDQVWKRUDFLF
'RSSOHUHFKRFDUGLRJUDPYDOXHVZLOOEHVXPPDUL]HGE\YLVLWDQGWUHDWPHQWDUP3XOPRQDU\
K\SHUWHQVLRQZLOOEHWDEXODWHGZLWKIUHTXHQF\DQGSHUFHQWDJH
7KHOHDG(&*UHVXOWVZLOOEHSUHVHQWHGLQDOLVWLQJ(&*VKLIWWDEOH7UDQVWKRUDFLF'RSSOHU
HFKRFDUGLRJUDPDQGSXOPRQDU\K\SHUWHQVLRQZLOOEHDOVRSUHVHQWHGLQVHSDUDWHGOLVWLQJV
&RORQRVFRS\DQG8SSHU*DVWURLQWHVWLQDO(QGRVFRS\
&RORQRVFRS\DQG8SSHU*DVWURLQWHVWLQDO(QGRVFRS\GDWDIURPVFUHHQLQJWHVWVZLOOEHSUHVHQWHG
LQDOLVWLQJ
+HDG&705,6FDQ
+HDGFRPSXWHGWRPRJUDSK\&7PDJQHWLFUHVRQDQFHLPDJLQJ05,VFDQGDWDZLOOEH
SUHVHQWHGLQDOLVWLQJ
6HUXP3UHJQDQF\7HVW
6HUXPSUHJQDQF\WHVWUHVXOWVZLOOEHSUHVHQWHGLQDOLVWLQJ
3KDUPDFRNLQHWLFV
3ODVPDVDPSOHIRU3.DQDO\VLVWREHREWDLQHGSULRUWRWKHGHPFL]XPDELQIXVLRQRQ'D\V
DQGDQGDWWKHHQGRIWKHGHPFL]XPDELQIXVLRQSULRUWRFKHPR
LQIXVLRQRQ'D\VDQGDQGDWWHUPLQDWLRQYLVLW




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
3KDUPDFRNLQHWLFVZLOOEHDQDO\]HGXVLQJWKH3.SRSXODWLRQZKLFKLVFRPSULVHGRIDOOSDWLHQWV
ZKRUHFHLYHDWOHDVWRQHSDUWLDORUFRPSOHWHGRVHRIGHPFL]XPDEDQGZKRKDYHVXIILFLHQW
PHDVXUDEOHFRQFHQWUDWLRQVDVGHILQHGE\WKH3.VSHFLDOLVWWRFDOFXODWHWKH3.SDUDPHWHUV
3DWLHQWVZLWKSURWRFROYLRODWLRQVZLOOEHDVVHVVHGRQDSDWLHQWE\SDWLHQWEDVLVIRULQFOXVLRQLQWKH
3.3RSXODWLRQ
7KHSODVPDFRQFHQWUDWLRQVZLOOEHOLVWHGE\SDWLHQWDQGE\7LPH3RLQW3ODVPDFRQFHQWUDWLRQV
ZLOODOVREHVXPPDUL]HGE\7LPH3RLQWLH'D\DQGSUHRUSRVWGRVHXVLQJQRPLQDOWLPH
SRLQWVZLWKWKHIROORZLQJGHVFULSWLYHVWDWLVWLFVQDULWKPHWLFPHDQ6'FRHIILFLHQWRIYDULDWLRQ
&9PLQLPXPPHGLDQDQGPD[LPXP
,PPXQRJHQLFLW\
,PPXQRJHQLFLW\HQGSRLQWVZLOOEHDQDO\]HGXVLQJWKH,77SRSXODWLRQ$'$DQWLGUXJ
DQWLERGLHVRUDQWL2030DQWLERGLHVIRUPDWLRQZLOOEHUHSRUWHGLQVFUHHQLQJDQG
FRQILUPDWRU\DVVD\V6DPSOHVZLWKFRQILUPHG$'$IRUPDWLRQZLOOKDYHHQGSRLQWWLWHUV(37
UHSRUWHG6DPSOHVZLWKFRQILUPHG$'$IRUPDWLRQZLOODOVREHDVVHVVHGIRUIRUPDWLRQRI
QHXWUDOL]LQJDQWLERGLHV1$ELQVFUHHQLQJFRQILUPDWRU\DQG(37DVVD\V
'HILQLWLRQRIYDULDEOHV
x ,QFLGHQFHRI$'$DVXEMHFWLVLGHQWLILHGDV$'$SRVLWLYHLIWKHVXEMHFWKDVDQ\SRVW
GRVH VDPSOH FRQILUPHG SRVLWLYH IRU $'$ WKH LQFLGHQFH RI $'$ LV WKH QXPEHU RI
$'$SRVLWLYHVXEMHFWVLQDUHOHYDQWDQDO\VLVFRKRUWHJGRVHFRKRUW
x ,QFLGHQFHRI1$ELIDSSOLFDEOHDVXEMHFWLVLGHQWLILHGDV1$ESRVLWLYHLIWKHVXEMHFW
KDVDQ\SRVWGRVHVDPSOHFRQILUPHGSRVLWLYHIRU1$EWKHLQFLGHQFHRI 1$ELVWKH
QXPEHURI1$ESRVLWLYHVXEMHFWVLQDUHOHYDQWDQDO\VLVFRKRUWHJGRVHFRKRUW
'DWD6DIHW\0RQLWRULQJ%RDUG5HYLHZ
'DWD6DIHW\0RQLWRULQJ%RDUG'60%5HYLHZPHHWLQJVDUHFRQGXFWHGRQDTXDUWHUO\EDVLV
,QWHULP$QDO\VLV
'XULQJWKHWULDOWKHSURSRUWLRQRIVXEMHFWVGHYHORSLQJ*UDGHKHDUWIDLOXUHRUSXOPRQDU\
K\SHUWHQVLRQZLOOEHFORVHO\PRQLWRUHGE\WKH'60%RQDQRQJRLQJEDVLV,QDGGLWLRQWRWKH
RQJRLQJUHYLHZRIVDIHW\GDWDE\WKH'60%RQHIRUPDOMRLQWLQWHULPVDIHW\DQDO\VLVRIWKH
*UDGH!KHDUWIDLOXUHDQG*UDGH!SXOPRQDU\K\SHUWHQVLRQGDWDIURPWKLVWULDODQGWKHRQJRLQJ
FRPSDQLRQWULDOLQVWOLQHSDQFUHDWLFFDQFHUZLOORFFXUDIWHUGHPFL]XPDEWUHDWHGVXEMHFWV
EHWZHHQWKHWZRVWXGLHVKDYHFRPSOHWHGDPLQLPXPRIWUHDWPHQWF\FOHVDQGWKHODVWRIWKHVH
GHPFL]XPDEVXEMHFWVKDVEHHQIROORZHGIRUGD\V+HUHLVWKHGHWDLO
)RUWKH2QFR0HG0VWXG\SDWLHQWVZLOOEHLQFOXGHGLIWKH\UHFHLYHGDWOHDVWGRVHVRI
GHPFL]XPDESODFHERDWDQ\WLPHDQGIRUWKH2QFR0HG0VWXG\SDWLHQWVKDYHUHFHLYHGDW
OHDVWGRVHVRIGHPFL]XPDESODFHERDWDQ\WLPH




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
$1'
3DWLHQWVKDYHDWOHDVWGD\VRI$(IROORZXSIURP'D\7KLVFDQEHDFFRPSOLVKHGE\HLWKHU
EHLQJRQWKHFRUUHVSRQGLQJVWXG\IRUDWOHDVWGD\VRUEHLQJRQVWXG\IRUGD\SOXV
KDYLQJEHHQRXWIDUHQRXJKLQWKHLUSRVWWUHDWPHQWWHUPLQDWLRQ$(IROORZXSWKDWGD\VIRU
$(GDWDDUHDYDLODEOH
)ROORZLQJUHYLHZRIWKHVHGDWDWKH'60%ZLOOLQIRUP2QFR0HGLQZULWLQJZKHWKHUWKH
LQFLGHQFHRI!*UDGHKHDUWIDLOXUHDQGWKHLQFLGHQFHRI!*UDGHSXOPRQDU\K\SHUWHQVLRQLQ
WKHGHPFL]XPDEWUHDWHGVXEMHFWVLVOHVVWKDQRUJUHDWHUWKDQRUHTXDOWRDERYHWKHLQFLGHQFH
LQWKHFRQWURODUP





,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
5HIHUHQFHV

'LFNVWHLQ.&RKHQ6RODO$)LOLSSDWRV*HWDO(6&JXLGHOLQHVIRUWKHGLDJQRVLVDQG
WUHDWPHQWRIDFXWHDQGFKURQLFKHDUWIDLOXUHWKH7DVN)RUFHIRUWKHGLDJQRVLVDQG
WUHDWPHQWRIDFXWHDQGFKURQLFKHDUWIDLOXUHRIWKH(XURSHDQ6RFLHW\RI&DUGLRORJ\
'HYHORSHGLQFROODERUDWLRQZLWKWKH+HDUW)DLOXUH$VVRFLDWLRQRIWKH(6&+)$DQG
HQGRUVHGE\WKH(XURSHDQ6RFLHW\RI,QWHQVLYH&DUH0HGLFLQH(6,&0(XU-+HDUW
)DLOXUH




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
$SSHQGLFHV
$33(1',;$
/,67,1*62)7$%/(6/,67,1*6$1'),*85(6
/LVWLQJRI7DEOHV
1XPEHU
7LWOH
7DEOH
6XPPDU\RI2YHUDOO'LVSRVLWLRQ,773RSXODWLRQ
7DEOH
6XPPDU\RI3URWRFRO'HYLDWLRQV,773RSXODWLRQ
7DEOH
6XPPDU\RI'HPRJUDSKLFV,773RSXODWLRQ
7DEOH
6XPPDU\RI&DQFHU'LDJQRVLV+LVWRU\DQG6WUDWLILFDWLRQ)DFWRUV,773RSXODWLRQ
7DEOH
6XPPDU\RI3ULRU&DQFHU7UHDWPHQW,773RSXODWLRQ
7DEOH
6XPPDU\RI*HQHUDO0HGLFDO+LVWRU\,773RSXODWLRQ
7DEOHD
&RQFRPLWDQW0HGLFDWLRQV$OSKDEHWLF2UGHU,773RSXODWLRQ
7DEOHE
&RQFRPLWDQW0HGLFDWLRQV'HVFHQGLQJ2UGHURI)UHTXHQF\,773RSXODWLRQ
7DEOHD
$QWLK\SHUWHQVLYH&RQFRPLWDQW0HGLFDWLRQV±DW6FUHHQLQJ,773RSXODWLRQ
7DEOHE
$QWLK\SHUWHQVLYH&RQFRPLWDQW0HGLFDWLRQV±RQ6WXG\,773RSXODWLRQ
7DEOHD
$&(,QKLELWRURU&DUYHGLOROIRU%13,QFUHDVH±DW6FUHHQLQJ,773RSXODWLRQ
7DEOHE
$&(,QKLELWRURU&DUYHGLOROIRU%13,QFUHDVH±RQ6WXG\,773RSXODWLRQ
7DEOH
6XPPDU\RI([WHQWRI([SRVXUHWR%OLQGHG6WXG\'UXJ6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI([WHQWRI([SRVXUHWR$EUD[DQH6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI([WHQWRI([SRVXUHWR*HPFLWDELQH6DIHW\3RSXODWLRQ
7DEOH
'HVFULSWLYH6WDWLVWLFVIRU'HPFL]XPDE&RQFHQWUDWLRQ3.3RSXODWLRQ
7DEOH
,QFLGHQFHRI$QWL'UXJ$QWLERGLHV$'$DQG1HXWUDOL]LQJ$QWLERGLHV1DE
,773RSXODWLRQ
7DEOH
6XPPDU\RI,QYHVWLJDWRU$VVHVVHG.DSODQ0HLHU(VWLPDWHVRI3URJUHVVLRQ)UHH
6XUYLYDOIRU$UPDQG3RROHG'HPFL]XPDE$UPV,773RSXODWLRQ
DEOH6
6XPPDU\RI,QYHVWLJDWRU$VVHVVHG.DSODQ0HLHU(VWLPDWHVRI3URJUHVVLRQ)UHH
6XUYLYDOIRU(DFK7UHDWPHQW$UP,773RSXODWLRQ
7DEOH
6XPPDU\RI,QYHVWLJDWRU$VVHVVHG.DSODQ0HLHU(VWLPDWHVRI3URJUHVVLRQ)UHH
6XUYLYDOIRU$UPDQG3RROHG'HPFL]XPDE$UPV333RSXODWLRQ
7DEOH
6XPPDU\RI,QYHVWLJDWRU$VVHVVHG.DSODQ0HLHU(VWLPDWHVRI3URJUHVVLRQ)UHH
6XUYLYDOIRU(DFK7UHDWPHQW$UP333RSXODWLRQ
7DEOH
6HQVLWLYLW\$QDO\VLVRI3URJUHVVLRQ)UHH6XUYLYDO,773RSXODWLRQ
7DEOH
6XPPDU\RI%HVW2YHUDOO5HVSRQVHIRU$UPDQG3RROHG'HPFL]XPDE$UPV
,773RSXODWLRQ
7DEOH
6XPPDU\RI%HVW2YHUDOO5HVSRQVHIRU(DFK$UP,773RSXODWLRQ
7DEOH
6XPPDU\RI%HVW2YHUDOO5HVSRQVHIRU$UPDQG3RROHG'HPFL]XPDE$UPV
333RSXODWLRQ
7DEOH
6XPPDU\RI%HVW2YHUDOO5HVSRQVHIRU(DFK7UHDWPHQW$UP333RSXODWLRQ
7DEOH
6XPPDU\RI7XPRU0DUNHU&$,773RSXODWLRQ
7DEOH
6XPPDU\RI7XPRU/HQJWK,773RSXODWLRQ
7DEOH
$QDO\VLVRI7XPRU/HQJWK&KDQJHIRU$UPDQG3RROHG'HPFL]XPDE$UPV
,773RSXODWLRQ




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
1XPEHU
7LWOH
7DEOH
$QDO\VLVRI7XPRU/HQJWK&KDQJHIRU(DFK7UHDWPHQW$UP,773RSXODWLRQ
7DEOH
6XPPDU\RI5DWHRI&KDQJHLQ7XPRU9ROXPHDW3URJUHVVLRQ,773RSXODWLRQ
7DEOH
6XPPDU\RI5DWHRI&KDQJHLQ7XPRU9ROXPHDW3URJUHVVLRQ333RSXODWLRQ
7DEOH
6XPPDU\RI,QYHVWLJDWRU$VVHVVHG.DSODQ0HLHU(VWLPDWHVRI'XUDWLRQRI
5HVSRQVHIRU$UPDQG3RROHG'HPFL]XPDE$UPV5HVSRQVH(YDOXDEOH
3RSXODWLRQ
7DEOH
6XPPDU\RI,QYHVWLJDWRU$VVHVVHG.DSODQ0HLHU(VWLPDWHVRI'XUDWLRQRI
5HVSRQVHIRU(DFK7UHDWPHQW$UP5HVSRQVH(YDOXDEOH3RSXODWLRQ
7DEOH
6XPPDU\RI.DSODQ0HLHU(VWLPDWHVRI2YHUDOO6XUYLYDOIRU$UPDQG3RROHG
'HPFL]XPDE$UPV,773RSXODWLRQ
7DEOH
6XPPDU\RI.DSODQ0HLHU(VWLPDWHVRI2YHUDOO6XUYLYDOIRU(DFK7UHDWPHQW
$UP,773RSXODWLRQ
7DEOH
6XPPDU\RI.DSODQ0HLHU(VWLPDWHVRI2YHUDOO6XUYLYDOIRU$UPDQG3RROHG
'HPFL]XPDE$UPV333RSXODWLRQ
7DEOH
6XPPDU\RI.DSODQ0HLHU(VWLPDWHVRI2YHUDOO6XUYLYDOIRU(DFK7UHDWPHQW
$UP333RSXODWLRQ
7DEOH
6XPPDU\RI7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV6DIHW\3RSXODWLRQ
7DEOH
$OO7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVE\6\VWHP2UJDQ&ODVVDQG3UHIHUUHG
7HUP6DIHW\3RSXODWLRQ
7DEOH
7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVLQ'HVFHQGLQJ2UGHURI)UHTXHQF\E\
3UHIHUUHG7HUP6DIHW\3RSXODWLRQ
7DEOH
'HPFL]XPDERU3ODFHER'UXJ5HODWHG7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVE\
6\VWHP2UJDQ&ODVVDQG3UHIHUUHG7HUP6DIHW\3RSXODWLRQ
7DEOH
'UXJ5HODWHG7UHDWPHQW(PHUJHQW$GYHUVH(YHQWVLQ'HVFHQGLQJ2UGHURI
)UHTXHQF\E\3UHIHUUHG7HUP6DIHW\3RSXODWLRQ
7DEOH
7UHDWPHQW(PHUJHQW*UDGHRU+LJKHU$GYHUVH(YHQWVE\6\VWHP2UJDQ&ODVV
DQG3UHIHUUHG7HUP6DIHW\3RSXODWLRQ
7DEOH
'HPFL]XPDERU3ODFHER'UXJ5HODWHG7UHDWPHQW(PHUJHQW*UDGHRU+LJKHU
$GYHUVH(YHQWVE\6\VWHP2UJDQ&ODVVDQG3UHIHUUHG7HUP6DIHW\3RSXODWLRQ
7DEOH
$OO7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH(YHQWV6DIHW\3RSXODWLRQ
7DEOH
'HPFL]XPDERU3ODFHER'UXJ5HODWHG7UHDWPHQW(PHUJHQW6HULRXV$GYHUVH
(YHQWVE\6\VWHP2UJDQ&ODVVDQG3UHIHUUHG7HUP6DIHW\3RSXODWLRQ
7DEOH
7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV5HVXOWLQJLQ6WXG\'LVFRQWLQXDWLRQ6DIHW\
3RSXODWLRQ
7DEOH
6XPPDU\RI'HDWKV6DIHW\3RSXODWLRQ
7DEOH
'HPFL]XPDERU3ODFHER'UXJ5HODWHG'HDWKV6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI(&2*3HUIRUPDQFH6WDWXV6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI(&2*3HUIRUPDQFH6FRUH6KLIWIURP%DVHOLQHWR:RUVW6DIHW\
3RSXODWLRQ
7DEOH
6XPPDU\RI(&2*3HUIRUPDQFH6FRUH6KLIWIURP%DVHOLQHWR/DVW6DIHW\
3RSXODWLRQ
7DEOH
6XPPDU\RI&KHPLVWU\'DWD6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI&KHPLVWU\6KLIWVIURP%DVHOLQHWR:RUVWRQ6WXG\%DVHGRQ&7&$(
*UDGH6DIHW\3RSXODWLRQ




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
1XPEHU
7LWOH
7DEOH
6XPPDU\RI+HPDWRORJ\'DWD6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI+HPDWRORJ\6KLIWVIURP%DVHOLQHWR:RUVWRQ6WXG\%DVHGRQ
&7&$(*UDGH6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI%W\SH1DWULXUHWLF3HSWLGH%13&ROOHFWLRQ6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI/HDG(&*6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI7UDQVWKRUDFLF'RSSOHU(FKRFDUGLRJUDP6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI3XOPRQDU\+\SHUWHQVLRQ6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI+HDUW)DLOXUH6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI%OHHGLQJ(YHQWV6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI&73XOPRQDU\$QJLRJUDP6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI9LWDO6LJQV6DIHW\3RSXODWLRQ
7DEOHD
6XPPDU\RI3K\VLFDO([DP±DW6FUHHQLQJ6DIHW\3RSXODWLRQ
7DEOHE
6XPPDU\RI3K\VLFDO([DP±RQ6WXG\6DIHW\3RSXODWLRQ
7DEOH
6XPPDU\RI))3(7LVVXH6DPSOH,773RSXODWLRQ
7DEOH
6XPPDU\RI6\VWHPLF7KHUDS\IRU3DQFUHDWLF&DQFHUGXULQJ)ROORZXS3HULRG
,773RSXODWLRQ







,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
/LVWLQJRI/LVWLQJV
1XPEHU
7LWOH
/LVWLQJ
2YHUDOO'LVSRVLWLRQ,773RSXODWLRQ
/LVWLQJ
'HPRJUDSKLFV,773RSXODWLRQ
/LVWLQJ
,QFOXVLRQ([FOXVLRQ&ULWHULD,773RSXODWLRQ
/LVWLQJ
3URWRFRO'HYLDWLRQV,773RSXODWLRQ
/LVWLQJ
*HQHUDO0HGLFDO+LVWRU\,773RSXODWLRQ
/LVWLQJD
&DQFHU'LDJQRVLV+LVWRU\DQG6WUDWLILFDWLRQ)DFWRUV,773RSXODWLRQ
/LVWLQJE
&DQFHU'LDJQRVLV0HWDVWDVLV,773RSXODWLRQ
/LVWLQJ
3ULRU6\VWHPLF7KHUDS\,773RSXODWLRQ
/LVWLQJ
3ULRU5DGLRWKHUDS\7UHDWPHQW,773RSXODWLRQ
/LVWLQJ
3ULRU6XUJHU\,773RSXODWLRQ
/LVWLQJ
3ULRUDQG&RQFRPLWDQW0HGLFDWLRQ,773RSXODWLRQ
/LVWLQJ
$QWLK\SHUWHQVLYH0HGLFDWLRQ,773RSXODWLRQ
/LVWLQJ
$&(,QKLELWRURU&DUYHGLOROIRU%13,QFUHDVH,773RSXODWLRQ
/LVWLQJ
6WXG\'UXJ'RVH$GPLQLVWUDWLRQ6DIHW\3RSXODWLRQ
/LVWLQJ
'HPFL]XPDE&RQFHQWUDWLRQ3.3RSXODWLRQ
/LVWLQJ
$QWL'UXJ$QWLERGLHV$'$,773RSXODWLRQ
/LVWLQJ
1HXWUDOL]LQJ$QWLERGLHV1DE,773RSXODWLRQ
/LVWLQJ
5DGLRJUDSKLF(YDOXDWLRQ7DUJHW/HVLRQV,773RSXODWLRQ
/LVWLQJ
5DGLRJUDSKLF(YDOXDWLRQ1RQ7DUJHW/HVLRQV,773RSXODWLRQ
/LVWLQJ
5DGLRJUDSKLF(YDOXDWLRQ1HZ/HVLRQV,773RSXODWLRQ
/LVWLQJ
2YHUDOO5HVSRQVH,773RSXODWLRQ
/LVWLQJ
7XPRU0DUNHU&$,773RSXODWLRQ
/LVWLQJ
3URJUHVVLRQ)UHH6XUYLYDO,773RSXODWLRQ
/LVWLQJ
'XUDWLRQRI5HVSRQVH5HVSRQVH(YDOXDEOH3RSXODWLRQ
/LVWLQJ
2YHUDOO6XUYLYDO,773RSXODWLRQ
/LVWLQJ
6XUJHU\IRU3DQFUHDWLF&DQFHUGXULQJ)ROORZXS3HULRG,773RSXODWLRQ
/LVWLQJ
5DGLRWKHUDS\IRU3DQFUHDWLF&DQFHUGXULQJ)ROORZXS3HULRG,773RSXODWLRQ
/LVWLQJ
6\VWHPLF7KHUDS\IRU3DQFUHDWLF&DQFHUGXULQJ)ROORZXS3HULRG,77
3RSXODWLRQ
/LVWLQJ
$GYHUVH(YHQWV6DIHW\3RSXODWLRQ
/LVWLQJ
6HULRXV$GYHUVH(YHQWV6DIHW\3RSXODWLRQ
/LVWLQJ
&7&$(*UDGHRU+LJKHU+HDUW)DLOXUHRU3XOPRQDU\+\SHUWHQVLRQ6DIHW\
3RSXODWLRQ
/LVWLQJ
&7&$(*UDGHRU+LJKHU%OHHGLQJ(YHQW6DIHW\3RSXODWLRQ
/LVWLQJ
$OO$GYHUVH(YHQWVWKDW5HVXOWHGLQ6WXG\'LVFRQWLQXDWLRQ6DIHW\3RSXODWLRQ
/LVWLQJ
$OO$GYHUVH(YHQWVWKDW5HVXOWHGLQ'HDWK6DIHW\3RSXODWLRQ
/LVWLQJ
/DERUDWRU\5HVXOWV&KHPLVWU\6DIHW\3RSXODWLRQ
/LVWLQJ
/DERUDWRU\5HVXOWV&RDJXODWLRQ6DIHW\3RSXODWLRQ
/LVWLQJ
/DERUDWRU\5HVXOWV+HPDWRORJ\6DIHW\3RSXODWLRQ
/LVWLQJ
%W\SH1DWULXUHWLF3HSWLGH%13&ROOHFWLRQ6DIHW\3RSXODWLRQ




,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
1XPEHU
7LWOH
/LVWLQJ
/DERUDWRU\5HVXOWV8ULQDO\VLV6DIHW\3RSXODWLRQ
/LVWLQJ
/HDG(&*6DIHW\3RSXODWLRQ
/LVWLQJ
7UDQVWKRUDFLF'RSSOHU(FKRFDUGLRJUDP6DIHW\3RSXODWLRQ
/LVWLQJ
9LWDO6LJQV6DIHW\3RSXODWLRQ
/LVWLQJ
3K\VLFDO([DP6DIHW\3RSXODWLRQ
/LVWLQJ
&73XOPRQDU\$QJLRJUDP6DIHW\3RSXODWLRQ
/LVWLQJ
&RORQRVFRS\DQG8SSHU*DVWURLQWHVWLQDO(QGRVFRS\6DIHW\3RSXODWLRQ
/LVWLQJ
+HDG&705,6FDQ6DIHW\3RSXODWLRQ
/LVWLQJ
6HUXP3UHJQDQF\7HVW6DIHW\3RSXODWLRQ
/LVWLQJ
(&2*3HUIRUPDQFH6WDWXV6DIHW\3RSXODWLRQ
/LVWLQJ
)ROORZXSDIWHU7HUPLQDWLRQ9LVLW6DIHW\3RSXODWLRQ
/LVWLQJ
%LRPDUNHU%ORRG6DPSOHV,773RSXODWLRQ
/LVWLQJ
3KDUPDFRJHQRPLFV%ORRG6DPSOHV,773RSXODWLRQ
/LVWLQJ
))3(7LVVXH6DPSOH,773RSXODWLRQ







,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
/LVWLQJRI)LJXUHV
1XPEHU
7LWOH
)LJXUH
.DSODQ0HLHU3ORWRI,QYHVWLJDWRU$VVHVVHG3URJUHVVLRQ)UHH6XUYLYDOIRU
$UPDQG3RROHG'HPFL]XPDE$UPV,773RSXODWLRQ
)LJXUH
.DSODQ0HLHU3ORWRI,QYHVWLJDWRU$VVHVVHG3URJUHVVLRQ)UHH6XUYLYDOIRU
(DFK7UHDWPHQW$UP,773RSXODWLRQ
)LJXUHD
.DSODQ0HLHU3ORWRI,QYHVWLJDWRU$VVHVVHG3URJUHVVLRQ)UHH6XUYLYDOIRU
$UPDQG3RROHG'HPFL]XPDE$UPVE\6WUDWLILFDWLRQ)DFWRUV
&RPELQDWLRQ,773RSXODWLRQ
)LJXUHE
.DSODQ0HLHU3ORWRI,QYHVWLJDWRU$VVHVVHG3URJUHVVLRQ)UHH6XUYLYDOIRU
$UPDQG3RROHG'HPFL]XPDE$UPVE\6WUDWLILFDWLRQ)DFWRUV6LQJOH/HYHO
,773RSXODWLRQ
)LJXUHD
.DSODQ0HLHU3ORWRI,QYHVWLJDWRU$VVHVVHG3URJUHVVLRQ)UHH6XUYLYDOIRU
(DFK7UHDWPHQW$UPE\6WUDWLILFDWLRQ)DFWRUV&RPELQDWLRQ,773RSXODWLRQ
)LJXUHE
.DSODQ0HLHU3ORWRI,QYHVWLJDWRU$VVHVVHG3URJUHVVLRQ)UHH6XUYLYDOIRU
(DFK7UHDWPHQW$UPE\6WUDWLILFDWLRQ)DFWRUV±6LQJOH/HYHO,773RSXODWLRQ
)LJXUH
.DSODQ0HLHU3ORWRI2YHUDOO6XUYLYDOIRU$UPDQG3RROHG'HPFL]XPDE
$UPV,773RSXODWLRQ
)LJXUH
.DSODQ0HLHU3ORWRI2YHUDOO6XUYLYDOIRU(DFK7UHDWPHQW$UP,77
3RSXODWLRQ
)LJXUHD
.DSODQ0HLHU3ORWRI2YHUDOO6XUYLYDOIRU$UPDQG3RROHG'HPFL]XPDE
$UPVE\6WUDWLILFDWLRQ)DFWRUV&RPELQDWLRQ,773RSXODWLRQ
)LJXUHE
.DSODQ0HLHU3ORWRI2YHUDOO6XUYLYDOIRU$UPDQG3RROHG'HPFL]XPDE
$UPVE\6WUDWLILFDWLRQ)DFWRUV±6LQJOH/HYHO,773RSXODWLRQ
)LJXUHD
.DSODQ0HLHU3ORWRI2YHUDOO6XUYLYDOIRU(DFK7UHDWPHQW$UPE\
6WUDWLILFDWLRQ)DFWRUV&RPELQDWLRQ,773RSXODWLRQ
)LJXUHE
.DSODQ0HLHU3ORWRI2YHUDOO6XUYLYDOIRU(DFK7UHDWPHQW$UPE\
6WUDWLILFDWLRQ)DFWRUV6LQJOH/HYHO,773RSXODWLRQ
)LJXUH
:DWHUIDOO3ORWRI7XPRU5HVSRQVHIRU(DFK7UHDWPHQW$UP5HVSRQVH
(YDOXDEOH3RSXODWLRQ,773RSXODWLRQ
)LJXUH
%R[3ORWRI7XPRU0DUNHU&$2YHU7LPH,773RSXODWLRQ
)LJXUH
6ZLPPHU3ORWIRU6HULRXV7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV6DIHW\
3RSXODWLRQ
)LJXUH
%R[3ORWRI&KHPLVWU\'DWD2YHU7LPH6DIHW\3RSXODWLRQ
)LJXUH
6FDWWHU3ORWRI%DVHOLQHYV:RUVW3RVWEDVHOLQHLQ&KHPLVWU\'DWD6DIHW\
3RSXODWLRQ
)LJXUH
%R[3ORWRI+HPDWRORJ\'DWD2YHU7LPH6DIHW\3RSXODWLRQ
)LJXUH
6FDWWHU3ORWRI%DVHOLQHYV:RUVW3RVWEDVHOLQHLQ+HPDWRORJ\'DWD6DIHW\
3RSXODWLRQ
)LJXUH
%R[3ORWRI%W\SH1DWULXUHWLF3HSWLGH%13&ROOHFWLRQ2YHU7LPH6DIHW\
3RSXODWLRQ






,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
$33(1',;%
,0387$7,21$/*25,7+0)253$57,$/250,66,1*
'$7(6
$GYHUVH(YHQW
,IRQVHWGDWHLVFRPSOHWHO\PLVVLQJWKHQRQVHWGDWHLVVHWWRGDWHRIILUVWGRVH
,I\HDULVSUHVHQWDQGPRQWKDQGGD\DUHPLVVLQJRU\HDUDQGGD\DUHSUHVHQWDQGPRQWK
LVPLVVLQJ
,I\HDU \HDURIILUVWGRVHWKHQVHWRQVHWPRQWKDQGGD\WRPRQWKDQGGD\RIILUVWGRVH
,I\HDU\HDURIILUVWGRVHWKHQVHWRQVHWPRQWKDQGGD\WR'HFHPEHUVW
,I\HDU!\HDURIILUVWGRVHWKHQVHWRQVHWPRQWKDQGGD\WR-DQXDU\VW
,IPRQWKDQG\HDUDUHSUHVHQWDQGGD\LVPLVVLQJ
,I\HDU \HDURIILUVWGRVHDQG
,IPRQWK PRQWKRIILUVWGRVHWKHQVHWGD\WRGD\RIILUVWGRVHGDWH
,IPRQWKPRQWKRIILUVWGRVHWKHQVHWGD\WRODVWGD\RIPRQWK
,IPRQWK!PRQWKRIILUVWGRVHWKHQVHWGD\WRVWGD\RIPRQWK
,I\HDU\HDURIILUVWGRVHWKHQVHWGD\WRODVWGD\RIPRQWK
,I\HDU!\HDURIILUVWGRVHWKHQVHWGD\WRVWGD\RIPRQWK
)RUDOORWKHUFDVHVVHWRQVHWGDWHWRGDWHRIILUVWGRVH
&RQFRPLWDQW0HGLFDWLRQV
,I\HDUDQGPRQWKDUHSUHVHQWDQGGD\LVPLVVLQJWKHQVHWGD\WRILUVWGD\RIPRQWKIRU
VWDUWGDWHDQGVHWGD\WRODVWGD\RIPRQWKIRUHQGGDWH
,I\HDUDQGGD\DUHSUHVHQWDQGPRQWKLVPLVVLQJWKHQVHWPRQWKWR-DQXDU\IRUVWDUWGDWH
DQGVHWPRQWKWR'HFHPEHUIRUHQGGDWH
,I\HDULVSUHVHQWDQGPRQWKDQGGD\DUHPLVVLQJWKHQVHWPRQWKDQGGD\WR-DQXDU\IRU
VWDUWGDWHDQGVHWPRQWKDQGGD\WR'HFHPEHUIRUHQGGDWH
&RPSOHWHO\PLVVLQJGDWHZLOOQRWEHLPSXWHG





,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
$33(1',;&
'(7$,/62)&$/&8/$7,216,17$%/(
7KLVDSSHQGL[SURYLGHVGHWDLOVIRUWKHFDOFXODWLRQVXQGHUO\LQJ7DEOH
7KHUHDUHWKUHHGLVWLQFWGLVMRLQWZD\VWKDWWKHVWXG\FDQEHH[WHQGHG

7KHH[WHQVLRQERXQGDU\LVFURVVHGDWLQWHULPDQGWKH3KDVHERXQGDU\LVQRWFURVVHG

7KHH[WHQVLRQERXQGDU\LVQRWFURVVHGDWLQWHULPDQGLWLVFURVVHGDWLQWHULPDQGWKH3KDVHERXQGDU\LVQRWFURVVHG

7KHH[WHQVLRQERXQGDU\LVQRWFURVVHGDWLQWHULPDQGLQWHULPDQGLWLVFURVVHGDWLQWHULPDQGWKH3KDVHERXQGDU\LVQRW
FURVVHG
6RWRGHWHUPLQHWKHSUREDELOLW\RIFURVVLQJWKH3KDVHERXQGDU\DWLQWHULPVDQGZHFDQDGGWKHSUREDELOLWLHVRIFURVVLQJWKH
3KDVHERXQGDU\DWLQWHULPVDQGIRUWKHWKUHHGLVMRLQWVLWXDWLRQVOLVWHGDERYH7KLVLVFDUULHGRXWLQWKHFDOFXODWLRQVEHORZ
7DEOHVKRZVWKHFDOFXODWLRQWKDWGHWHUPLQHVWKH3KDVHHIILFDF\ERXQGDU\,WLVEDVHGRQWKHWDXIDPLO\RIVSHQGLQJIXQFWLRQVZLWK
SDUDPHWHUHTXDOWR7KHSKDVHHIILFDF\ERXQGDU\ZDVFUHDWHGDVDGHVLJQWKDWZRXOGSURYLGHSHUFHQWSRZHUDWDW\SHHUURURI
RQHVLGHGZLWKQRIXWLOLW\RUH[WHQVLRQERXQGDU\
7DEOH

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFUHMHFWWKH$OW






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRUHMHFWWKHDOW






1RQELQGLQJH[WHQVLRQDQGIXWLOLW\






&XPXODWLYH3RZHU+5 

H
H
H


&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 










,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFUHMHFWWKH$OW






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRUHMHFWWKHDOW






&XPXODWLYH3RZHU+5 

H
H
H


&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 







7DEOHSUHVHQWVDQDSSUR[LPDWLRQRIWKHSUREDELOLWLHVDVVRFLDWHGZLWKWKLVGHVLJQ7KHDSSUR[LPDWLRQLVLPSOHPHQWHGE\XVLQJDQ
H[WHQVLRQERXQGDU\RI,IWKHH[SDQVLRQERXQGDU\LVFURVVHGDWRULWZLOOPRVWRIWHQDOVRFURVVDW





,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
7KHH[SDQVLRQERXQGDU\LVFURVVHGDWLQWHULPRQHDQGWKH3KDVHHIILFDF\ERXQGDU\LVQRWFURVVHG

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFUHMHFWWKH$OW






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRUHMHFWWKHDOW






&XPXODWLYH3RZHU+5 

H
H
H


&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






$ &ROXPQV&ROXPQ






,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
7KHH[SDQVLRQERXQGDU\LVQRWFURVVHGDWLQWHULPDQGLWLVFURVVHGDWLQWHULPZKLOHWKH3KDVHHIILFDF\ERXQGDU\LVQRWFURVVHG

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFUHMHFWWKH$OW






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRUHMHFWWKHDOW






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






$ &ROXPQV&ROXPQ






,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
7KHH[SDQVLRQERXQGDU\LVQRWFURVVHGDWLQWHULPDQGLQWHULPEXWLWLVFURVVHGDWLQWHULPZKLOHWKH3KDVHHIILFDF\ERXQGDU\LV
QRWFURVVHG

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFUHMHFWWKH$OW






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRUHMHFWWKHDOW






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






$ &ROXPQV&ROXPQ






,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
7KHSUREDELOLWLHVRIFURVVLQJWKH3KDVHHIILFDF\ERXQGDU\DWLQWHULPVDQG

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFUHMHFWWKH$OW






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRUHMHFWWKHDOW






&XPXODWLYH3RZHU+5 

H
H



&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






$






,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI


2QFR0HG3KDUPDFHXWLFDOV,QF

6WDWLVWLFDO$QDO\VLV3ODQ9HUVLRQ
0

'DWH,VVXHG0$5
7DEOH
7KHSUREDELOLW\RI&URVVLQJWKH3KDVHHIILFDF\ERXQGDU\DFFRXQWLQJIRUVWXG\H[SDQVLRQDWLQWHULPVDQG

,QWHULP
,QWHULP
,QWHULP
,QWHULP
,QWHULP
)LQDO$QDO\VLV
7RWDO1XPEHURI(YHQWV






=6WDWLVWLFUHMHFWWKHQXOO






=VWDWLVWLFUHMHFWWKH$OW






+D]DUG5DWLRUHMHFWWKHQXOO






+D]DUG5DWLRUHMHFWWKHDOW






&XPXODWLYH3RZHU+5 

H
H



&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






&XPXODWLYH3RZHU+5 






$$$$


5FRGHWRFDOFXODWHWKHSUREDELOLWLHVIRULQWHULPDQGDVZHOODVWKHILQDODQDO\VLVDFFRXQWLQJIRUWKHH[SDQVLRQERXQGDU\
DPDWUL[FE\URZ 7QFRO 
DDD>@


DPDWUL[FE\URZ 7QFRO 
DDD>@


DPDWUL[FE\URZ 7QFRO 
DDD>@


DDDD

EF

ILQDOED
SULQWILQDO






,1'61
6WDWLVWLFDO$QDO\VLV3ODQ09HUVLRQ0DUFK
'HPFL]XPDE
2QFR0HG3KDUPDFHXWLFDOV,QF
0DU
&21),'(17,$/
,19(67,*$7,21$/1(:'58*
3DJHRI

Prot_ICF_001.pdf: 
OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 1 of 130 
CONFIDENTIAL 
 
19 December 2016 
CLINICAL PROTOCOL 
Protocol No. 
M18-006 
Title: 
YOSEMITE:  A 3-Arm Phase 2 Double-Blind Randomized StudY of Gemcitabine, 
Abraxane® Plus PlacebO versuS GEMcitabIne, Abraxane® plus 1 or 2 
TruncatEd Courses of Demcizumab in Subjects with 1st-Line Metastatic 
Pancreatic Ductal Adenocarcinoma 
Version: 
23 October 2014 
 
Amendment 1:  24 November 2014 
 
Amendment 2:  10 February 2015 
 
Amendment 3:  28 May 2015 
 
Amendment 4:  31 March 2016 
Amendment 5: 19 December 2016 
 
 
EudraCT Number: 
2014‐003355‐56 
 
 
Sponsor: 
OncoMed Pharmaceuticals, Inc. 
800 Chesapeake Drive 
Redwood City, CA 94063 
Phone:  650-995-8200 
 
 
 
 
CONFIDENTIAL 
This document contains proprietary and confidential information of OncoMed Pharmaceuticals, Inc.  Acceptance of 
this document constitutes agreement by the recipient that no previously unpublished information contained herein 
will be published or disclosed without the prior written approval of OncoMed Pharmaceuticals, Inc. with the 
exception that this document may be disclosed to study personnel under your supervision who need to know the 
contents for conducting the study and appropriate Institutional Review Boards/Ethics Committees under the 
condition that the personnel have agreed to keep this information confidential.  The foregoing shall not apply to 
disclosure required by governmental regulations or laws; however, OncoMed Pharmaceuticals, Inc. shall be 
promptly notified of any such disclosure. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 2 of 130 
CONFIDENTIAL 
 
19 December 2016 
SPONSOR CONTACTS 
Medical Monitor:    
___________________ 
(Primary) 
 
___________________________ 
 
 
 
Email: ___________________ 
 
 
 
Phone:  ____________________ 
Medical Monitor:    
___________________ 
(Secondary) 
 
___________________ 
Email: ___________________ 
 
 
 
Phone:  ___________________ 
Safety Reporting: 
Europe, Australia  
 
 
 
Phone: ___________________  
 
 
 
Fax: ___________________ 
 
 
 
United States  
 
 
 
Phone: ___________________ 
 
 
 
Fax: ___________________ 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 3 of 130 
CONFIDENTIAL 
 
19 December 2016 
INVESTIGATOR SIGNATURE PAGE 
OncoMed Pharmaceuticals 
Protocol No. M18-006 
Amendment 5:  19 December 2016 
I will provide copies of the protocol, any subsequent protocol amendments, and access to all 
information provided by the Sponsor to the study personnel under my supervision.  I will discuss 
this material with them to ensure that they are fully informed about the investigational drug and 
the study protocol. 
I agree to conduct this clinical trial according to the attached protocol.  I also agree to conduct 
this study in compliance with Good Clinical Practice (GCP), all federal, state, and local 
regulations as well as with the requirements of the appropriate Institutional Review Board or 
Ethics Committee and any other institutional requirements. 
 
 
 
 
 
 
 
 
Principal Investigator 
 
Date 
Printed Name: 
 
Institution: 
 
Address: 
 
Telephone Number: 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 4 of 130 
CONFIDENTIAL 
 
19 December 2016 
SPONSOR SIGNATURE PAGE 
 
OncoMed Pharmaceuticals, Inc. 
Protocol No. M18-006 
Amendment 5:  19 December 2016 
 
This study protocol has been reviewed and approved by the undersigned person.  It is confirmed 
that the information and guidance given in this protocol complies with the scientific principles, 
the guideline of Good Clinical Practices, the Declaration of Helsinki in the latest relevant 
version, and the applicable legal and regulatory requirements. 
 
 
 
 
 
 
Signature of Sponsor Representative 
 
Date 
Printed Name of Sponsor Representative 
 
 
 
 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 5 of 130 
CONFIDENTIAL 
 
19 December 2016 
SYNOPSIS 
Title of Study: 
YOSEMITE: A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo versus 
Gemcitabine, Abraxane® plus 1 or 2 Truncated Courses of Demcizumab in Subjects with  1st-Line Metastatic 
Pancreatic Ductal Adenocarcinoma 
Study Period:  Approximately 12–16 months 
Development Phase:  Phase 2 
Objectives: 
Primary Objective: 
 
To compare the efficacy of Arm 1 to the pooled decizumab arms (i.e., Arm 1 to Arms 2 and 3) (See 
Section 5.0 for description of Treatment Arms) in subjects with 1st-line  metastatic pancreatic ductal 
adenocarcinoma. 
Secondary Objectives: 
 
To compare the efficacy of Arm 1 to Arm 2 and Arm 1 to Arm 3 in subjects with 1st-line  metastatic  
pancreatic ductal adenocarcinoma. 
 
To compare the safety of Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 pooled in subjects with 
1st-line  metastatic pancreatic ductal adenocarcinoma. 
 
To determine the rate of immunogenicity against demcizumab when combined with Abraxane® and 
gemcitabine in subjects with 1st-line  metastatic pancreatic ductal adenocarcinoma. 
 
 . To determine population pharmacokinetics of demcizumab in subjects receiving demcizumab and 
Abraxane® and gemcitabine in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma.  
Exploratory Objectives: 
 
To compare the safety and efficacy of Arm 2 to Arm 3 in subjects with 1st-line  metastatic pancreatic 
ductal adenocarcinoma. 
 
To compare the exploratory biomarkers of Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 pooled 
in subjects with 1st-line  metastatic pancreatic ductal adenocarcinoma. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 6 of 130 
CONFIDENTIAL 
 
19 December 2016 
Study Design: 
This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal 
adenocarcinoma.  Prior to randomization, subjects will undergo screening to determine study eligibility. Two 
hundred and one evaluable subjects will be randomized via an IWRS system.   
Gemcitabine will be given by intravenous (IV) infusion at a dose of 1000 mg/m2 on Days 1, 8 and 15 of each 28-day 
treatment cycle (or until toxicity necessitates reducing or holding a dose).  Abraxane® will be administered by IV 
infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8 and 15 of each 28-day treatment cycle.  Demcizumab 
3.5 mg/kg or placebo will be administered by IV infusion (prior to the administration of Abraxane® and 
gemcitabine) once every 2 weeks for either one (1st course through Study Day 70) or two (2nd course begun on Study 
Day 168 and continued through Study Day 238) 70 day courses. 
Randomized subjects will be treated in the following manner (See Appendix A):  
Arm 1 – Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and 
gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression  
Arm 2 - Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), 
Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression  
Arm 3 - Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), 
Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease 
progression  
Dosing of gemcitabine, Abraxane® and demcizumab or placebo must be done within ± 2 days of the Study Day 
listed in the protocol.  If a drug cannot be given within this 2 day window, then the dose of that drug is permanently 
missed.  Subjects will only receive their second 70 day course of placebo or demcizumab if their Day 168 BNP is 
≤100 pg/mL, peak tricuspid velocity is ≤ 3.0 m/s and LVEF is ≥50% and they did not develop pulmonary 
hypertension or heart failure while on study. Any subject who has two consecutive B-type natriuretic (BNP) values 
>100 pg/mL or one value >200 pg/mL will be unblinded by the Investigator through the IWRS system.  If the 
subject is receiving demcizumab they will be started on an ACE inhibitor or carvedilol, unless the BNP elevation 
occurred more than 100 days after the discontinuation of demcizumab or there is a contraindication to administering 
these agents and if appropriate, referred to a cardiologist.  If they are not receiving demcizumab they will be cared 
for according to standard medical practice.  
Subjects will be assessed for disease status every 8 weeks and for safety at every visit and through 30 days following 
the termination visit.  In all three arms, subjects should remain on study until disease progression, Immunogenicity 
will be assessed at baseline, every 8 weeks while on study and at treatment termination.  Biomarker assessment will 
be performed at Days 0, 21, 35, 49 and 63 and at treatment termination.  Plasma sample for PK analysis to be 
obtained prior to the demcizumab infusion on Days 0, 14, 56, 70, 168, 182, 224 and 238, and at the end of the 
demcizumab infusion (prior to chemo infusion) on Days 0, 56, 70, 168, 224 and at treatment termination.  If all of 
the study drugs are discontinued prior to disease progression, the subject should remain on study until disease 
progression or withdrawal of consent.  Once discontinuation criteria for the study are met (disease progression, use 
of other anti-cancer therapy, subject or investigator decision or protocol non-compliance) a termination visit should 
occur ≤14 days later.  The termination visit may occur later after discussion with the OncoMed Medical Monitor for 
specific circumstances, such as prolonged hospitalization.  After the termination visit, subjects should have regular 
follow-up for survival and other assessments as required per protocol.  
Study Population: 
Subjects must have histologically confirmed metastatic pancreatic ductal adenocarcinoma.  In addition, subjects 
must measurable disease per RECIST 1.1.   


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 7 of 130 
CONFIDENTIAL 
 
19 December 2016 
Diagnosis and Main Criteria for Eligibility (for Complete Eligibility Criteria, See Section 6.0): 
Inclusion Criteria: 
1. Subjects must have cytologically or histologically confirmed metastatic pancreatic ductal adenocarcinoma.. 
Prior chemotherapy and/or radiotherapy either in the adjuvant or neoadjuvant setting or for metastatic disease is 
not allowed.  
2. Age >21 years 
3. ECOG performance status 0 or 1 (see Appendix C) 
4. Measurable disease per RECIST v1.1 (see Appendix D) 
Exclusion Criteria: 
1. Subjects with a neuroendocrine tumor of the pancreas, an acinar tumor of the pancreas or a pancreatic tumor 
with mixed histologies.  
2. Subjects receiving heparin, warfarin, factor Xa inhibitors or other similar anticoagulants.  Note:  Subjects may 
be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents. 
3. Any of the following cardiac-related criteria: 
 
B-type natriuretic peptide (BNP) value of >100 pg/mL 
 
Left ventricular ejection fraction (LVEF) <50% 
 
Peak tricuspid velocity >3.0 m/s on Doppler echocardiogram 
 
Receiving any medications for cardiac ischemia 
 
Current evidence of cardiac ischemia 
 
History of acute myocardial infarction within 6 months prior to randomization 
 
New York Heart Association Classification II, III, or IV (See Appendix E). 
For subjects to meet class II criteria with mild shortness of breath and/or angina, as defined by the NYHA 
guidelines, the cardiac etiology of the symptoms should be confirmed by a cardiologist taking 12-lead 
electrocardiogram, transthoracic Doppler echocardiogram and other studies into consideration, as 
appropriate. 
 
History of heart failure or pulmonary hypertension 
 
Received a total cumulative dose of ≥400 mg/m2 doxorubicin 
 
Grade ≥2 ventricular arrhythmia 
Test Product, Dose, and Mode of Administration 
Demcizumab is an IgG2 humanized monoclonal antibody that is directed against the Delta-Like Ligand 4 (DLL4).  
Demcizumab is supplied at a concentration of 10 mg/mL in 25-mL single-use glass vials filled to 20 mL to deliver a 
total of 200 mg per vial.  Demcizumab vials must be stored at 2°–8°C.  DO NOT FREEZE.  DO NOT SHAKE. 
Placebo is a clear to slightly opalescent, colorless to slightly yellow liquid formulation of 50 mM Histidine, 
100mM Sodium Chloride, 45mM Sucrose and 0.01% (v/v) Polysorbate-20, pH 6.0.  
Study drug (demcizumab at 3.5 mg/kg or placebo) will be administered as an intravenous infusion over at least 
30 minutes once every 2 weeks for 6 doses (e.g., the last dose given on Day 70).  A second course of study drug 
(demcizumab at 3.5 mg/kg or placebo) will be administered once every 2 weeks for 6 doses starting on Day 168 
(e.g., the last dose given on Day 238) if the subject’s Day 168 BNP is ≤100 pg/mL, peak tricuspid velocity is 
<3.0 m/s and LVEF is ≥50%, and the subject did not develop pulmonary hypertension or heart failure while on 
study. 
Duration of Treatment: 
Subjects should remain on study until they develop progressive disease per the Response Evaluation Criteria in 
Solid Tumors (RECIST) criteria 1.1, develop unacceptable toxicity or withdrawal consent.  Disease progression 
should be based on radiographic assessment rather than an elevation of CA 19-9.  If disease progression is suspected 
due to an elevation in CA 19-9 an early radiographic assessment may be performed to determine if progression has 
occurred.  If all of the study drugs are discontinued prior to disease progression, the subject should still remain on 
study until disease progression. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 8 of 130 
CONFIDENTIAL 
 
19 December 2016 
Safety Evaluation: 
Safety will be assessed by adverse event monitoring (including attribution of adverse events and serious adverse 
events), physical examination, vital signs, clinical laboratory testing including assessment of BNP every 14 days, 
doppler echocardiogram, anti-demcizumab testing, and subject interview on an ongoing basis (as outlined in the 
Schedule of Assessments) from randomization through 30 days following the termination visit.   
Efficacy Evaluation: 
Subjects will be assessed for response using RECIST criteria 1.1 at Study Day 56 and then every 8 weeks.  In 
addition, CA 19-9 levels will be obtained at baseline and then every 8 weeks.  Disease progression should be based 
on radiographic assessment rather than an elevation of CA 19-9.  If disease progression is suspected due to an 
elevation in CA 19-9 an early radiographic assessment may be performed to determine if progression has occurred. 
Investigator-assessed response rates, duration of response, time to progression, and survival will be evaluated.  In 
addition, an optional independent assessment of the radiographs may be performed. 
Immunogenicity: 
Subjects will be assessed at baseline and then every 8 weeks while the subject is on study. In addition, subjects will 
be assessed for immunogenicity at the time of treatment termination. 
Pharmacokinetics: 
Sparse PK sampling will be obtained on all subjects. Plasma sample for PK analysis to be obtained prior to the 
demcizumab infusion on Days 0, 14, 56, 70, 168, 182, 224 and 238, and at the end of the demcizumab infusion 
(prior to chemo infusion) on Days 0, 56, 70, 168, 224 and at treatment termination. 
Biomarker Evaluation: 
Whole blood will be obtained for biomarker evaluations on Study Days 0, 21, 35, 49 and 63, and at treatment 
termination as outlined in the Schedule of Assessments.  In addition, a pharmacogenomics sample will be collected 
at baseline from subjects who give informed consent.  If available, archival FFPE tumor tissue (from either the 
primary tumor, locoregional disease or a metastatic site) obtained by core biopsy or surgical resection will be 
collected.  Analysis of candidate genes and/or proteins relevant to the Notch pathway may be performed (e.g., 
DLL4, Notch1, Hey1, FBXW7). 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 9 of 130 
CONFIDENTIAL 
 
19 December 2016 
1.0 
TABLE OF CONTENTS 
SPONSOR CONTACTS ...............................................................................................................2 
INVESTIGATOR SIGNATURE PAGE......................................................................................3 
SPONSOR SIGNATURE PAGE ..................................................................................................4 
1.0 
TABLE OF CONTENTS ..................................................................................................9 
LIST OF TABLES .......................................................................................................................12 
LIST OF FIGURES .....................................................................................................................12 
LIST OF APPENDICES .............................................................................................................13 
2.0 
LIST OF ABBREVIATIONS .........................................................................................14 
3.0 
BACKGROUND ..............................................................................................................16 
3.1 
Investigational Medicinal Product .........................................................................16 
3.2 
Disease Background...............................................................................................16 
3.3 
Nonclinical Background ........................................................................................16 
3.3.1 
Activity of Anti-DLL4 in Pancreatic Cancer Xenografts .....................17 
3.3.2 
Potential for Immune-Mediated Mechanism of Action for Anti-
DLL4 .....................................................................................................19 
3.4 
Clinical Background ..............................................................................................22 
3.4.1 
Phase 1a Study M18-001 ......................................................................23 
3.4.2 
Phase 1b Studies M18-002, M18-003, and M18-004 and Phase 1b/2 
Study M18-005 .....................................................................................24 
3.5 
Risks/Benefits ........................................................................................................31 
3.6 
Dose Rationale .......................................................................................................33 
3.7 
Study Conduct ........................................................................................................33 
3.8 
Subject Population .................................................................................................34 
4.0 
STUDY OBJECTIVES AND ENDPOINTS ..................................................................34 
4.1 
Study Objectives ....................................................................................................34 
5.0 
OVERALL STUDY DESIGN AND PLAN – DESCRIPTION....................................36 
6.0 
SELECTION OF STUDY POPULATION ...................................................................37 
6.1 
Inclusion Criteria ...................................................................................................37 
6.2 
Exclusion Criteria ..................................................................................................39 
7.0 
REMOVAL OF SUBJECTS FROM STUDY ...............................................................41 
8.0 
TREATMENT OF SUBJECTS ......................................................................................41 
8.1 
Study Drug (DEMCIZUMAB OR PLACEBO) ....................................................41 
8.1.1 
Administration ......................................................................................41 
8.1.2 
Description ............................................................................................42 
8.1.3 
Packaging ..............................................................................................42 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 10 of 130 
CONFIDENTIAL 
 
19 December 2016 
8.1.4 
Drug Ordering, Storage, and Accountability ........................................42 
8.1.5 
Study Drug Preparation .........................................................................43 
8.1.6 
Treatment Modification and Termination Criteria ................................43 
8.1.7 
Infusion Reaction Management ............................................................44 
8.2 
Gemcitabine and Abraxane® ..................................................................................44 
8.2.1 
Abraxane® .............................................................................................45 
8.2.2 
Gemcitabine ..........................................................................................45 
8.2.3 
Gemcitabine and Abraxane® Dose Modification Guidelines................46 
8.3 
Anti-Emetics and Hematopoietic Supportive Care ................................................50 
8.4 
Concomitant and Prohibited Therapy ....................................................................50 
8.5 
Treatment Compliance ...........................................................................................51 
9.0 
SAFETY ASSESSMENTS ..............................................................................................51 
9.1 
Adverse Events Definitions and Reporting Procedures .........................................51 
9.1.1 
Definition of Adverse Event .................................................................52 
9.1.2 
Definition of Serious Adverse Event ....................................................52 
9.1.3 
Serious Adverse Event Reporting Procedures ......................................53 
9.2 
Clinical Laboratory Assessments ...........................................................................53 
9.2.1 
Hematology ...........................................................................................53 
9.2.2 
Serum Chemistry ...................................................................................53 
9.2.3 
BNP Assessment ...................................................................................54 
9.2.4 
Urinalysis ..............................................................................................54 
9.2.5 
Pregnancy Testing .................................................................................54 
9.3 
Vital Signs and Other Physical Findings ...............................................................54 
9.4 
Cardiac Studies ......................................................................................................55 
9.5 
Immunogenicity Assessments ................................................................................55 
9.6 
Pharmacokinetic Assessments ...............................................................................55 
10.0 
EFFICACY ASSESSMENTS .........................................................................................55 
11.0 
EXPLORATORY ASSESSMENTS ...............................................................................57 
12.0 
STUDY VISIT SCHEDULE AND ASSESSMENTS ....................................................57 
12.1 
Screening................................................................................................................58 
12.2 
Study Day 0............................................................................................................59 
12.3 
Study Days 7, 14, 21, 28, 35, 42, and 49 ...............................................................60 
12.4 
Study Day 56..........................................................................................................61 
12.5 
Study Days 63, 70 ..................................................................................................62 
12.6 
Study Day 77..........................................................................................................62 
12.7 
Study Days 84, 91, 98 ............................................................................................62 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 11 of 130 
CONFIDENTIAL 
 
19 December 2016 
12.8 
Study Day 105........................................................................................................63 
12.9 
Termination Visit ...................................................................................................64 
12.10  Follow-up after Termination Visit .........................................................................65 
13.0 
DATA QUALITY ASSURANCE ...................................................................................65 
14.0 
STATISTICAL PLAN .....................................................................................................66 
14.1 
Data Safety Monitoring Board ...............................................................................69 
14.2 
Study Stopping Rules .............................................................................................69 
14.3 
Subject Populations for Analysis ...........................................................................71 
14.4 
Demographics and Baseline Characteristics ..........................................................71 
14.5 
Treatment Exposure ...............................................................................................71 
14.6 
Endpoints ...............................................................................................................72 
14.6.1 
Safety Endpoints ...................................................................................72 
14.6.2 
Immunogenicity Endpoints ...................................................................73 
14.6.3 
Pharmacokinetic Endpoints ...................................................................73 
14.6.4 
Efficacy Endpoints ................................................................................73 
14.6.5 
Continuous Variable Assessment of Tumor Length .............................75 
14.6.6 
Duration of Response ............................................................................76 
14.6.7 
Overall Survival ....................................................................................76 
14.7 
Termination Criteria...............................................................................................77 
14.8 
Deviation Reporting ...............................................................................................77 
15.0 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTATION ................................77 
16.0 
ETHICAL CONSIDERATIONS ....................................................................................77 
17.0 
INVESTIGATOR REQUIREMENTS ..........................................................................77 
17.1 
Informed Consent...................................................................................................77 
17.2 
Institutional Review Board/Ethics Committee Approval ......................................78 
17.3 
Study Monitoring ...................................................................................................78 
17.4 
Auditing Procedures...............................................................................................79 
17.5 
Data Collection ......................................................................................................79 
17.6 
Investigational Medicinal Product Accountability ................................................79 
17.7 
Disclosure of Data and Publication ........................................................................79 
17.8 
Retention of Records ..............................................................................................80 
18.0 
REFERENCES .................................................................................................................81 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 12 of 130 
CONFIDENTIAL 
 
19 December 2016 
LIST OF TABLES 
Table 1: 
Summary of the Activity of Anti-DLL4 (Demcizumab + 21R30) in 
Human Pancreatic Xenografts ...................................................................18 
Table 2: 
Overall Response Assessment for Subjects Enrolled in Study M18-002 
(n=52) .........................................................................................................25 
Table 3: 
Overall Response Assessment for Subjects in Study M18-004 (n =40) ....28 
Table 4: 
Dose Modifications ....................................................................................46 
Table 5: 
Dose Recommendation and Modifications for Neutropenia and/or 
Thrombocytopenia at the Start of a Cycle or Within a Cycle ....................47 
Table 6: 
Dose Modifications for Other Adverse Drug Reactions ............................48 
Table 7: 
Power for a Two Arm Comparison ............................................................67 
Table 8: 
Summary of Power and Type 1 Error ........................................................68 
Table 9: 
Probability CHF Rate will Exceed 15 Percent over Control .....................70 
 
LIST OF FIGURES 
Figure 1: 
Inhibition of Pancreatic Tumor Growth by Anti-DLL4 as a Single 
Agent and in Combination with Gemcitabine ...........................................18 
Figure 2: 
Reduction of Cancer Stem Cell Frequency after Treatment with 
Anti-DLL4 .................................................................................................19 
Figure 3: 
Activity of Anti-DLL4 in Combination with Anti-PD1 in Reducing the 
Growth of CT26wt Tumors in Immunocompetent Mice ...........................20 
Figure 4: 
Increase in IL-2 Expression by Splenocytes after Treatment with Anti-
DLL4 in Combination with Anti-PD1 .......................................................21 
Figure 5: 
Anti-DLL4 Treatment Increases Memory T cells in Splenocytes of 
Tumor-Bearing Mice .................................................................................22 
Figure 6: 
Percent Change in Tumor Target Lesion Size - Study M18-002 ...............26 
Figure 7: 
Percent Change in Tumor Target Lesion Size of the 
Abraxane®/Gemcitabine/Demcizumab Subjects - Study M18-002 ...........27 
Figure 8: 
Percent Change in Tumor Target Lesion Size - Study M18-004 ...............29 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 13 of 130 
CONFIDENTIAL 
 
19 December 2016 
LIST OF APPENDICES 
APPENDIX A: 
STUDY SCHEMA.....................................................................................83 
APPENDIX B: 
SCHEDULE OF ASSESSMENTS ............................................................84 
APPENDIX C: 
ECOG PERFORMANCE STATUS CRITERIA.......................................88 
APPENDIX D: 
RECIST CRITERIA 1.1 ............................................................................89 
APPENDIX E: 
NEW YORK HEART ASSOCIATION CLASSIFICATION ...................95 
APPENDIX F: 
SAMPLE INFORMED CONSENT ..........................................................96 
APPENDIX G: 
SAMPLE PHARMACOGENOMICS AND TUMOR DNA TESTING 
INFORMED CONSENT .........................................................................121 
APPENDIX H: 
PROTOCOL AMENDMENTS SUMMARY OF CHANGES ................126 
AMENDMENT 1: 
24 NOVEMBER 2014 .............................................................................126 
AMENDMENT 2: 
10 FEBRUARY 2015 ..............................................................................127 
AMENDMENT 3: 
28 MAY 2015 ..........................................................................................128 
AMENDMENT 4: 
31 MARCH 2016 .....................................................................................129 
AMENDMENT 5: 
19 DECEMBER 2016 ..............................................................................130 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 14 of 130 
CONFIDENTIAL 
 
19 December 2016 
2.0 
LIST OF ABBREVIATIONS 
Abbreviation or Term 
Definition/Explanation 
aPTT 
activated partial thromboplastin time 
AE 
adverse event 
ALT (SGPT) 
alanine aminotransferase (serum glutamic pyruvic transaminase) 
ANC 
absolute neutrophil count 
AST (SGOT) 
aspartate aminotransferase (serum glutamic oxaloacetic transaminase) 
BNP 
B-type natriuretic peptide 
BP 
blood pressure 
BUN 
Blood Urea Nitrogen 
CBC 
complete blood count 
CR 
complete response 
CRA 
Clinical Research Associate 
CRF 
Case Report Form 
CT 
computed tomography (scan) 
CTC 
circulating tumor cell 
CTCAE 
Common Toxicity Criteria for Adverse Events (National Cancer Institute) 
dL 
deciliter(s) 
DLL 
Delta-like ligand (DLL1, 3, 4) 
DLT 
dose-limiting toxicity 
DSMB 
Data Safety Monitoring Board 
ECG 
electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
FACS 
Fluorescent-activated cell sorting 
GI 
gastrointestinal 
GCP 
Good Clinical Practice 
HIPAA 
Health Insurance Portability and Accountability Act OF 1996 
IEC 
Independent Ethics Committee 
IGS 
Invasiveness gene signature 
IMP 
Investigational Medicinal Product 
INR 
International normalized ration 
IRB 
Institutional Review Board 
ITT 
intent-to-treat (population) 
IV 
intravenous 
IWRS 
Interactive web randomization system 
kg 
kilogram(s) 
LD 
longest diameter (of a lesion) 
LDH 
lactic dehydrogenase 
LVEF 
left ventricular ejection fraction 
MedDRA 
Medical Dictionary for Regulatory Activities 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 15 of 130 
CONFIDENTIAL 
 
19 December 2016 
Abbreviation or Term 
Definition/Explanation 
mg 
milligram(s) 
mL 
milliliter(s) 
MRI 
magnetic resonance imaging 
NCI 
National Cancer Institute 
NE 
Not evaluable 
NOAEL 
no observed adverse effect level 
PD 
progressive disease 
PK 
pharmacokinetic(s) 
POC 
point of care 
PR 
partial response 
RDC 
remote data capture 
RECIST 
Response Evaluation Criteria in Solid Tumors 
SAE 
serious adverse event 
SD 
stable disease 
ULN 
upper limit of normal 
US 
ultrasound 
VEGF 
vascular endothelial growth factor 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 16 of 130 
CONFIDENTIAL 
 
19 December 2016 
3.0 
BACKGROUND 
3.1 
Investigational Medicinal Product 
Demcizumab (OMP-21M18) is an IgG2 humanized monoclonal antibody directed against 
Delta-Like Ligand 4 (DLL4), which is one of the ligands that bind to the Notch 1, 2, 3, and 
4 receptors. 
3.2 
Disease Background 
Pancreatic cancer is an aggressive malignancy that is usually unresectable at the time of 
diagnosis, 80%–85%.  As complete resection offers the only hope of cure, 5-year survival rates 
are less than 10%.  For patients diagnosed locally advanced or metastatic pancreatic ductal 
adenocarcinoma the median survival is 8–12 months.  Single agent chemotherapy, including the 
commonly used agents gemcitabine, Abraxane®, oxaliplatin, irinotecan, leucovorin, fluorouracil, 
produce objective partial responses in 5-15% of subjects.  More recently, gemcitabine and 
Abraxane® has resulted in somewhat higher response rate, time to progression and survival 
(Ref 1).  In addition, other combinations, such as FOLFIRINOX have reported encouraging 
activity.  However, unresectable metastatic pancreatic ductal adenocarcinoma remains and 
incurable disease. Consequently, there is a significant need to develop novel approaches for the 
treatment of unresectable and metastatic pancreatic ductal adenocarcinoma. 
3.3 
Nonclinical Background 
Many current cancer treatments, while producing an initial reduction in tumor burden and/or a 
prolongation of time to progression, have not resulted in meaningful long-term benefit.  A 
possible explanation for this observation is the presence of cancer stem cells (CSC) 
(Ref 2, Ref 3), which represent a subset of the tumor, but are the most tumorigenic component 
driving growth and metastasis and are more resistant to traditional cytotoxic therapy, including 
both radiotherapy (Ref 4) and chemotherapy (Ref 5), than the remaining bulk of the tumor. 
Consequently, efforts have been made to isolate cancer stem cells and then identify active 
pathways in these cells, which could serve as targets for antibody treatment.  Using this 
approach, the Notch pathway was identified as a potential target.  There are four Notch receptors 
(1–4) and five ligands, including two Jagged (1 and 2) and three Delta-Like Ligands (DLLs) 
(1, 3, and 4).  There appears to be differential binding of these ligands to specific members of the 
Notch family, with DLL4, for example, having a higher specificity for Notch 1 than DLL1 
(Ref 6).  Among the breast, colon, and lung cancers assessed at OncoMed by IHC, all but two 
lung cancers expressed both Notch 1 and the Notch ligand DLL4.  In addition to its important 
role on cancer stem cells, Notch 1 is also important in the cell signaling process of the remaining 
nontumorigenic cancer cells.  Finally, DLL4 and Notch 1 have also been shown to be essential 
for angiogenesis (Ref 7).  Blockade of DLL4 results in tumor-associated endothelial cell 
hyperproliferation, coupled to a non-productive angiogenesis associated with poor tumor 
perfusion, regional hypoxia and an inhibition of tumor growth (Ref 8, Ref 9).  Thus, inhibition of 
the Notch pathway could potentially produce an anti-tumor effect by 1) impacting the growth of 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 17 of 130 
CONFIDENTIAL 
 
19 December 2016 
the cancer stem cells, 2) impacting the growth of the remaining cancer cells, and 3) dysregulating 
tumor angiogenesis. 
Demcizumab is a humanized IgG2 monoclonal antibody directed against DLL4.  Demcizumab is 
not anticipated to exhibit a high rate of immunogenicity.  The antibody binds to DLL4 with high 
affinity, as measured by Biacore, the affinity of demcizumab for human DLL4 is 0.64 nM.  The 
binding of demcizumab to DLL4 blocks its interactions with Notch receptors however, the Notch 
signaling pathway may still be activated by other ligands, as demcizumab is specific for DLL4. 
Nonclinical mouse xenograft studies have suggested that demcizumab possess anti-tumor 
activity via all three of the potential mechanisms described above.  In mouse xenograft models, 
demcizumab and the murine antibody (m21M18) that was humanized to produce demcizumab 
have been demonstrated to have a direct effect on cancer stem cells, reducing the frequency of 
this population.  In these same models, demcizumab and m21M18 have been shown to also have 
a direct effect on the nontumorigenic cancer cells.  Finally, in these models, a phage-derived 
antibody against DLL4 that is capable of binding to murine DLL4, but not human DLL4, has 
been shown to have dys-angiogenic effects coupled to an inhibition of tumor growth. 
3.3.1 
Activity of Anti-DLL4 in Pancreatic Cancer Xenografts 
Pancreatic cancer remains a disease with a generally poor clinical prognosis and one of the most 
difficult malignancies to treat effectively (Ref 10).  The Notch pathway has been implicated in 
playing a role in normal pancreatic development where active Notch signaling is required for 
maintaining cells in undifferentiated state (Ref 11).  Activation of Notch signaling has been also 
been associated with drug resistance in pancreatic cancer (Ref 12).  We have found that blockade 
of Notch signaling with anti-DLL4 is efficacious in a variety of pancreatic xenograft models 
(Table 1).  Representative tumor growth data is shown for PN4 in Figure 1.  Inhibition of 
DLL4-Notch signaling in the tumor stroma and vasculature was associated with 
hyperproliferation of endothelial cells as shown by immunofluorescence with an anti-CD31 
(data not shown) as was previously shown in colon tumors.  Activity in reducing cancer stem 
cells was observed in both the PN4 (Figure 2) as well as the PN8 and PN13 xenograft models. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 18 of 130 
CONFIDENTIAL 
 
19 December 2016 
Table 1: 
Summary of the Activity of Anti-DLL4 (Demcizumab + 21R30) in 
Human Pancreatic Xenografts 
Tumor 
Single Agent 
Combination 
Reduction in CSCs 
PN4  
+ 
+  
+ 
PN8  
+ 
+  
+ 
PN9  
+ 
+  
 
PN13  
+ 
+  
+ 
PN16  
+ 
+  
 
PN17  
+ 
+  
 
PN21 
+ 
+ 
 
PN23 
+ 
- 
 
PN35 
+ 
+ 
 
PN38 
 
- 
 
PN40 
- 
+ 
 
PN42 
 
+ 
 
Anti-DLL4 were tested as a single agent and in combination with gemcitabine or gemcitabine + Abraxane® in 
pancreatic tumors.  The activity of anti-DLL4 treatment as a single agent or in combination with gemcitabine is 
indicated.  A “+” for the single agent activity indicates that tumor volume was less than the control antibody 
treated group, while “+” in the combination activity column indicates the effect on tumor volume relative to the 
chemotherapeutic agent(s)  plus control antibody (p < 0.05).  For PN4, PN8 and PN13 tumors, anti-DLL4 
treatment resulted in a reduction cancer stem cell frequency as shown by in vivo limiting dilution analyses.  
 
Figure 1: 
Inhibition of Pancreatic Tumor Growth by Anti-DLL4 as a Single 
Agent and in Combination with Gemcitabine 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 19 of 130 
CONFIDENTIAL 
 
19 December 2016 
Figure 2: 
Reduction of Cancer Stem Cell Frequency after Treatment with 
Anti-DLL4 
 
PN4 pancreatic tumors were treated with control Ab, anti-DLL4 (Demcizumab + 21R30), gemcitabine, or the 
combination of anti-DLL4.  Following treatment, human tumor cells were isolated, and the tumorigenic cell 
frequency was determined by serial transplantation, in vivo limiting dilution analysis.  Tumor growth frequency 
after 84 days of tumor growth was used to calculate the CSC frequency. 
 
We determined that targeting DLL4-Notch signaling in both tumor and stromal/vasculature cells 
was required for anti-tumor efficacy (Ref 13).  In addition to carrying combination studies with 
gemcitabine alone, we have tested anti-DLL4 in combination with gemcitabine plus Abraxane 
and observed combination activity in this setting as well.  These data indicate that anti-DLL4 
exhibits broad spectrum activity in pancreatic tumor models.  Strikingly, synergy with 
gemcitabine or gemcitabine plus Abraxane was observed in the vast majority of the models 
(Table 1).  The reduction in CSC frequency after anti-DLL4 treatment indicates that Notch 
signaling in the tumorigenic cells is required for CSC function. 
3.3.2 
Potential for Immune-Mediated Mechanism of Action for Anti-DLL4 
Notch signaling is now known to play a key role in various aspects of the immune response 
(Ref 14).  Notch signaling has been shown to upregulate PD1 expression during the immune 
response (Ref 15).  Since PD1 functions to limit T-cell activation, inhibition of DLL4-Notch 
signaling might be expected to increase anti-tumor immune responses.  Our previous studies 
were carried out using patient-derived xenografts that necessitated the use of 
immunocompromised mice and, thus, were not suitable for testing the effect of anti-DLL4 on the 
interaction of lymphocytes in the tumor microenvironment.  To investigate the potential role of 
anti-DLL4 on the host immune response during tumor growth, we have carried out a series of 
experiments using murine tumors implanted in an isogenic murine host strain.  An example 
combining anti-DLL4 and anti-PD1 is shown in Figure 5.  This experiment utilized the CT26wt 
colon tumor model and was carried out in Balb/C mice. Anti-DLL4 reduced tumor growth as a 
single agent and showed additive activity in combination with anti-PD1 (Figure 3).  Subsequent 
analyses indicated that the combination of anti-DLL4 and anti-PD1 increased the expression of 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 20 of 130 
CONFIDENTIAL 
 
19 December 2016 
IL-2 in tumor-specific splenocytes (Figure 4).  Furthermore, anti-DLL4 administration increased 
the fraction of memory T cells in the spleens of tumor-bearing mice (Figure 5).  In addition to 
these results, we have observed in other experiments an increase in the cytotoxic activity of 
CD8+ T cells in killing tumor cells using an ex vivo assay (data not shown).  Collectively, our 
experiments in immunocompetent animals suggest that anti-DLL4 may increase the anti-tumor 
immune response.  Thus, in addition, to its previously characterized mechanisms of action 
(targeting CSCs and disrupting tumor vasculature), promotion of anti-tumor immunity may 
contribute to the efficacy of demcizumab treatment.  This immune-mediated mechanism may be 
particularly important for the long-term, durable responses that have been observed in the Phase 
1b clinical testing of demcizumab.  
Figure 3: 
Activity of Anti-DLL4 in Combination with Anti-PD1 in Reducing the 
Growth of CT26wt Tumors in Immunocompetent Mice 
 
Anti-DLL4 treatment reduces tumor growth in an immune-competent mouse model. CT26wth murine colon tumors 
were implanted subcutaneously in Balb/C mice.  Treatment was initiated on Day 7 with either control antibody, 
anti-PD1, anti-mDLL4 (OMP-21R30), or the combination of anti-DLL4 and anti-PD1. Anti-DLL4 inhibited 
tumor growth, either as a single agent or in combination with anti-PD1. 
 
0
5
10
15
20
25
0
300
600
900
anti-DLL4
Control Ab
anti-PD1
anti-DLL4 + anti-PD1
Days
tumor volume (mm3)


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 21 of 130 
CONFIDENTIAL 
 
19 December 2016 
Figure 4: 
Increase in IL-2 Expression by Splenocytes after Treatment with 
Anti-DLL4 in Combination with Anti-PD1 
 
Anti-DLL4 treatment increases IL-2 expression in combination with anti-PD1.  Splenocytes from tumor-bearing 
mice from the four treatment groups shown in Figure 3 were analyzed for IL-2 expression by Elispot assay.  
 
Control Ab 
Anti-DLL4 
Anti-PD1 
Anti-DLL4 
+ Anti-PD1 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 22 of 130 
CONFIDENTIAL 
 
19 December 2016 
Figure 5: 
Anti-DLL4 Treatment Increases Memory T cells in Splenocytes of 
Tumor-Bearing Mice 
 
Anti-DLL4 treatment increases memory T cells in splenocytes from tumor-bearing mice. Splenocytes from the four 
treatment groups shown in Figure 5 were analyzed for the total number of CD4+ or CD8+ T cells.  Anti-PD1 
treatment increased the percentages of both CD4+ and CD8+ T cells. Anti-DLL4 treatment increased the 
effector memory (EM) and central memory (CM) T cell populations in the CD+ subset and the CM population 
in CD4+ T cells. 1B7-11 = negative control antibody. 21R30 = anti-mDLL4. 
 
3.4 
Clinical Background 
Five clinical studies (M18-001, M18-002, M18-003, M18-004 and M18-005) have been or are 
being conducted with demcizumab.  M18-001 was a Phase 1a single-agent dose escalation trial 
of demcizumab in subjects with previously treated advanced solid tumors.  Study M18-002 is an 
ongoing open-label Phase 1b study of gemcitabine or gemcitabine and Abraxane® plus 
demcizumab in subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma.  
Study M18-003 was an open-label Phase 1b study of 5-fluorouracil, folinic acid and irinotecan 
(FOLFIRI ) plus demcizumab in subjects with metastatic colorectal cancer that was closed after 
seven subjects were treated on the trial due to changing corporate priorities.  Study M18-004 is 
an ongoing open-label Phase 1b study of carboplatin and pemetrexed plus demcizumab in 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 23 of 130 
CONFIDENTIAL 
 
19 December 2016 
subjects with unresectable locally advanced, recurrent, or metastatic non-squamous NSCLC.  
Finally, study M18-005 is an ongoing Phase 1b/2 study of paclitaxel plus demcizumab in 
subjects with platinum-resistant ovarian cancer.  
3.4.1 
Phase 1a Study M18-001 
M18-001 was a Phase 1a single-agent dose escalation trial of demcizumab in subjects with 
previously treated advanced solid tumors.  This trial was conducted to determine the maximum 
tolerated dose (MTD), safety, pharmacokinetics, immunogenicity, and preliminary efficacy of 
demcizumab.  A total of 61 subjects were enrolled in the trial, and 55 subjects received 
treatment.  In the dose-escalation phase of the study, 39 subjects received treatment at 0.5 (n=3), 
1.0 (n=3), 2.5 (n=6), and 5.0 (n=3) mg/kg once weekly for the first 56 days and then once every 
other week, and 2.5 (n=6), 5 (n=6) and 10 (n =12) mg/kg once every other week until disease 
progression.  In the expansion phase of the study, an additional 15 subjects were treated with 
10 mg/kg once every other week.  Finally, one subject was treated with 10 mg/kg weekly on 
Day 0, 7, and 14 (as a loading dose) and then 10 mg/kg once every other week.   
The MTD as assessed by DLTs observed over the first 28 days was not reached at 10 mg/kg once 
every other week.  Hypertension or blood pressure increased that was managed with oral 
anti-hypertensives was the most frequent related event occurring in 55% of subjects.  Other 
common related events included fatigue, anemia, headache, hypoalbuminemia, and dyspnea.  
A decline in hemoglobin of >2 g/dL was also observed in 17 of the 55 (31%) treated subjects. 
During the conduct of the study, cardiotoxicity was identified as a potential toxicity in the 
ongoing 6-month cynomolgus monkey study.  As a result, the protocol was amended to include 
monitoring with brain natriuretic peptide (BNP) and echocardiograms.  Increases in BNP to 
>400 pg/mL (or NT-pro-BNP >800 pg/mL) considered to be possibly related to study drug were 
observed in 6 subjects who received 10 mg/kg once every other week.  This toxicity is 
considered dose-, schedule- and duration-related.  High doses of demcizumab administered 
frequently for prolonged periods of time can result in the emergence of cardiotoxicity as was 
seen on study M18-001 in the subjects treated at 10mg/kg dosed every other week for a 
prolonged period of time (>100 days).  Three of the subjects who had a screening left ventricular 
ejection fraction of at least 50% subsequently had a value that was <40% after receiving therapy 
for >100 days.  
Four subjects who received 10 mg/kg once every other week developed congestive heart failure 
(3 Grade 3 and 1 Grade 4).  A rise in BNP above 250 pg/mL occurred prior to the development 
of congestive heart failure in 3 of these 4 subjects.  In addition, 1 subject who received 2.5 mg/kg 
once every week developed Grade 3 right ventricular failure.  In all 5 subjects, demcizumab 
therapy was discontinued, and the subjects were started on medication to treat their heart failure 
when the event occurred.  The symptoms of heart failure subsequently diminished in all 
5 subjects.  In addition, 2 subjects developed pulmonary hypertension.  One of these subjects 
received 2.5 mg/kg once every week and developed Grade 1 pulmonary hypertension.  
Enrollment in the study was stopped early due to an unacceptably high rate of congestive heart 
failure in subjects treated at 10 mg/kg once every other week for longer than 100 days.  The data 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 24 of 130 
CONFIDENTIAL 
 
19 December 2016 
from this trial suggest that high (i.e., 10 mg/kg) doses of demcizumab administered for a 
prolonged period of time (i.e., >100 days) results in an increased incidence of heart failure. 
One unconfirmed partial response as per RECIST version 1.1 (v1.1) was observed in a refractory 
pancreatic cancer subject treated at 10 mg/kg once every other week.  In addition, a number of 
subjects with a variety of solid tumors including NSCLC, renal cell carcinoma, colorectal cancer, 
and pancreatic cancer, had a reduction in the size of their target lesions of <30%.  A high 
percentage of subjects (59%; 16 of 27) treated at 10 mg/kg once every other week had stable 
disease (n=15) or a partial response (n=1).  One subject at 10 mg/kg once every other week with 
a refractory ovarian cancer (granulosa cell) who had progressed through 12 prior treatment 
regimens remained on therapy with disease control for 518 days.  
3.4.2 
Phase 1b Studies M18-002, M18-003, and M18-004 and Phase 1b/2 Study 
M18-005 
Three Phase 1b studies (M18-002, M18-003, and M18-004) and one Phase 1b/2 study 
(M18-005) of demcizumab plus chemotherapy have been or are being conducted.  As of the 
cut-off dates of 23 July 2013 (M18-003), 25 July 2014 (M18-004), 17 Sept 2014 (M18-002) and 
21 August 2014 (M18-005), 104 subjects have been treated in these trials.  Study M18-002 is an 
ongoing open-label Phase 1b study of gemcitabine or gemcitabine and Abraxane® plus 
demcizumab in subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma.  
Study M18-003 was an open-label Phase 1b study of 5-fluorouracil, folinic acid and irinotecan 
(FOLFIRI) plus demcizumab in subjects with metastatic colorectal cancer that was closed after 
seven subjects were treated on the trial due to changing corporate priorities.  Study M18-004 is 
an ongoing open-label Phase 1b study of carboplatin and pemetrexed plus demcizumab in 
subjects with unresectable locally advanced, recurrent, or metastatic non-squamous NSCLC.  
Finally, study M18-005 is an ongoing Phase 1b/2 study of paclitaxel plus demcizumab in 
subjects with platinum-resistant ovarian cancer.  
3.4.2.1 
Phase 1b Efficacy Data 
Study M18-002 is an ongoing Phase 1b trial of demcizumab in combination with gemcitabine or 
gemcitabine and Abraxane® in subjects with previously untreated adenocarcinoma of the 
pancreas.  Thirty-eight of the 52 subjects were evaluable for response.  Four of the 16 (25%) 
evaluable subjects treated with gemcitabine and demcizumab had a partial response, and 7 (44%) 
had stable disease.  Ten of the 22 (45%) evaluable subjects treated with Abraxane®, gemcitabine 
and demcizumab had a partial response, and 9 (41%) had stable disease.  Table 2 summarizes the 
RECIST v1.1 response data for this study.  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 25 of 130 
CONFIDENTIAL 
 
19 December 2016 
Table 2: 
Overall Response Assessment for Subjects Enrolled in Study M18-002 
(n=52) 
 
Cohort 1 
 
5 mg/kg 
q2w 
(n=8) 
Cohort 2 
 
2.5 
mg/kg 
q4w 
(n=8) 
Cohort 3 
 
5 mg/kg 
q4w 
(n=8) 
TOTAL 
Gem + 
Dem 
(evaluable: 
n=16) 
Cohort 
4 
Tr. Dem
2.5 
mg/kg 
q2w 
(n=6) 
Cohort 
5 
Tr. Dem
5 mg/kg 
q2w 
(n=8) 
Cohort 
6 
Tr. Dem
3.5 mg/kg
q2w 
(n=9) 
Cohort  
7 
Tr. Dem 
3.5 mg/kg 
q2w 
(n=5) 
TOTAL 
Nab/Gem +
Dem 
(evaluable: 
n=22) 
Complete 
Response 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Partial 
Response 
1 
1 
2 
4 (25%) 
4 
3 
3 
- 
10 (45%) 
Stable 
Disease 
4 
2 
1 
7 (44%) 
1 
4 
4 
- 
9 (41%) 
Progressive 
Disease 
- 
3 
2 
5 (31%) 
1 
1 
1 
- 
3 (14)% 
Not 
evaluable 
3 
2 
3 
8 
- 
- 
1 
5 
6 
Dem = demcizumab; Gem = gemcitabine; Nab = Abraxane®; q2w = every 2 weeks; q4w = every 4 weeks; Tr. Dem 
= truncated demcizumab dosing regimen (last demcizumab dose on Day 70; see Section 3.4.2.2). Subjects in 
Cohorts 1-3 received gemcitabine plus demcizumab. Subjects in Cohorts 4-6 received Abraxane®, gemcitabine 
and demcizumab (truncated dosing regimen). 
 
Figure 6 and Figure 7 are the waterfall plots showing the best % reduction in target lesion size 
for all of the subjects on the study and those who received demcizumab, gemcitabine and 
Abraxane®, respectively.  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 26 of 130 
CONFIDENTIAL 
 
19 December 2016 
Figure 6: 
Percent Change in Tumor Target Lesion Size - Study M18-002 
 
Figure 6 provides the best % change in tumor target lesion size for all subjects (i.e., subjects treated with 
gemcitabine and demcizumab and subjects treated with Abraxane®, gemcitabine and demcizumab) enrolled in 
study M18-002.  Thirty-one of the 38 evaluable subjects had a reduction in the size of their target lesions, and 
7 subjects had an increase in the size of their target lesions.  Each bar represents an individual subject.  Subjects 
were dosed either once every 2 weeks or every 4 weeks. 
 
Waterfall Plot 
% Change in Tumor Target Lesions 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 27 of 130 
CONFIDENTIAL 
 
19 December 2016 
Figure 7: 
Percent Change in Tumor Target Lesion Size of the Abraxane®/Gemcitabine/Demcizumab Subjects - 
Study M18-002 
 
 
% Change in Tumor Target Lesions 
‐100
‐80
‐60
‐40
‐20
0
20
5Q2W* 2.5Q2W*3.5Q2W*3.5Q2W* 5Q2W* 5Q2W* 3.5Q2W* 5Q2W* 3.5Q2W*3.5Q2W* 5Q2W* 5Q2W* 2.5Q2W*2.5Q2W*2.5Q2W*2.5Q2W*3.5Q2W*2.5Q2W* 5Q2W* 5Q2W*


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 28 of 130 
CONFIDENTIAL 
 
19 December 2016 
Only 7 1st- or 2nd-line colorectal cancer subjects were enrolled in study M18-003, and their 
treatment was stopped early. Thus, response data are not displayed. 
Table 3 summarizes the RECIST v1.1 response data for study M18-004 that is an ongoing 
Phase 1b study in subjects with 1st-line NSCLC who were treated with demcizumab in 
combination with pemetrexed and carboplatin.  Thirty-three of the 40 subjects were evaluable for 
response.  Sixteen of the 33 (48%) evaluable subjects had a response, and 13 (39%) subjects had 
stable disease. 
Table 3: 
Overall Response Assessment for Subjects in Study M18-004 (n =40) 
 
Cohort 1 
 
 
5 mg/kg 
q3w 
(n=6) 
Cohort 2 
 
 
2.5 mg/kg 
q3w 
(n=6) 
Cohort 3
 
 
5 mg/kg 
q3w 
(n=8) 
Cohort 4 
(Expansion)
 
5 mg/kg 
q3w 
(n=6) 
Cohort 5 
 
Trunc Dem
7.5 mg/kg
q3w 
(n=6) 
Cohort 6 
 
Trunc Dem 
5 mg/kg 
q3w 
(n=7) 
Cohort 7 
(Expansion) 
Trunc Dem 
5 mg/kg 
q3w 
(n=1) 
TOTAL 
(evaluable: 
n=33) 
Best Overall Response, n (%) 
Complete 
Response 
- 
- 
- 
1 
- 
- 
- 
1 (3%) 
Partial 
Response 
2 
4 
2 
- 
4 
3 
- 
15 (45%) 
Stable 
Disease 
2 
2 
4 
2 
1 
2 
- 
13 (39%) 
Progressive 
Disease 
- 
- 
1 
2 
1 
- 
- 
4 (12%) 
Not 
evaluable  
2 
- 
1 
1 
- 
2 
1 
7 
q3w = every 3 weeks; Trunc Dem = truncated demcizumab dosing regimen (last demcizumab dose on Day 63, see 
Section 3.4.2.2). 
 
Figure 8 provides the best percent change in tumor target lesion size for study M18-004.  
Twenty-seven of the 31 evaluable subjects had a reduction the size of their target lesions. 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 29 of 130 
CONFIDENTIAL 
 
19 December 2016 
Figure 8: 
Percent Change in Tumor Target Lesion Size - Study M18-004 
 
Each bar represents an individual subject.  All subjects were dosed once every 3 weeks. 
 
‐100
‐80
‐60
‐40
‐20
0
20
40
60
80
100
% Change in Tumor Target Lesions 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 30 of 130 
CONFIDENTIAL 
 
19 December 2016 
Five subjects with platinum-resistant ovarian cancer have been enrolled in study M18-005 and 
were treated with paclitaxel and demcizumab.  Two of these subjects had stable disease, and 
3 had progressive disease. 
3.4.2.2 
Phase 1b Safety Data 
The treatment-emergent adverse events (AEs) in the 104 subjects treated in the 3 Phase 1b 
studies and the 1 Phase 1b/2 study considered to be related or possibly related to demcizumab by 
the Investigators and that occurred in >10 % of subjects were fatigue (44.2%), nausea (41.3%), 
hypertension/blood pressure increased (30.8%), vomiting (25%), edema peripheral (22.1%), 
diarrhea (21.1%), appetite decreased (17.3%), increased BNP (17.3%),  anemia (13.5%), 
thrombocytopenia (13,5%), neutropenia (13.5%), dyspnea (11.5%), headache (10.6%) and 
pulmonary hypertension (10.6%). 
The Grade 3-5 treatment-emergent AEs considered to be related to demcizumab that occurred in 
> 5% of subjects were hypertension/blood pressure increased (15.4%), neutropenia (7.7%) and 
thrombocytopenia (6.7%). 
While subjects were being dosed in the first cohorts of the Phase 1b studies (M18-002, M18-003 
and M18-004), some subjects in the Phase 1a single-agent study (M18-001) developed 
congestive heart failure, and, thus, the enrollment and treatment of subjects in the first dose 
cohort of the Phase 1b trials was stopped while the data for the subjects with congestive heart 
failure were analyzed.  A decision was made to close study M18-003, but, subsequently, 
enrollment was resumed in studies M18-002 and M18-004 after the protocols were amended to 
include the following changes: 1) modified demcizumab dosing approach to include less frequent 
and lower doses; 2) standard bed-side Alere Triage BNP testing, 3) exclusion of subjects with a 
screening BNP of >100 pg/mL, 4) exclusion of subjects with a left ventricular ejection fraction 
(LVEF) of <50% or with pulmonary hypertension defined as a peak tricuspid velocity >3.4 m/s 
on Doppler echocardiogram, and 5) implementation of a dosing risk mitigation strategy 
including the administration of a cardioprotective agent (ACE inhibitor or carvedilol) to subjects 
with one BNP value >200 pg/mL or two values >100 pg/mL.  As 3 subjects in the 2 ongoing 
Phase 1b studies (M18-002 and M18-004) subsequently developed pulmonary hypertension 
and/or heart failure between Days 168-184, further modifications were made including the 
utilization of truncated dosing with the last dose of demcizumab being administered on Day 63 
in the NSCLC trial and on Day 70 in the pancreatic cancer trial.  The use of truncated dosing 
allowed for washout of the drug prior to the timeframe when cardiopulmonary events had been 
observed.  The utilization of truncated demcizumab dosing and further modifications of the risk 
mitigation strategy have resulted in none of the subsequent 50 subjects developing Grade >2 
pulmonary hypertension or heart failure; i.e., only 1 subject has developed Grade 1 
asymptomatic pulmonary hypertension, and none have developed heart failure. 
These data demonstrate that the risk mitigation strategy that was employed in the Phase 1b 
studies was successful in preventing any clinically significant cases of pulmonary hypertension 
or heart failure.   


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 31 of 130 
CONFIDENTIAL 
 
19 December 2016 
3.5 
Risks/Benefits 
The toxicology and pharmacokinetics of demcizumab were studied in the cynomolgus monkey.  
The toxicology findings in the initial definitive 8 week cynomolgus monkey study were limited 
to minor clinical pathology alterations, minimal effects on body weight (seen in selected 
monkeys that received 200 mg/kg), minimal-to-slight congestion or hemorrhage in the 
gastrointestinal tract, and dose-related degeneration/necrosis of the physis-metaphysis of the 
distal femur.  The body weight, clinical pathology and gastrointestinal effects were not 
considered to be adverse. Based on the severity, the degeneration/necrosis of the physis-
metaphysis of the distal femur noted at 50 and 200 mg/kg/week was considered adverse.  
Following recovery, degeneration/necrosis and loss of the physis-metaphysis of the distal femur 
was limited to one male that previously had been dosed at 200 mg/kg/week.  Whether this 
finding was persistent or delayed in onset is uncertain.  However, it should be noted that the 
monkeys that were treated in this study were adolescent monkeys with growth plates that were 
not yet fused.  These finding would probably not have been observed if adult monkeys with 
fused growth plates had been studied.  Similarly, as demcizumab will only be administered to 
patients who are at least 21 years of age in the human clinical trials this effect is unlikely to 
occur.  
Based upon the results of this study, demcizumab was generally well tolerated at doses up to 
200 mg/kg/week.  The maximum tolerated dose (MTD) of demcizumab was at least 
200 mg/kg/week, corresponding to a mean Day 50 AUC of 497 mg.hr/mL. 
A subsequent cynomolgus monkey study was performed in which the animals received doses of 
demcizumab as a weekly infusion, 10, 30 or 100 mg/kg, for 26 weeks.  In this study, long term 
administration of the two highest doses was not tolerated.  Histopathologic findings present in 
the heart included hypertrophy, both of the cardiac myofibers and of the endothelial cells lining 
the small vessels within the myocardium, and myofiber degeneration and necrosis.  In addition, 
test-article related changes in the liver included atrophy of centrilobular hepatocytes and dilation 
of the centrilobular sinusoids.  Data from this study revealed that cardiotoxicity related to 
demcizumab occurred principally in monkeys that were treated with high doses (30 and 
100 mg/kg) of demcizumab weekly, for prolonged periods of time.  However, animals that 
received lower doses (10 mg/kg/week) of demcizumab did not manifest any clinical signs of 
cardiotoxicity with prolonged treatment (up to 6 months). 
This nonclinical study, in addition to emerging clinical data, was pivotal to the redesign of the 
clinical trials of demcizumab to incorporate lower dose administration of the drug to patients and 
to institute the cardiac risk mitigation plan on the ongoing Phase 1b trials, although subsequently 
the use of truncated dosing was also incorporated.  These findings prompted changes to the 
clinical protocols to include more frequent ECG monitoring and to add echocardiography and 
BNP measurements.   
The emerging clinical data from the 5 demcizumab studies conducted to date suggest that the 
primary drug-related toxicities associated with demcizumab administration are hypertension, 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 32 of 130 
CONFIDENTIAL 
 
19 December 2016 
bleeding, pulmonary hypertension and heart failure.  Newly diagnosed hypertension or 
exacerbation of pre-existing hypertension occurred in about one-third to one-half of the subjects 
on the demcizumab clinical trials.  Thus, subjects receiving demcizumab should be closely 
monitored for the development of hypertension or the exacerbation of pre-existing hypertension, 
and patients with hypertension should be treated according to the standard treatment guidelines 
for managing hypertension (Ref 16).  Serious bleeding, primarily from luminal tumors in the 
gastrointestinal tract occurred in 5 subjects in the Phase 1 dose escalation study.  As a result, 
subjects having luminal tumors were subsequently excluded from the demcizumab clinical trials 
and, subsequently, there was only 1 case of possible serious tumor-associated bleeding in the 
gastrointestinal tract in the Phase 1b or Phase 1b/2 studies.  Grade 3 or greater right- and/or left-
sided heart failure with or without Grade 3 pulmonary hypertension has occurred in 8 of the 
subjects treated with continuous demcizumab between Days 112-184.  As a result, several 
modifications to the risk mitigation strategy, monitoring and dosing of demcizumab were 
instituted.  Subsequent to implementation of this updated risk mitigation procedure, none of the 
50 subjects treated according to this approach have developed Grade 2 or greater pulmonary 
hypertension or heart failure; i.e., only 1 patient has developed Grade 1 pulmonary hypertension.  
Strict adherence to the risk mitigation, monitoring and demcizumab dosing guidelines (provided 
in Section 7 of the Investigator Brochure) is required to avoid pulmonary hypertension and/or 
heart failure. 
As the 5 clinical studies conducted to date have all been at the Phase 1 stage of development 
(with the exception of Phase 1b/2 study in patients with ovarian cancer, which at present has data 
reported on 5 subjects), the extent of efficacy data is limited.  Nevertheless, there are 
observations of activity in the Phase 1b studies (see Section 6.4 of the Investigator’s Brochure 
for a comprehensive overview).  Most relevant for the upcoming Phase 2 study in pancreatic 
cancer is the ongoing Phase 1b study in subjects with 1st-line pancreatic cancer who were treated 
with demcizumab in combination with gemcitabine or gemcitabine plus Abraxane® 
(protocol M18-002).  Four of the sixteen (25%) evaluable subjects treated with gemcitabine and 
demcizumab had partial response and 7 (44%) had stable disease and nine of the twenty-two 
(41%) evaluable subjects treated with Abraxane®, gemcitabine and demcizumab had a partial 
response and 10 (45%) had stable disease.  In addition, twenty of the twenty-one evaluable 
subjects had a reduction in the size of their target lesions. 
In summary, OncoMed has gained critical safety experience from the cynolmolgus monkey 
studies and from Phase 1 clinical development in understanding the primary risks associated with 
demcizumab treatment.  OncoMed instituted a risk mitigation procedure early on in the program, 
as a result of histopathologic findings from the second cynomolgus study.  The risk mitigation 
plan was further refined during clinical development, and subsequent to implementation of the 
updated risk mitigation plan, no patients have developed greater than Grade 1 cardiotoxicity to 
date.  This risk mitigation strategy has been incorporated into the proposed Phase 2 protocol and 
is reviewed extensively in the Investigator’s Brochure (Section 7).  There have been observations 
of clinical activity in the Phase 1b trials as reviewed in Section 6.4 of the Investigator’s Brochure 
and as briefly described above.  Thus, the current risk/benefit assessment of demcizumab 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 33 of 130 
CONFIDENTIAL 
 
19 December 2016 
supports the continued clinical development of this novel investigational anti-cancer therapeutic 
in a randomized, placebo-controlled Phase 2 trial, which will more rigorously assess the clinical 
potential of demcizumab in the treatment of1st line pancreatic cancer. 
3.6 
Dose Rationale 
In the Phase 1b study of demcizumab and gemcitabine or demcizumab plus gemcitabine and 
Abraxane® (study M18-002), subjects in the 1st 3 dose cohorts received demcizumab doses of 
either 5 mg/kg once every 2 weeks or 2.5 or 5 mg/kg once every 4 weeks until disease 
progression.  As 1 of the subjects in the 3rd dose cohort of this study and 2 additional patients in 
the ongoing non-small cell lung cancer Phase 1b study developed pulmonary hypertension and 
heart failure at approximately Day 168, the 38 subjects in the subsequent 4 cohorts received a 
truncated dosing regimen of 2.5, 3.5 or 5 mg/kg once every 2 weeks for 70 days (i.e., 6 doses 
over 70 days).  No cases of Grade 2 pulmonary hypertension or heart failure were observed in 
any of these subjects.  However, the data safety monitoring board (DSMB) for the study felt that 
the BNP and peak tricuspid velocity data of subjects in the.5 mg/kg cohort suggested that the 
dose may be too high and thus recommended that the truncated dosing regimen of 3.5 mg/kg 
once every 2 weeks be used for the Phase 2 study.  Subjects in the 3rd arm of this study will 
receive 2 truncated courses of demcizumab at 3.5 mg/kg once every 2 weeks (one from Days 
0-70 and one from Days 168-238).  Only subjects who meet the original cardiac-related 
inclusion/exclusion criteria at Day 168 will receive the 2nd truncated course of demcizumab in 
this arm of the study.  With a terminal half life of 16 days, the 3-month washout period will 
allow more than 99.5% of the drug to be eliminated before re-dosing.  This arm was included in 
the study to determine if a second truncated course of demcizumab can enhance efficacy 
compared to a single truncated course of demcizumab.  Whereas the demcizumab regimen of the 
3rd arm was not directly tested in the supporting Phase 1b program, the risk/benefit ratio for 
subjects in this arm is deemed acceptable, since the truncated dosing regimen has demonstrated 
an excellent safety profile, cardiac-related demcizumab toxicity appears reversible and subjects 
have to meet stringent criteria for the second course of demcizumab.  Furthermore, the DSMB 
for this study will be monitoring the emerging safety data very closely to ensure that this 
approach is safe for continued use in the trial.  
3.7 
Study Conduct 
This study will be conducted in compliance with the protocol approved by the Institutional 
Review Board (IRB) or Independent Ethics Committee (IEC), and in accordance with Good 
Clinical Practice (GCP) standards and all applicable regulatory requirements.  No deviation from 
the protocol will be implemented without the prior review and approval of the IRB/IEC except 
where it may be necessary to eliminate an immediate hazard to a research subject.  In such a 
case, the deviation will be reported to the IRB or IEC as soon as possible. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 34 of 130 
CONFIDENTIAL 
 
19 December 2016 
3.8 
Subject Population 
Subjects must be at least 21 years of age, have 1st line metastatic pancreatic ductal 
adenocarcinoma, have not received prior chemotherapy for their metastatic pancreatic ductal 
adenocarcinoma, have adequate organ and bone marrow function, have an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 or 1, and have a life expectancy of more than 
3 months.  In addition, subjects must have measurable disease per RECIST 1.1. 
4.0 
STUDY OBJECTIVES AND ENDPOINTS 
4.1 
Study Objectives 
Primary Objective: 
 To compare the efficacy of Arm 1 to the pooled decizumab arms (i.e., Arm 1 to Arms 2 
and 3)  (See Section 5.0 for description of Treatment Arms) in subjects with 1st-line 
metastatic pancreatic ductal adenocarcinoma 
Secondary Objectives: 
 To compare the efficacy of Arm 1 to Arm 2 and Arm 1 to Arm 3 in subjects with 1st-line  
metastatic pancreatic ductal adenocarcinoma 
 To compare the safety of Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 pooled in 
subjects with 1st-line  metastatic pancreatic ductal adenocarcinoma. 
 
To determine the rate of immunogenicity against demcizumab when combined with Abraxane® and 
gemcitabine in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. 
  To determine population pharmacokinetics of demcizumab in subjects receiving 
demcizumab and Abraxane® and gemcitabine in subjects with 1st-line metastatic pancreatic 
ductal adenocarcinoma.  
Exploratory Objectives: 
 To compare the safety and efficacy of Arm 2 to Arm 3 in subjects with 1st-line  metastatic 
pancreatic ductal adenocarcinoma. 
 To compare the exploratory biomarkers of Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 
and 3 pooled in subjects with 1st-line  metastatic pancreatic ductal adenocarcinoma. 
Primary Endpoint 
 To compare the hazard of progression using the Investigator assessed progression-free 
survival time between subjects in Arm 1 and the pooled demcizumab arms  
(i.e., Arms 2 + 3)in 1st-line metastatic pancreatic ductal adenocarcinoma. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 35 of 130 
CONFIDENTIAL 
 
19 December 2016 
Secondary Endpoints 
 To compare the hazard of progression using the Investigator assessed progression-free 
survival time between subjects in Arm 1 and Arm 2 and Arm 1 and Arm 3 in 1st-line 
metastatic pancreatic ductal adenocarcinoma. 
 To compare the Investigator-assessed RECIST response rate in Arm 1 to Arm 2 , Arm 1 to 3 
and Arm 1 to Arms 2 and 3 pooled in subjects with 1st-line metastatic pancreatic cancer.  
 To compare the Investigator-assessed RECIST clinical benefit rate (i.e., the rate of complete 
response + partial response + stable disease) in Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to 
Arms 2 and 3 pooled in subjects with 1st-line  metastatic pancreatic ductal adenocarcinoma. 
 To compare the Investigator-assessed progression-free survival at 6 months in Arm 1 to Arm 
2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 pooled in subjects with 1st-line  metastatic 
pancreatic ductal adenocarcinoma. 
 To compare the Independent Review Facility (IRF)-assessed RECIST response rate and 
progression-free survival based solely on radiographs in Arm 1 to Arm 2, Arm 1 to 3 and 
Arm 1 to Arms 2 and 3 pooled (Optional). 
 To determine the half-life, volume of distribution and clearance of demcizumab when 
combined with Abraxane® and gemcitabine in with subjects with 1st-line metastatic 
pancreatic ductal adenocarcinoma. 
 To compare the safety profile through adverse event monitoring (including attribution of 
adverse events and serious adverse events [SAEs]), physical examination, vital signs, and 
clinical laboratory testing as outlined in the Schedule of Assessments (see Appendix B) 
between Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 pooled in subjects with 1st-
line  metastatic pancreatic ductal adenocarcinoma.  To compare the incidence of anti-
demcizumab antibody development and neutralizing antibody development in subjects with 
1st-line locally advanced or  metastatic pancreatic ductal adenocarcinoma being treated with  
Abraxane® and gemcitabine plus demcizumab in Arm 1 to Arm 2, Arm 1 to 3 and Arms 1 to 
Arms 2 and 3 pooled. 
 To compare the median survival in Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 
pooled  in subjects with 1st-line  metastatic pancreatic ductal adenocarcinoma  
 The compare the Kaplan Meier estimates of survival at 6, 12, 18 and 24 months in Arm 1 to 
Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 pooled in subjects with 1st-line metastatic 
pancreatic ductal adenocarcinoma. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 36 of 130 
CONFIDENTIAL 
 
19 December 2016 
Exploratory Endpoints 
 To compare the pharmacodynamic and predictive biomarkers for demcizumab and determine 
their correlation with response in Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 
pooled (see Section 11.0). 
 To compare the CA-19-9 response rate (i.e., at least a 50% decline from baseline) between 
Arm 1 to Arm 2, Arm 1 to 3 and Arm 1 to Arms 2 and 3 pooled in subjects with 1st-  
metastatic pancreatic ductal adenocarcinoma. 
5.0 
OVERALL STUDY DESIGN AND PLAN – DESCRIPTION 
This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic 
pancreatic ductal adenocarcinoma.  Prior to randomization, subjects will undergo screening to 
determine study eligibility. Two hundred and one evaluable subjects will be randomized via an 
IWRS system.   
Gemcitabine will be given by intravenous (IV) infusion at a dose of 1000 mg/m2 on Days 1, 8 
and 15 of each 28-day treatment cycle (or until toxicity necessitates reducing or holding a dose).  
Abraxane® will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 
1, 8 and 15 of each 28-day treatment cycle.  Demcizumab 3.5 mg/kg or placebo will be 
administered by IV infusion (prior to the administration of Abraxane® and gemcitabine) once 
every 2 weeks for either one (1st course through Study Day 70) or two (2nd course begun on 
Study Day 168 and continued through Study Day 238) 70 day courses (i.e., 6 doses per course).   
Randomized subjects will be treated in the following manner:  
Arm 1 – Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine 
(3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and 
gemcitabine until disease progression  
Arm 2 - Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine 
(3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and 
gemcitabine until disease progression  
Arm 3 - Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine 
(3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and 
gemcitabine until disease progression  
Dosing of gemcitabine, Abraxane® and demcizumab or placebo must be done within ± 2 days of 
the Study Day listed in the protocol.  If a drug cannot be given within this 2 day window, then 
the dose of that drug is permanently missed.  Subjects will only receive their second 70 day 
course of placebo or demcizumab if their Day 168 BNP is ≤100 pg/mL, peak tricuspid velocity is 
≤3.0 m/s and LVEF is ≥50% and they did not develop pulmonary hypertension or heart failure 
while on study.  Any subject who has two consecutive B-type natriuretic (BNP) values 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 37 of 130 
CONFIDENTIAL 
 
19 December 2016 
˃100 pg/mL or one value >200 pg/mL will be unblinded by the Investigator (these subjects will 
remain on study) through the IWRS system.  If the subject is receiving demcizumab they will be 
started on an ACE inhibitor or carvedilol, unless the BNP elevation occurred more than 100 days 
after the discontinuation of demcizumab or there is a contraindication to administering these 
agents and if appropriate, referred to a cardiologist.   If they are not receiving demcizumab they 
will be cared for according to standard medical practice.  
Subjects will be assessed for disease status every 8 weeks and for safety at every visit and 
through 30 days following the termination visit.  In all three arms, subjects should remain on 
study until disease progression.  Immunogenicity will be assessed at baseline, every 8 weeks 
while on study and at treatment termination.  Biomarker assessment will be performed at Days 0, 
21, 35, 49 and 63 and at treatment termination.  Plasma sample for PK analysis to be obtained 
prior to the demcizumab infusion on Days 0, 14, 56, 70, 168, 182, 224 and 238, and at the end of 
the demcizumab infusion (prior to chemo infusion) on Days 0, 56, 70, 168, 224 and at treatment 
termination.  If all of the study drugs are discontinued prior to disease progression, the subject 
should remain on study until disease progression or withdrawal of consent. Once discontinuation 
criteria for the study are met (disease progression, use of other anti-cancer therapy, subject or 
investigator decision or protocol non-compliance) a termination visit should occur ≤14 days 
later. The termination visit may occur later after discussion with the OncoMed Medical Monitor 
for specific circumstances, such as prolonged hospitalization. After the termination visit, subjects 
should have regular follow-up for survival and other assessments as required per protocol. 
6.0 
SELECTION OF STUDY POPULATION 
6.1 
Inclusion Criteria 
Subjects must meet all of the following criteria to be eligible for the study: 
1. 
Subjects must have cytologically or histologically confirmed metastatic pancreatic ductal 
adenocarcinoma.  Prior chemotherapy and/or radiotherapy either in the adjuvant or 
neoadjuvant setting or for metastatic disease is not allowed.   
2. 
Age >21 years 
3. 
ECOG performance status 0 or 1 (see Appendix C) 
4. 
Measurable disease per RECIST v1.1 (Appendix D) 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 38 of 130 
CONFIDENTIAL 
 
19 December 2016 
5. 
Adequate organ and marrow function as defined below: 
 Absolute neutrophil count >1.5 x 109/L 
o Without granulocyte colony-stimulating factor support within 2 weeks prior to  
randomization 
 Hemoglobin >100 g/L  
o Without transfusion within 2 weeks prior to randomization 
 Platelets >125 X 109/L 
o Without transfusion within 2 weeks prior to randomization 
 Total bilirubin <1 X institutional upper limit of normal (ULN) 
 Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) 
<5 X institutional ULN 
 Alkaline phosphatase <5 X institutional ULN 
 Albumin > 3 g/dL 
 International normalized ratio (INR) and activated partial thromboplastin time (aPTT) 
within 1.5 X the institutional ULN 
 Creatinine <1.5 X institutional ULN 
OR 
 Calculated creatinine clearance >60 mL/min using the Cockcroft and Gault formula 
as follows: 
Creatinine clearance (mL/min) =  (140 - age) x ideal body weight [kg]  
 
 
 
 
 
 
0.814 x serum creatinine [µmol/L] 
o For women, multiply the value from the equation above by 0.85. 
o Where age is in years, weight is in kg, and serum creatinine is in µmol/L 
 The ideal body weight for use in the Cockcroft and Gault formula should be 
determined as follows: 
 Men:  50 + [(Height (cm) -154) X 0.9]  
 Women:  45.5 + [(Height (cm) -154) X 0.9] 
6. 
For women of childbearing potential and men with partners of childbearing potential, 
agreement (by subject and/or partner) to use two effective forms of contraception 
(e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive 
hormone implants) from study entry through at least 6 months after the termination visit.  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 39 of 130 
CONFIDENTIAL 
 
19 December 2016 
 Women of childbearing potential are those women who have not been permanently 
sterilized or are not postmenopausal.  Postmenopausal is defined as 12 months with no 
menses without an alternative medical cause. 
 Highly effective methods of birth control include those that result in a low failure rate 
(i.e., less than 1% per year) when used consistently and correctly, such as implants, 
injectables, combined oral contraceptives, levonorgestrel-releasing intrauterine system, 
intra-uterine devices (IUDs), vasectomized partner, and true sexual abstinence. 
7. 
Ability to understand and the willingness to sign a written informed consent document 
6.2 
Exclusion Criteria 
Subjects who meet any of the following criteria will not be eligible for participation in the study: 
1. 
Subjects with a neuroendocrine tumor of the pancreas, an acinar tumor of the pancreas or 
a pancreatic tumor with mixed histologies.  
2. 
Subjects receiving any other investigational medicinal products or anti-cancer therapy. 
3. 
Subjects with brain metastases (subjects must have a CT scan or MRI of the head within 
28 days prior to randomization to rule out brain metastases), uncontrolled seizure 
disorder, or active neurologic disease 
4. 
Subjects with leptomeningeal disease 
5. 
Subjects with > Grade 2 peripheral neuropathy 
6. 
History of interstitial pulmonary disease or pneumonitis 
7. 
Malignancies other than pancreatic cancer successfully treated within 3 years prior to 
randomization, except for adequately treated carcinoma in situ of the cervix, basal or 
squamous cell skin cancer, treated superficial bladder cancer, localized prostate cancer 
treated surgically with curative intent, ductal carcinoma in situ treated surgically with 
curative intent 
8. 
Prior radiation to the chest wall or mediastinum if the radiation field involves the heart 
9. 
History of a significant allergic reaction attributed to humanized or human monoclonal 
antibody therapy 
10. 
Significant intercurrent illness that will limit the patient’s ability to participate in the 
study or may result in their death over the next 18 months. 
11. 
Pregnant women or nursing women 
12. 
Subjects with known HIV infection 
13. 
Known bleeding disorder or coagulopathy 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 40 of 130 
CONFIDENTIAL 
 
19 December 2016 
14. 
Subjects receiving therapeutic doses of heparin, warfarin, factor Xa inhibitors or other 
similar anticoagulants.  Note:  Subjects may be receiving prophylactic doses of heparin, 
warfarin, factor Xa inhibitors or other similar anticoagulants, low-dose aspirin and/or 
non-steroidal anti-inflammatory agents. 
15. 
Subjects with known clinically significant gastrointestinal disease including, but not 
limited to, inflammatory bowel disease 
16. 
Subjects with a blood pressure of >140/90 mmHg.  The BP should be taken using the 
method described in Section 9.3.  Subjects taking antihypertensive medications must be 
taking ≤2 medications to obtain this level of BP control. 
17. 
Subjects with tumors that are currently involving the lumen of the gastrointestinal tract 
18. 
History of cerebral vascular accident (CVA) or transient ischemic attacks (TIAs) within 
6 months prior to randomization, major surgical procedure, open biopsy, or significant 
traumatic injury within 28 days prior to randomization, or anticipation of need for major 
surgical procedure during the course of the study.  Placement of vascular access device 
will not be considered major surgery. 
19. 
Subjects with an active infection requiring antibiotics 
20. 
Subjects with an uncontrolled seizure disorder or active neurologic disease 
21. 
Any of the following cardiac-related criteria: 
 B-type natriuretic peptide (BNP) value of >100 pg/mL 
 Left ventricular ejection fraction (LVEF) <50% 
 Peak tricuspid velocity >3.0 m/s on Doppler echocardiogram 
 Receiving any medications for cardiac ischemia 
 Current evidence of cardiac ischemia 
 History of acute myocardial infarction within 6 months prior to randomization 
 New York Heart Association Classification II, III, or IV (See Appendix E) 
For subjects to meet class II criteria with mild shortness of breath and/or angina, as 
defined by the NYHA guidelines, the cardiac etiology of the symptoms should be 
confirmed by a cardiologist taking 12-lead electrocardiogram, transthoracic Doppler 
echocardiogram and other studies into consideration, as appropriate. 
 History of heart failure or pulmonary hypertension 
 Received a total cumulative dose of ≥400 mg/m2 doxorubicin 
 Grade ≥2 ventricular arrhythmia 
 Inability to comply with study and follow-up procedures 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 41 of 130 
CONFIDENTIAL 
 
19 December 2016 
7.0 
REMOVAL OF SUBJECTS FROM STUDY 
Subjects must be withdrawn from the study for the following reasons: 
 Disease progression according to RECIST v1.1 
 Use of other anti-cancer therapy 
 Subject decision 
 Investigator decision based on subject’s best interest 
 Significant protocol non-compliance (as assessed by the Sponsor) 
Subjects who meet one of the above criteria will undergo the termination evaluations for the 
study (see Section 12.9). After the termination visit, subjects will have regular follow-up for 
survival and other assessments as required per protocol (see Section 12.10). 
If a subject has permanently discontinued one, two or all three of the study drugs due to toxicities 
or any other reasons, the subject should remain on study until one of the above criteria is met. 
Subjects who have discontinued all study drugs and continue on study should have assessments 
performed as outlined in Section 12.0. 
8.0 
TREATMENT OF SUBJECTS 
Dosing of gemcitabine, Abraxane® and demcizumab or placebo must be done within ± 2 days of 
the Study Day listed in the protocol.  If a drug cannot be given within this 2 day window, then 
the dose of that drug is permanently missed.  If one or more of these drugs needs to be 
temporarily or permanently discontinued the subject should continue to receive the other drug(s) 
and remain on study until disease progression.   
8.1 
Study Drug (DEMCIZUMAB OR PLACEBO) 
8.1.1 
Administration 
Study drug (demcizumab at 3.5 mg/kg or placebo) will be administered once every 2 weeks for 
6 doses (i.e., the last dose is given on Day 70).  A second course of study drug (demcizumab at 
3.5 mg/kg or placebo) will be administered once every 2 weeks for 6 doses starting at Day 168 if 
the subject’s Day 168 BNP is ≤100 pg/mL, peak tricuspid velocity is <3.0 m/s and LVEF is 
≥50%, and the subject did not develop pulmonary hypertension or heart failure while on study. 
No dose reductions of demcizumab/placebo are allowed for required modifications of 
demcizumab/placebo dosing). 
The demcizumab or placebo dose should be based on the Day 0 weight throughout the study, 
unless the weight changes by >10%.  Study drug must be delivered as an intravenous infusion 
over 30 minutes as an infusion prior to the administration of Abraxane® and gemcitabine, if 
applicable.  If a semipermanent peripheral or central line is used to administer the drug, the 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 42 of 130 
CONFIDENTIAL 
 
19 December 2016 
catheter should be flushed per institutional standard procedures prior to and at the end of each 
infusion. 
If an infusion reaction occurs, the infusion must be stopped and any appropriate medical care 
administered (see Section 8.1.7).  Once the infusion reaction has resolved, and at the discretion 
of the Investigator, the infusion may be resumed at one-half of the initial rate of infusion.  All 
subsequent infusions for that subject should then be administered at the reduced rate of infusion.   
Study drug should not be held for chemotherapy-induced toxicity, such as hematologic toxicity.  
The Investigator should contact the OncoMed Medical Monitor if he/she wishes to hold 
demcizumab or placebo therapy for what is believed to be chemotherapy-induced toxicity.  If 
demcizumab/placebo cannot be administered within the specified time window (+/- 2days) 
(See Section 12.0) , the missed dose cannot be administered at a later time point.  Instead, no 
demcizumab/placebo is to be administered until the next scheduled dose. 
8.1.2 
Description 
Demcizumab is an IgG2 humanized monoclonal antibody that is directed against the DeltaLike 
Ligand 4 (DLL4). 
Demcizumab is supplied at a concentration of 10 mg/mL in a 25-mL single-use glass vial filled 
to 20 mL to deliver at total of 200 mg per vial. 
Placebo is a clear to slightly opalescent, colorless to slightly yellow liquid formulation of 
50 mM Histidine, 100mM Sodium Chloride, 45mM Sucrose and 0.01% (v/v) Polysorbate-20, 
pH 6.0. 
All investigational products should be kept in a secure area inaccessible to unauthorized 
individuals.   
8.1.3 
Packaging 
Labeling of demcizumab or placebo vials and cartons will comply with all applicable 
regulations. 
8.1.4 
Drug Ordering, Storage, and Accountability 
The instructions for drug ordering via the IWRS are provided in the Pharmacy Binder. 
Demcizumab or placebo vials must be refrigerated at 2°C–8°C.  Demcizumab or placebo must 
not be shaken or frozen.  An accurate study drug accountability log must be maintained and kept 
up to date at all times.  Blinded study drug perforated labels must be kept for drug accountability. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 43 of 130 
CONFIDENTIAL 
 
19 December 2016 
8.1.5 
Study Drug Preparation 
Demcizumab or placebo should be diluted for infusion using aseptic technique.  Withdraw the 
necessary amount of demcizumab or placebo to obtain the required dose and dilute with 
5% dextrose in water, USP, to a total volume of 250 mL.  For example, if a 70-kg subject is to be 
dosed at 3.5 mg/kg, then the subject’s dose would be 245 mg.  Because the vials contain a 
concentration of 10 mg/mL, a total of 24.5 mL containing 245 mg should be withdrawn from the 
vial and diluted with 5% dextrose in water, USP, to a total volume of 250 mL. 
Any unused portion left in a vial may not be used for another subject, as the product contains no 
preservative (i.e., they are single-use vials). 
The diluted demcizumab or placebo solutions may be stored at room temperature (19°C–25°C) 
for up to 4 hours. 
8.1.6 
Treatment Modification and Termination Criteria 
Any subject who has two consecutive BNP values ˃100 pg/mL or one value >200 pg/mL will be 
unblinded by the Investigator through the IWRS system. If the subject is receiving demcizumab 
they will started on a cardioprotective agent such as an ACE inhibitor or carvedilol, unless the 
BNP elevation occurred more than 100 days after the discontinuation of demcizumab or there is 
a contraindication to the use of these agents and if appropriate referred to a cardiologist.  If they 
are not on demcizumab they should be cared for according to standard medical practice.  The 
selection and dose of the ACE inhibitor to be administered or the dose of carvedilol to be 
administered should be based on the recommendations in standard guidelines for treating heart 
failure (Ref 17).  If there is a contraindication to administering both of these agents, the patient’s 
treatment should be discussed with the OncoMed Medical Monitor.   
In addition, any subject who develops a BNP of ≥300 pg/mL, a LVEF decline of ≥10% from 
baseline and a LVEF value that is <50%, clinically significant pulmonary hypertension (i.e., the 
subject has a peak tricuspid velocity >3.4 m/s on doppler echocardiogram and has been seen by a 
cardiologist and diagnosed with clinically significant pulmonary hypertension) and/or symptoms 
of heart failure must have their dose of demcizumab held, but administration of their 
chemotherapy may be continued.  Dosing of demcizumab must continue to be held until the 
subjects BNP is <300 pg/mL, the decline in LVEF is <10% and a LVEF value that is >50%, their 
clinically significant pulmonary hypertension has resolved and symptoms of heart failure has 
resolved.   
Any subject who has a BNP of >300 pg/mL that is considered to be related to demcizumab, 
≥10% decline in left ventricular ejection fraction and a LVEF value that is <50%, signs and 
symptoms of heart failure or clinically significant pulmonary hypertension (i.e., the subject has a 
peak tricuspid velocity >3.4 m/s on doppler echocardiogram and has been seen by a cardiologist 
and diagnosed with clinical significant pulmonary hypertension) that persists beyond Day 70 or 
occurs beyond Day 70 must have their demcizumab permanently discontinued.   


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 44 of 130 
CONFIDENTIAL 
 
19 December 2016 
Demcizumab/placebo must also be discontinued for any of the following: 
 BNP of ≥400 pg/mL 
 ≥Grade 2 pulmonary hypertension 
 Evidence of Grade >2 bleeding (except for readily manageable local bleeding, such as 
hemorrhoidal bleeding) 
 Hypertensive crisis 
 Hypertensive encephalopathy 
 Blood pressure of  200/120 mmHg 
 Need for therapeutic anti-coagulation 
o If therapeutic anti-coagulation is no longer required, the subject may receive any 
remaining demcizumab/placebo administrations. 
If the demcizumab/placebo need to be held or discontinued, the administration of the 
chemotherapy should continue until disease progression, unless contraindicated. 
8.1.7 
Infusion Reaction Management 
The administration of monoclonal antibodies may result in an infusion reaction that may consist 
of a symptom complex characterized by symptoms such as fever, chills, nausea, vomiting, 
headache, dizziness, bronchospasm, dyspnea, hypotension, and/or rash including urticaria.  
Subjects experiencing a Grade 2 infusion reaction of dyspnea (asymptomatic bronchospasm) or 
generalized urticaria should be premedicated prior to subsequent infusions.  Premedications may 
include medications such as corticosteroids, diphenhydramine, and/or bronchodialators as 
indicated.  If the Grade 2 allergic reaction recurs during subsequent infusions despite the 
premedications, the subject should be removed from treatment.  In addition, permanently 
discontinue demcizumab therapy in any subject who experiences a Grade 3 or 4 acute allergic 
reaction (e.g., symptomatic bronchospasm with or without urticaria, edema, angioedema, or 
hypotension).  Grade 3/4 acute allergic reactions should be medically managed as appropriate 
and treatment may include the administration of epinephrine, corticosteroids, diphenhydramine, 
bronchodialators, and/or oxygen as indicated. 
8.2 
Gemcitabine and Abraxane® 
The dose of gemcitabine and Abraxane® should be modified according to the criteria in 
Section 8.2.3.  All dose modifications are permanent.  Dosing of gemcitabine and Abraxane® 
must be done within ± 2 days of the Study Day listed in the protocol.  If a gemcitabine or 
Abraxane® cannot be given within this 2 day window, then the dose of that drug is permanently 
missed.  The administration of the chemotherapy should not be held if the demcizumab/placebo 
needs to be held or discontinued. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 45 of 130 
CONFIDENTIAL 
 
19 December 2016 
8.2.1 
Abraxane® 
8.2.1.1 
Administration 
Abraxane® must be administered after the demcizumab, but before gemcitabine administration 
on days when three drugs are given.  Abraxane® should be administered by IV infusion at a dose 
of 125 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.  The Study Day 0  
weight should be used to calculate the body surface area that is used to calculate the total dose 
(mg) of Abraxane® throughout the study, unless the weight changes by >5%, in which case the 
current weight should be used to calculate the body surface area.  
Subjects do not require premedication prior to Abraxane® administration, as hypersensitivity 
reactions are not expected.  If a hypersensitivity reaction occurs, the infusion should be stopped 
and not restarted.  If felt to be in the subject’s best interest, at the investigator’s discretion, 
treatment may continue on subsequent cycles using the premedication regimen the institution 
typically uses for solvent-based paclitaxel. 
8.2.1.2 
Description 
Abraxane®, a microtubule inhibitor, is an albumin bound form of paclitaxel with a mean particle 
size of approximately 130 nanometers.  The active agent in Abraxane® is paclitaxel.  The 
chemical name for paclitaxel is 5, 20-Epoxy-1, 2, 4, 7, 10, 13-hexahydroxytax-11-en-9-
one 4, 10-diacetate 2-benzoate, 13 ester with (2R, 3S) –N-benzoyl-3-phenylisoserine. 
8.2.1.3 
Storage 
Abraxane® vials must be stored as recommended in the label. 
8.2.1.4 
Packaging 
The labeling of Abraxane® will comply with all applicable regulations. 
8.2.2 
Gemcitabine 
8.2.2.1 
Administration 
Gemcitabine must be administered after the administration of demcizumab and Abraxane®. 
Gemcitabine should be administered by IV infusion at a dose of 1000 mg/m2 
over 30 minutes 
once weekly (Days 1, 8 and 15 of each 28 day cycle) for 3 weeks (or until toxicity necessitates 
reducing or holding a dose), followed by a week of rest every 28 days. 
The Day 0 weight should be used to calculate the total dose (mg) of gemcitabine throughout the 
study, unless the weight changes by >5%, in which case the current weight should be used to 
calculate the dose.  Clearance in women and the elderly is reduced and women are 
somewhat less able to receive subsequent cycles. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 46 of 130 
CONFIDENTIAL 
 
19 December 2016 
8.2.2.2 
Description 
Gemcitibine is a nucleoside metabolic inhibitor that exhibits antitumor activity.  Gemcitabine 
HCl is 2´-deoxy-2´, 2´-difluorocytidine monohydrochloride (-isomer). 
8.2.2.3 
Storage 
Gemcitibine must be stored as recommended on the label. 
The labeling of gemcitabine will comply with all applicable regulations. 
8.2.3 
Gemcitabine and Abraxane® Dose Modification Guidelines 
Dose reductions/modifications of gemcitabine and Abraxane® are permanent, except in some 
circumstances when the dose reduction was a result of neutropenia (see Section 8.2.3.1). Doses 
of gemcitabine and Abraxane® must be given within +/- 2 days of the Study Day specified in the 
protocol.  If a dose is not given in the window it is permanently missed.  Doses will be reduced 
for hematologic and other toxicities.  Dose adjustments are to be made according to the system 
showing the greatest degree of toxicity.  Toxicities will be graded using the NCI CTCAE 
Version 4.03.  
Two levels of dose modifications are permitted according to the criteria below.  If a toxicity 
requiring dose modification occurs following the second dose reduction of either drug, further 
treatment with Abraxane® and gemcitabine should be discontinued, although demcizumab and/or 
placebo therapy should be continued. 
Table 4: 
Dose Modifications 
Dose Level 
Abraxane® Dose (mg/m2)i. 
Gemcitabine (mg/m2)
Study Dose 
125 
1000 
-1 
100 
800 
-2ii. 
75 
600 
i.Dose reductions may or may not be concomitant, refer to Table 5.  If the dose is withheld due to hematologic 
toxicity on Day 15, resume at the next lower dose level when the subject has adequate ANC and platelet counts 
to begin Day 1 of the next cycle. Refer to Table 5 for specific recommendations regarding dose modifications 
for Day 1.  
ii.A maximum of 2 dose level reductions are allowed.  
 
Subjects who have had two dose level reductions as outlined in Table 4 and are still unable to 
tolerate the gemcitabine/Abraxane regimen may receive the -2 dose levels on Days 1 and 15 (i.e., 
omit Day 8) of each 28 day cycle. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 47 of 130 
CONFIDENTIAL 
 
19 December 2016 
8.2.3.1 
Dose Modifications 
In the event dose modifications are required at the start of a cycle or within a cycle due to 
hematologic toxicities of neutropenia and/or thrombocytopenia, doses of Abraxane® and 
gemcitabine may be adjusted as detailed in Table 5.  WBC growth factor may be given according 
to institutional guidelines for the treatment of neutropenic fever or infections associated with 
neutropenia and for the prevention of febrile neutropenia in subjects with an ANC 
<500 cells/mm3.  Subject’s not experiencing resolution of neutropenia within 21 days, despite 
uninterrupted WBC growth factor treatment, will discontinue gemcitabine and Abraxane®.  In 
addition, WBC growth factors may be administered as supportive therapy to recover ANC 
adequately such that dosing levels may be maintained.  If a dose reduction was required due to 
neutropenia, a dose re-escalation may be considered with continued growth factor support.  If a 
dose reduction is required for a reason other than neutropenia, no dose re-escalation will be 
permitted for the duration of the study.  If hematologic toxicity is restricted to platelet counts 
alone, dose modification of only gemcitabine could be considered after discussion with the 
sponsor. 
Table 5: 
Dose Recommendation and Modifications for Neutropenia and/or 
Thrombocytopenia at the Start of a Cycle or Within a Cycle 
Cycle 
Day 
ANC 
(cells/mm3) 
 
Platelet count 
(cells/mm3) 
Abraxane® Dose 
Gemcitabine Dose 
Day 1 
≥1500  
AND 
≥100,000 
Treat on time at current dose levels 
 
<1500  
OR 
<100,000 
Delay doses until recovery 
Day 8 
≥1000  
AND 
≥ 5,000  
Treat on time at current dose levels 
 
≥500 but <1000 
OR 
≥50,000 but <75,000 
Reduce doses 1 dose level 
 
<500 
OR 
< 50,000 
Withhold doses  
Day 15:  IF Day 8 doses were given without modification:  
Day 15 
≥1000  
AND 
≥75,000 
Treat on time at current dose levels 
 
≥500 but <1000 
OR 
≥50,000 but <75,000 
Reduce doses 1 dose level from Day 8; consider 
following with WBC growth factors for support* 
 
<500 
OR 
<50,000 
Withhold doses 
Day 15:  IF Day 8 doses were reduced:  
Day 15 
≥1000  
AND 
≥75,000  
Treat with same doses as Day 8; consider following 
with WBC growth factors for support*  
 
≥500 but <1000 
OR 
≥50,000 but <75,000 
Reduce doses 1 dose level from Day 8; consider 
following with WBC growth factors for support*  
 
<500 
OR 
<50,000 
Withhold doses 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 48 of 130 
CONFIDENTIAL 
 
19 December 2016 
Table 5: 
Dose Recommendation and Modifications for Neutropenia and/or 
Thrombocytopenia at the Start of a Cycle or Within a Cycle (Cont’d) 
Day 15:    IF Day 8 doses were withheld:  
Day 15 
≥000 
AND 
≥75,000  
Option A: Maintain dose level from Day 1 and 
follow with WBC growth factors for support*  
OR 
Option B:  Reduce doses 1 dose levels from Day 1  
 
≥500 but <1000 
OR 
≥50,000 but <75,000 
Option A: Reduce 1 dose level from Day 1 and 
follow with WBC growth factors for support*  
OR 
Option B:  Reduce doses 2 dose levels from Day 1  
 
<500 
OR 
<50,000 
Withhold doses 
Abbreviations: ANC = absolute neutrophil count; WBC = white blood cell 
*The use of WBC growth factors is only applicable if the dose limiting hematologic toxicity was limited to 
neutropenia or febrile neutropenia. 
 
Dose modifications for other adverse drug reactions are provided in Table 6. 
Table 6: 
Dose Modifications for Other Adverse Drug Reactions 
Adverse Drug Reaction 
Abraxane® Dose 
Gemcitabine Dose 
Febrile Neutropenia: 
    Grade 3 or 4 
Withhold doses until fever resolves and ANC is ≥1500; resume at 
next lower dose levelb 
Peripheral Neuropathy: 
    Grade 3 or 4 
Withhold dose until improvement 
to ≤Grade 1; 
resume at next lower dose level 
Treat with same dose 
Cutaneous Toxicity: 
    Grade 2 or 3 
Reduce doses to next lower dose level; 
discontinue treatment if ADR persists 
For all other nonhematologic 
toxicities (except nausea, 
vomiting, alopecia and pulmonary 
embolism) of >Grade 3 
Withhold doses until improvement to ≤Grade 1; 
resume at next lower dose leveli. 
Abbreviations: ADR, adverse drug reaction; ANC = absolute neutrophil count 
i.White blood cell growth factor may be given according to institutional guidelines for the treatment of neutropenic 
fever or infections associated with neutropenia and for the prevention of febrile neutropenia in subjects with an 
ANC of <500 cells/mm3  
b See Table 5 for dose level reductions.  
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 49 of 130 
CONFIDENTIAL 
 
19 December 2016 
8.2.3.1.1 
Administration of Abraxane® and Gemcitabine to Subjects with Abnormal 
Hepatic Function 
Abraxane® and gemcitabine should only be administered if hepatic function is within the 
parameters established in the eligibility criteria.  Hepatic toxicity may occur but it is uncommon.  
Therefore, hepatic dysfunction that occurs while the subject is on study should prompt an 
evaluation to determine the cause, including the possibility of metastatic disease and 
hepatotoxicity from concurrent medications, alcohol use, or other factors. 
8.2.3.1.2 
Interstitial Pneumonitis 
While participating in this study, subjects should be carefully monitored to prevent or minimize 
the occurrence of interstitial pneumonitis.  Careful pre-study screening with continuous on-study 
monitoring for signs and symptoms is required.  Should a subject develop symptoms of 
pneumonitis during this study, the timely initiation of appropriate management is required. 
Recommended guidelines are as follows: 
1. 
Before randomization, evaluate candidate subjects for familial, environmental, or 
occupational exposure to opportunistic pathogens, and do not enroll those with a history 
of slowly progressive dyspnea and unproductive cough, or of conditions such as 
sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity 
pneumonitis, or multiple allergies. 
2. 
During study treatment, provide close attention to episodes of transient or repeated 
dyspnea with unproductive persistent cough or fever.  Radiographic evaluation with chest 
x-rays and CT scans (normal or high resolution) may be indicated to evaluate for 
infiltrates, ground-glass opacities, or honeycombing patterns.  Pulse oximetry and 
pulmonary function tests can show respiratory and ventilation compromise.  
3. 
Infections should be ruled out with routine immunological/ microbiological methods.  
Transbronchial lung biopsy is not recommended, given its limited value and risk of 
pneumothorax and hemorrhage, and should be reserved for cases with unclear etiology.  
4. 
Administration of Abraxane® and gemcitabine must be permanently discontinued from 
upon the diagnosis of interstitial pneumonitis.  However, the administration of the 
demcizumab or placebo should be continued, unless contraindicated.  After ruling out an 
infectious etiology, intravenous high-dose corticosteroid therapy should be instituted 
without delay, with appropriate premedication and secondary pathogen coverage.  
Subjects with an added immunological agent may also require immune modulation with 
azathioprine or cyclophosphamide.  Appropriate ventilation and oxygen support should 
be used when required.  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 50 of 130 
CONFIDENTIAL 
 
19 December 2016 
8.2.3.1.3 
Prophylaxis Against Sepsis 
In the MPACT metastatic pancreatic ductal adenocarcinoma Phase 3 study, an increase in cases 
of non-neutropenic sepsis was observed with the combination of Abraxane® and gemcitabine.  
An exploratory analysis suggested that the presence of biliary stents may have increased the risk 
of sepsis in that population.  Investigators were to provide oral broad spectrum antibiotics to 
subjects who were then to initiate these antibiotics at the first occurrence of fever.  Subjects 
enrolled in this clinical trial may not have the same risk of sepsis as metastatic pancreatic ductal 
adenocarcinoma patients.  Subjects should be advised that there could be an increased risk of 
serious infection and they should contact their physician for evaluation when they develop a 
fever.  Fever or similar symptoms should be fully evaluated as an early sign of a serious 
infection.  Broad spectrum antibiotics such as fluoroquinolones may be provided to subjects to 
treat or as prophylaxis for infection at the discretion of the treating physician. 
8.2.3.1.4 
Hypersensitivity Reactions 
Hypersensitivity reactions are infrequent with Abraxane®.  If they do occur, minor symptoms 
such as flushing, skin reactions, dyspnea, hypotension, or tachycardia may require temporary 
interruption of the infusion.  However, severe reactions, such as hypotension requiring treatment, 
dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate 
discontinuation of IP administration and aggressive symptomatic therapy. 
Subjects who develop a severe hypersensitivity reaction to Abraxane® should not be 
rechallenged. 
8.3 
Anti-Emetics and Hematopoietic Supportive Care 
Antiemetic therapy and/or hematopoietic growth factors and/or red blood cell/platelet 
transfusions may be administered at the discretion of the Investigator. 
8.4 
Concomitant and Prohibited Therapy 
All concomitant medication administered from randomization through 30 days following 
treatment termination will be recorded on the Concomitant Medication remote data capture 
(RDC) screen.   
Investigational medicinal products and anticancer agents (e.g., cytotoxic agents, biologics, and 
hormonal agents with known activity against the subjects’ specific tumor type) may not be 
administered from randomization through treatment termination.  However, subjects may have 
radiation or non-invasive surgical resection of a solitary non-target lesion for relief of significant 
signs or symptoms, such as pain or bleeding, in the absence of disease progression after 
consultation with the OncoMed medical monitor.  Such subjects will remain fully evaluable.  In 
addition, subjects who are receiving adjuvant hormonal therapy, such as tamoxifen for a history 
of breast cancer, may continue to receive this treatment.   


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 51 of 130 
CONFIDENTIAL 
 
19 December 2016 
DVT prophylaxis during a hospitalization according to institutional standards is permitted. 
Should a medical condition require therapeutic anti-coagulation, demcizumab/placebo must be 
discontinued while therapeutic anti-coagulation is administered, and the subject should continue 
on study with continued gemcitabine plus Abraxane® administrations and regular assessments to 
ensure close follow-up.  Once the therapeutic anti-coagulation is discontinued, subjects may 
receive any remaining scheduled demcizumab/placebo infusion. 
8.5 
Treatment Compliance 
Demcizumab, gemcitabine and Abraxane® will be administered IV by study site personnel.  
Thus, compliance with each infusion will be documented in the subject’s medical records and 
then recorded on the appropriate eCRF in Medidata.  In addition, drug accountability will be 
performed. 
9.0 
SAFETY ASSESSMENTS 
Safety will be assessed by adverse event monitoring (including attribution of AEs and SAEs), 
physical examination, vital signs, clinical laboratory testing, anti-demcizumab testing, and 
subject interview on an ongoing basis as outlined in the Schedule of Assessments 
(see Appendix B – Schedule of Assessments) 
Samples that test positive for demcizumab antibodies will be assessed for neutralizing capability.  
The impact of positive samples on safety and biologic activity will be assessed. 
9.1 
Adverse Events Definitions and Reporting Procedures 
All Adverse Events from the time of randomization through 30 days after discontinuation from 
the study (i.e., 30 days from the date of the treatment termination visit) must be documented in 
the medical record and reported on the AE Case Report Form (CRF). 
Adverse events will be coded in accordance with the Medical Dictionary for Regulatory 
Activities (MedDRA).  The grading of the adverse events will be done using the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.  In 
addition, for each adverse event the Investigator must indicate the attribution of AE to study drug 
(i.e., related or unrelated) and the attribution of the AE to the malignancy. 
The principal investigator is responsible for assessing whether an adverse event is related (or 
possibly related) to participation in the research.   
In general, adverse events are considered related to participation in the research if there is not 
a clear alternative explanation.  Adverse events are considered unrelated to participation in the 
research if they are solely caused by the subject’s disease or condition or by other circumstances 
unrelated to either the research or to the subject’s condition. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 52 of 130 
CONFIDENTIAL 
 
19 December 2016 
9.1.1 
Definition of Adverse Event 
An adverse event is any untoward or unfavorable medical occurrence in a human subject, 
including any abnormal sign (for example, abnormal physical exam or laboratory finding), 
symptom, or disease temporally associated with the subject’s participation in the research, 
whether or not considered related to the subject’s participation in the research.  Any medical 
condition or clinically significant laboratory abnormality with an onset date before 
randomization is a pre-existing condition that must be listed on the Medical History CRF and 
should not be considered an adverse event unless the condition worsens in intensity or frequency 
after randomization (e.g., Grade 2 nausea prior to randomization becomes Grade 3 nausea after 
randomization).  Pregnancy should not be reported as an AE. Should a subject enrolled in the 
study become pregnant or suspect she is pregnant while participating in this study or within 6 
months after discontinuation of study drug(s), the Medical Monitor should be informed within 
the same timeframe as required for SAEs (see Section 9.1.3).  Monitoring of the subject should 
continue through outcome of the birth, or longer if any fetal abnormality is present. 
9.1.2 
Definition of Serious Adverse Event 
A serious adverse event is any event that results in the following: 
 death 
 life-threatening condition (places the subject at immediate risk of death) 
 subject hospitalization or prolongation of existing hospitalization 
 persistent or significant disability/incapacity 
 congenital anomaly/birth defect 
 any other adverse event that, based upon the Investigators medical judgment, may require 
medical or surgical intervention to prevent one of the outcomes listed above (examples of 
such events include allergic bronchospasm requiring intensive treatment in the 
emergency room or at home, blood dyscrasias or convulsions that do not result in subject 
hospitalization, or the development of drug dependency or drug abuse) 
9.1.2.1 
Disease Progression and Death 
Disease progression (including progression of pancreatic cancer, and death due to 
disease progression) is generally recorded as part of the efficacy evaluation and should not be 
reported as an AE or SAE.  When an AE resulting from disease progression meets the 
requirements to be considered serious, the SAE verbatim term should be reported as the sign/ 
symptom that best describes the event rather than as disease progression.  For instance, a subject 
with pleural effusion presents with shortness of breath.  The cause of the shortness of breath is a 
pleural effusion resulting from disease progression.  The event term may be reported as “pleural 
effusion” instead of disease progression.  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 53 of 130 
CONFIDENTIAL 
 
19 December 2016 
Death should not be reported as a serious adverse event, but as a clinical outcome of a specific 
SAE.  The cause of death, reported on a source document such as the Death Certificate or 
autopsy report, should be used as the event term for the SAE.  
9.1.3 
Serious Adverse Event Reporting Procedures 
SAEs that occur during the study must be clearly documented in the medical record.  SAEs 
should be reported by completing the AE page in Medidata within 24 hours of the Investigator’s 
knowledge of the event.  By completing the ‘serious’ information, this will generate an auto-
notification to PVG. Only in the event of a system outage, a manual SAE form must be 
completed and faxed or emailed to PPD PVG (also within 24 hours of the Investigator’s 
knowledge of the event).  The following is the contact information for PPD Drug Safety. 
9.1.3.1 
Pharmacovigilance telephone contacts: 
 EMEA/APAC: ___________________ 
 United States: ___________________ 
9.1.3.2 
Pharmacovigilance fax contacts: 
 EMEA/APAC: ___________________ 
 United States: ___________________ 
9.1.3.3 
Pharmacovigilance email contact (all regions) 
 EMEAAsiaSafetyCentral.SM@ppdi.com 
All SAEs will continue to be followed until the end of the study or until such events have 
resolved or the Investigator, in conjunction with the Sponsor, deems them to be chronic or stable. 
9.2 
Clinical Laboratory Assessments 
9.2.1 
Hematology 
A complete blood count (CBC) with differential and platelet count will be obtained at each 
protocol-specified visit and an INR and aPTT will be obtained at baseline. 
9.2.2 
Serum Chemistry 
Serum chemistries (including albumin, alkaline phosphatase, total bilirubin, bicarbonate, blood 
urea nitrogen [BUN], calcium, chloride, creatinine, glucose, lactic dehydrogenase [LDH], 
phosphorus, potassium, total protein, AST [SGOT], ALT [SGPT], sodium) will be obtained at 
each protocol-specified visit. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 54 of 130 
CONFIDENTIAL 
 
19 December 2016 
9.2.3 
BNP Assessment 
BNP will be assessed during Screening and then every 14 days while on treatment, and at the 
time of treatment termination.  BNP will be measured using any Alere Triage POC device (or if 
approved by OncoMed the site’s laboratory).  BNP must be drawn on the day of dosing and 
assessed prior to dosing (or if approved by OncoMed it may be drawn the day before dosing and 
assessed prior to dosing) and elevations will be managed per Section 8.1.6. 
9.2.4 
Urinalysis 
Urinalysis (with microscopic analysis) will be obtained during screening, at Study Days 28, 56, 
and every 56 days thereafter, and at the time of treatment termination. 
9.2.5 
Pregnancy Testing 
For women of childbearing potential, a serum pregnancy test is required during Screening, every 
56 days while on study, at the termination visit and 56 and 112 days following the treatment 
termination visit. 
9.3 
Vital Signs and Other Physical Findings 
A full physical examination will be done at screening.  Subsequently, an abbreviated physical   
examination will performed at Day 0, every other week while on treatment and at treatment 
termination.  The abbreviated physical examination must include respiratory rate, auscultatory 
examination of the heart and lungs, abdominal examination, and assessment for the presence or 
absence of edema and/or ascites.  A more complete physical examination should be conducted 
when clinically indicated. 
Vitals signs will be done as outlined in Schedule A.  Blood pressure should be measured with the 
subject in the same position.  The same cuff method should be used to measure blood pressure 
throughout the study.  Diastolic BP will be measured by the disappearance of Kortokoff sounds, 
phase V.  If possible, measurements will be taken by the same staff member at each visit.  For 
subjects presenting with hypertension, their BP must be adequately controlled to <140/90 mmHg 
prior to randomization.  This may be achieved by adjusting the existing anti-hypertensive 
medications or adding new ones by following the guidelines for the management of high blood 
pressure in adults (Ref 16).  Any subject with hypertension (i.e., >150/90 mmHg) that is 
considered to be related to demcizumab or placebo at the time of the termination visit will 
continue to have BPs monitored once every 2 weeks until it is ≤150/90 mmHg over a 4-week 
period with every-2-week BP measurements. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 55 of 130 
CONFIDENTIAL 
 
19 December 2016 
9.4 
Cardiac Studies 
Twelve-lead electrocardiograms (ECGs) with assessment of PR interval, QRS duration, and QTc 
interval will be obtained at Screening, every 28 days, and at the termination visit.  
A transthoracic Doppler echocardiogram with left ventricular ejection fraction, right ventricular 
systolic pressure and peak tricuspid velocity determination will be obtained at Screening and 
then every 28 days.  The Day 168 Doppler echocardiogram must be performed prior to the Day 
168 visit, so that the peak tricuspid velocity and left ventricular ejection fraction values are 
available at the time of the Day 168 visit.  The Doppler echocardiograms may also be sent to an 
Independent Cardiologist of the Sponsor’s choice for central review. A CT pulmonary 
angiogram (CTPA) should be performed if pulmonary hypertension is diagnosed (i.e., the subject 
has a peak tricuspid velocity >3.4 m/s on Doppler echocardiogram, has been seen by a 
cardiologist and was diagnosed with clinically significant pulmonary hypertension) to determine 
if pulmonary embolism might be the cause of the pulmonary hypertension. An MR angiogram or 
VQ scan may be performed instead per local or country standards or if the subject has a contrast 
allergy. 
9.5 
Immunogenicity Assessments 
Subjects will be assessed during screening and then every 8 weeks while the subject is on study.  
In addition, subjects will be assessed for immunogenicity at the time of treatment termination.  
Samples that test positive will be assessed for neutralizing capability.  In addition, the impact of 
positive samples on safety and biologic activity will be assessed.  Instructions for sample 
collection, handling, storage, and shipping can be found in the Study Reference Binder. 
9.6 
Pharmacokinetic Assessments 
Sparse PK sampling will be done in all subjects on the study.  Plasma samples for PK analysis 
will be obtained prior to the demcizumab infusion on Days 0, 14, 56, 70, 168, 182, 224 and 238, 
and at the end of the demcizumab infusion (prior to chemo infusion) on Days 0, 56, 70, 168, 224 
and at treatment termination. The PK samples must be drawn from a location that is different 
from the site of study drug administration.  If the study drug is administered via a vein in the 
arm, post-dose PK samples must be drawn from a vein in the contralateral arm.  Instructions for 
sample collection, handling, storage, and shipping can be found in the Study Reference Binder. 
10.0 
EFFICACY ASSESSMENTS 
Tumor assessments will be performed at screening and then every 8 weeks.  The schedule of 
every 8 weeks is to be maintained throughout the study and will not be shifted if there are dose 
holds (see Appendix B).  Any measurable disease must be documented at screening and 
reassessed at each subsequent tumor evaluation.  Response, progression-free survival and 
duration of response will be assessed using the RECIST criteria v1.1 (see Appendix D) (Ref 18). 
The primary response outcomes will be based on the Investigator’s assessment.  However, the 
radiographs will be collected centrally (by VirtualScopics), and an optional independent read of 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 56 of 130 
CONFIDENTIAL 
 
19 December 2016 
the radiographs may be performed.  Please refer to the Investigator Manual for instructions of 
submission of the radiographs to VirtualScopics. 
Assessments of the tumor marker CA 19-9 will be performed on the same schedule as imaging 
studies. Response assessment should be based solely on the radiographic assessment and not 
based on changes in CA 19-9. 
Overall survival will be assessed by collecting survival data including the date and cause of 
death.  Once a patient has completed the treatment termination visit, overall survival follow up 
will be performed every three months for up to 5 years.  Follow up may be conducted by 
telephone interview or chart review. 
The same imaging method used at screening must be used throughout the study.  A documented 
standard-of-care tumor assessment performed within Study Days -28 to 0 may be used for the 
screening assessment provided it meets the below requirements. 
At baseline, tumor assessments should include the following: 
 
Diagnostic-quality, contrast-enhanced CT scans of chest, abdomen, and pelvis 
o To be suitable for RECIST v1.1 assessments, CT scans should have a maximum 
thickness of 5 mm and no gaps.   
o CT scan is the preferred imaging modality for tumor assessments of chest, abdomen, 
and pelvis. 
o In subjects for whom the preferred CT scans are contraindicated because of, for 
example, a CT IV contrast allergy, a CT of the chest without contrast and MRI of the 
abdomen and pelvis with contrast are recommended. 
o MRI scans may be performed in lieu of CT scans.  At screening, tumor assessments 
should include a diagnostic-quality, contrast-enhanced MRI scan of the chest, 
abdomen, and pelvis.  To be suitable for RECIST v1.1 assessments, MRI scans 
should ideally have a maximum thickness of 5 mm and minimal gaps. 
 
MRI of the brain 
o MRI is the preferred imaging modality for tumor assessments of the brain. 
o In subjects for whom MRI of the brain is not available, a CT scan of the brain with IV 
contrast may be performed. 
 
CT scan of the neck or bone scan should be included if clinically indicated.  
MRI scan of the neck may be substituted for CT scan of the neck. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 57 of 130 
CONFIDENTIAL 
 
19 December 2016 
Subsequent tumor assessments should include the following: 
 
Diagnostic-quality, contrast-enhanced CT scans of chest and abdomen 
o If another imaging method was used at baseline, the same imaging method must be 
used for subsequent tumor assessments. 
 
Imaging of all other known sites of disease 
o The same imaging method as at baseline must be used. 
11.0 
EXPLORATORY ASSESSMENTS 
Instructions for biomarker sample collection, handling, labeling, and shipping are provided in the 
Study Reference Binder. 
FFPE tumor tissue and predictive biomarkers:  If available, archival FFPE tumor specimens 
obtained at the time of surgical resection or from a core biopsy will be collected for protein and 
gene expression biomarker analysis.  Exploratory predictive biomarkers such as tumor 
endothelial cell DLL4 expression will be measured in FFPE tumor specimens.  Gene expression 
biomarker analysis including Notch pathway-related predictive biomarker genes may also be 
measured by RT-PCR and/or microarrays.  Tumor-derived DNA may be used to test for 
mutations in candidate genes relevant to the Notch pathway (e.g., Notch1, DLL4, FBXW7).  
Exploratory analysis of these tumors may help to identify biomarkers that could be used in the 
future to predict which subjects are more likely to respond to demcizumab, Abraxane® and 
gemcitabine treatment.  
Blood Biomarkers:  A predose sample of 9 mL of blood will be drawn on Study Days 0, 21, 35, 
49 and 63  and at treatment termination to evaluate changes in plasma proteins by 
immunochemistry (e.g., VEGF, βFGF, SDF1, PLGF, SCF, etc.), and Notch-related gene 
expression of mRNA using microarrays, e.g., Affymetrix platform.  Plasma microRNAs may 
also be evaluated by microRNA expression profiling.  A sample will also be obtained at the time 
of treatment termination unless one has been obtained during the prior 14 days. 
Optional Pharmacogenomics:  For subjects who sign the optional Pharmacogenomics Informed 
Consent (Appendix G), a blood sample (10 mL) will be collected pre-dose at Study Day 0 
(where local regulations permit).  Pharmacogenomic analysis of candidate genes relevant to 
demcizumab may influence safety, tolerability, or pharmacodynamic effects of demcizumab for 
the treatment of solid tumors.  Analysis of genes relevant to Notch/DLL4 target or pathway 
genes or disease genes may be performed (e.g., FBW7 and PTEN).  Analysis of genes related to 
gemcitabine metabolism may also be performed (e.g., CMPK and DCK).    
12.0 
STUDY VISIT SCHEDULE AND ASSESSMENTS 
Subjects must sign and date the Informed Consent Form (Appendix F) that has been approved by 
the IEC/IRB prior to undergoing any study-related procedures.  Once the screening process has 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 58 of 130 
CONFIDENTIAL 
 
19 December 2016 
been completed, the Investigator must complete a randomization form in the PPD IWRS system 
and submit it electronically for approval.  Once OncoMed or its representative has approved the 
randomization form, the investigator/study coordinator will use the IWRS system to randomize 
the subject.  The IWRS system will then assign a subject number and the subject will be 
officially enrolled in the study.  Study drug must be administered within 4 days from the date of 
randomization.   
Study Day 0 will be the first day of study drug administration. All on-study evaluations 
(i.e., those done from Day 0 and beyond) must be done within the following timeframe: 
 Dosing of gemcitabine, Abraxane® and demcizumab or placebo must be done within 
± 2 days of the Study Day listed in the protocol.  If a drug cannot be given within this 2 day 
window, then the dose of that drug is permanently missed. 
 Laboratory evaluations within ± 3 days of the Study Day listed in the protocol, except for 
BNP which must be done on the day of demcizumab/placebo dosing and must be done prior 
to the demcizumab/placebo dose. 
 Imaging studies (e.g., CT scans, MRI), ECG, and transthoracic Doppler echocardiogram 
within ± 7 days for the Study Day listed in the protocol. 
Unless otherwise indicated, all assessments must be performed prior to dosing for all study visits 
when dosing occurs. BNP must be drawn on the day of dosing and assessed prior to dosing 
(or if approved by OncoMed it may be drawn the day before dosing and assessed prior to 
dosing). 
For subjects who have discontinued demcizumab/placebo, all assessments as outlined in 
Appendix B should continue. 
12.1 
Screening 
All screening tests must be performed within Study Days -28 to 0, unless otherwise indicated.   
 Informed Consent (must be obtained before any study specific procedures are performed) 
 Past medical history 
 Physical examination 
 Peripheral neuropathy assessment 
 Vital signs 
 Height 
 Weight 
 ECOG performance status 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 59 of 130 
CONFIDENTIAL 
 
19 December 2016 
 CBC with differential and platelet count 
 Serum chemistry 
 INR/aPTT 
 B-type natriuretic peptide (BNP) measured using an Alere Triage POC device (or if approved 
by OncoMed the site’s laboratory) 
 Urinalysis with microscopic analysis 
 Electrocardiogram (ECG) including PR interval, QRS duration, and QTc interval 
 Transthoracic doppler echocardiogram with LVEF, and  peak tricuspid velocity determination 
 Tumor marker:  CA 19-9 
 Serum pregnancy test for all females of childbearing potential (a negative result must be 
obtained prior to randomization) (must be done within 7 days prior to randomization). 
 Tumor assessment:  Diagnostic-quality, contrast-enhanced CT scans of chest, abdomen, and 
pelvis (MRI scans may be performed in lieu of CT scans; see Section 10.0) performed as 
outlined by the RECIST criteria v1.1 (see Appendix D).  Note:  The same radiographic 
technique of each region must be used consistently throughout the study. 
 MRI of the brain, or CT scan of the brain with IV contrast (see Section 10.0) 
 Colonoscopy and/or upper gastrointestinal endoscopy to rule out gastrointestinal involvement 
in subjects having symptoms suggestive of possible gastrointestinal involvement. 
 FFPE (if tissue blocks are available; i.e., FNA is not adequate).  Note: FFPE may be shipped 
any time after enrollment. 
12.2 
Study Day 0 
 Demcizumab or placebo 
 Abraxane®  
 Gemcitabine 
 Abbreviated physical examination 
 Vital signs (prior to demcizumab or placebo infusion, 15 minutes after start of infusion, end 
of infusion, and 15 minutes post infusion). 
 Weight 
 ECOG performance status 
 CBC with differential and platelets (unless previously obtained on Study Days -3 to -1) 
 Serum chemistry (unless previously obtained on Study Days -3 to -1) 
 Serum for anti-demcizumab antibody collected prior to demcizumab or placebo infusion 
 Concomitant medications 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 60 of 130 
CONFIDENTIAL 
 
19 December 2016 
 Adverse event recording 
 Peripheral neuropathy assessment 
 Blood for biomarkers (must be obtained prior to dosing) 
 Blood for pharmacogenomics (Optional and only if subject has signed the separate 
pharmacogenomics Informed Consent Form) 
 Plasma for pharmacokinetics prior to the demcizumab or placebo infusion and at the end of 
the infusion (i.e., within 30 minutes prior to and post infusion, but prior to chemotherapy) 
12.3 
Study Days 7, 14, 21, 28, 35, 42, and 49 
 Demcizumab or placebo - Days 14, 28 and 42 
 Abraxane®  - Study Days 7, 14, 28, 35, and 42) 
 Gemcitabine - – Study Days 7, 14, 28, 35, and 42 ) 
 Abbreviated physical examination (Study Days 14, 28, and 42 only) 
 Vital signs (prior to demcizumab or placebo infusion, 15 minutes after start of infusion, end 
of infusion, and 15 minutes post infusion) (Study Days 14, 28 and 42 only) 
 Vital signs obtained once:  Study Days 7, 21, 35 and 49 only) 
 Weight 
 ECOG performance status 
 CBC with differential and platelet count 
 Serum chemistry 
 BNP measured using an Alere Triage POC device (or if approved by OncoMed the site’s 
laboratory) (Study Days 14, 28, and 42) 
 Urinalysis with microscopic analysis (Study Day 28 only) 
 ECG including PR interval, QRS duration, and QTc interval (Study Day 28 only) 
 Transthoracic doppler echocardiogram with LVEF and peak tricuspid velocity determination 
(Study Day 28 only) 
 Concomitant medication 
 Adverse event recording 
 Peripheral neuropathy assessment (Study Day 28 only) 
 Blood for biomarkers (Study Days 21, 35 and 49 only) 
 Plasma for pharmacokinetics prior to the infusion (i.e., with 30 minutes pre- infusion) (Study 
Day 14 only) 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 61 of 130 
CONFIDENTIAL 
 
19 December 2016 
12.4 
Study Day 56 
 Demcizumab or placebo  
 Abraxane®  
 Gemcitabine 
 Abbreviated physical examination 
 Vital Signs (prior to demcizumab or placebo infusion, 15 minutes after start of infusion, end 
of infusion, and 15 minutes post infusion) 
 Weight 
 ECOG performance status 
 CBC with differential and platelet count 
 Serum chemistry 
 BNP measured using any Alere Triage POC device (or if approved by OncoMed the site’s 
laboratory) 
 Urinalysis with microscopic analysis 
 ECG including PR interval, QRS duration, and QTc interval 
 Transthoracic doppler echocardiogram with LVEF and  peak tricuspid velocity determination 
 Tumor marker:  CA 19-9 (if elevated at baseline) 
 Serum pregnancy test for all females of childbearing potential 
 Tumor assessment:  Diagnostic-quality, contrast-enhanced CT scans of chest and abdomen, 
as well as imaging of all other known sites of disease, performed as outlined by the RECIST 
criteria v1.1 (see Appendix D).  Note:  If another imaging method was used at baseline, the 
same imaging method must be used consistently throughout the study.  
 Serum for anti-demcizumab antibody (prior to demcizumab or placebo infusion) 
 Concomitant medication 
 Adverse event recording 
 Peripheral neuropathy assessment 
 Plasma for pharmacokinetics prior to the demcizumab or placebo infusion and at the end of 
the infusion (i.e., within 30 minutes prior to and post infusion, but prior to chemotherapy) 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 62 of 130 
CONFIDENTIAL 
 
19 December 2016 
12.5 
Study Days 63, 70 
 Demcizumab or placebo – (Study Day 70 only) 
 Abraxane®  
 Gemcitabine  
 Abbreviated physical examination (Study Day 70 only) 
 Vital signs (prior to demcizumab or placebo infusion, 15 minutes after start of infusion, end 
of infusion, and 15 minutes post infusion) (Study Day 70 only) 
 Vital signs obtained once   (Study Day 63 only) 
 Weight 
 ECOG performance status 
 CBC with differential and platelet count 
 Serum chemistry 
 BNP measured using an Alere Triage POC device (or if approved by OncoMed the site’s 
laboratory) (Study Day 70 only) 
 Concomitant medication 
 Adverse event recording 
 Blood for biomarkers (Study Day 63 only) 
 Plasma for pharmacokinetics prior to the infusion and at the end of infusion (i.e., with 
30 minutes pre- and post infusion) (Study Day 70 only) 
12.6 
Study Day 77 
 Vital signs measured once 
 Weight 
 ECOG performance status 
 CBC with differential and platelet count 
 Serum chemistry 
 Concomitant medication 
 Adverse event recording 
12.7 
Study Days 84, 91, 98 
 Abraxane®  
 Gemcitabine  
 Abbreviated physical examination (Study Days 84 and 98 only) 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 63 of 130 
CONFIDENTIAL 
 
19 December 2016 
 Vital signs obtained once  
 Weight 
 ECOG performance status 
 CBC with differential and platelet count 
 Serum chemistry 
 BNP measured using an Alere Triage POC device (or if approved by OncoMed the site’s 
laboratory) (Study Days 84 and 98 only) 
 ECG including PR interval, QRS duration, and QTc interval (Study Day 84 only) 
 Transthoracic doppler echocardiogram with LVEF and peak tricuspid velocity determination 
(Study Day 84 only) 
 Concomitant medication 
 Adverse event recording 
 Peripheral neuropathy assessment (Study Day 84 only) 
12.8 
Study Day 105 
 Vital signs obtained once 
 Weight 
 ECOG performance status 
 CBC with differential and platelet count 
 Serum chemistry 
 Concomitant medication 
 Adverse event recording 
As long as the subject has stable disease or a response, the subject should continue to be treated 
and beginning weekly at Day 112 will undergo the tests designated for Study Days 84, 91, 98, 
and 105.  In addition, the following will be done every 8 weeks beginning at Day 112: 
 a CT, spiral CT, or MRI of the chest, abdomen, and pelvis performed as outlined by the 
RECIST criteria 1.1 (see Appendix D),  
 a CA 19-9 level obtained (if elevated at baseline), 
 Serum pregnancy test for all females of childbearing potential 
 a urinalysis with microscopic analysis 
 a serum sample for anti-demcizumab antibody 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 64 of 130 
CONFIDENTIAL 
 
19 December 2016 
Finally, a second course of demcizumab or placebo once every 2 weeks for 70 days will be given 
starting on Day 168 (see Section 8.1.1) and plasma for pharmacokinetics will be obtained prior 
to demcizumab or placebo infusion on Day 168, 182, 224 and 238, and at the end of demcizumab 
or placebo infusion on Day 168 and 224. 
12.9 
Termination Visit 
The termination visit should be done as soon as possible, but no later than 14 days, after one of 
the discontinuation criteria for the study are met. The following assessments must be performed 
on the day of study drug termination: 
 Abbreviated physical examination 
 Vital signs measured once 
 Weight 
 ECOG performance status 
 CBC with differential and platelet count 
 Serum chemistry 
 
BNP measured using an Alere Triage POC device (or if approved by OncoMed the site’s 
laboratory) (unless performed within the last 28 days) 
 Serum for anti-demcizumab antibody 
 Plasma for pharmacokinetics 
 Urinalysis with microscopic analysis (unless performed within the last 28 days) 
 ECG including PR interval, QRS duration, and QTc interval 
 Transthoracic doppler echocardiogram with LVEF and peak tricuspid velocity determination 
(unless done within the last 28 days) 
 Tumor marker:  CA 19-9 (if elevated at baseline) 
 Serum pregnancy test for all females of childbearing potential 
 Tumor assessment:  unless performed within 7 days of termination or at a prior response 
evaluation that documented progressive disease:  Diagnostic-quality, contrast-enhanced 
CT scans of chest and abdomen, as well as imaging of all other known sites of disease, 
performed as outlined by the RECIST criteria v1.1 (see Appendix D).  Note:  If another 
imaging method was used at baseline, the same imaging method must be used consistently 
throughout the study.  
 Concomitant medication (through 30 days following treatment termination) 
 Adverse event recording at the time of treatment termination and through 30 days following 
treatment termination 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 65 of 130 
CONFIDENTIAL 
 
19 December 2016 
 Peripheral neuropathy assessment 
 Blood for biomarkers (unless performed within the last 14 days) 
12.10 Follow-up after Termination Visit 
If the BP was >150/90 mmHg at the termination visit, the subject needs to be followed as 
outlined in Section 9.3. 
Serum pregnancy test for all females of childbearing potential 56 and 112 days following the 
treatment termination visit. 
RESPONSE ASSESSMENT DATA:  Response assessment data (i.e., progressive disease or no 
progression of disease) will continue to be collected (based on standard of care radiographs) on 
patients who have not progressed at the time of treatment termination until they receive 
subsequent treatment.  For these subjects, copies of the standard of care radiographs may be 
provided to the Sponsor in a de-identified manner.  These data and radiographs will continue to 
be collected until the subject starts alternative anti-cancer treatment or develops progressive 
disease, whichever occurs first. 
BNP AND DOPPLER ECHOCARDIOGRAM:  If a subject has a BNP of ≥400 pg/mL and/ or 
a diagnosis of pulmonary hypertension or heart failure at the time of termination, all subsequent 
standard of care BNP data until the value is <200 pg/mL and all subsequent standard of care 
LVEF and PTV values until they normalize will be collected and entered into the database.  
SURVIVAL DATA:  Once a patient has completed the treatment termination visit, overall 
survival follow up will be performed every three months +/- 1 week or more frequently at the 
request of the Sponsor for up to 5 years.  Follow up may be conducted by telephone interview or 
chart review 
13.0 
DATA QUALITY ASSURANCE 
Accurate, consistent, and reliable data will be ensured through the use of standard practices and 
procedures.  Clinical Research Associates (CRAs) will monitor the study and verify that the data 
are accurate.  OncoMed Pharmaceuticals, Inc. has contracted with PPD to perform the data 
management of this trial.  The data will be captured using a validated remote data capture (RDC) 
system.  The medical monitors, CRAs, and site personnel will be trained in the use of the RDC 
system.  The clinical data and the site-specific laboratory data will be entered by site personal 
into the RDC system.  Analysis of samples for antibodies to demcizumab will be performed by 
ICON Development Solutions.  Analysis of biomarker samples and pharmacogenomics samples 
will be performed at OncoMed Pharmaceuticals, Inc.  Drug safety reporting will be the 
responsibility of PPD.  System backups for data stored at OncoMed Pharmaceuticals, Inc. and at 
all CROs, and records retention for the study data will be consistent with the standard procedures 
for these organizations. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 66 of 130 
CONFIDENTIAL 
 
19 December 2016 
14.0 
STATISTICAL PLAN 
Table 7 presents the power to detect the difference between the control arm and the pooled 
demcizumab arms in the trial for the primary endpoint of PFS. Type 1 error is controlled at the 
0.10 one sided level.  Two hundred and one subjects followed until 125 PFS  events have been 
observed will provide 80 percent power to detect a hazard ratio of 0.67 which corresponds to an 
increase in median PFS from 5.5 months to 8.2 months. 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 67 of 130 
CONFIDENTIAL 
 
19 December 2016 
Table 7: 
Power for a Two Arm Comparison 
Total 
#Subjects 
Median 
Control 
Median 
Treatment 
Hazard 
Control 
Hazard 
Treatment 
Hazard 
Ratio 
End of 
Study 
(months) 
Total 
#Events 
Events 
Control 
Event 
Treat 
Type1
Error 
Power 
201 
5.5 
5.5 
0.126027 
0.126027 
1.000000 
23 
123.6 
42.6 
81.0 
0.1 
0.1000 
201 
5.5 
6.0 
0.126027 
0.115525 
0.916669 
24 
124.9 
43.7 
81.1 
0.1 
0.2068 
201 
5.5 
6.5 
0.126027 
0.106638 
0.846152 
24 
123.1 
43.7 
79.4 
0.1 
0.3466 
201 
5.5 
7.0 
0.126027 
0.099021 
0.785713 
25 
124.2 
44.7 
79.6 
0.1 
0.5033 
201 
5.5 
7.5 
0.126027 
0.092420 
0.733335 
26 
125.2 
45.4 
79.7 
0.1 
0.6507 
201 
5.5 
8.0 
0.126027 
0.086643 
0.687496 
26 
123.6 
45.4 
78.2 
0.1 
0.7664 
201 
5.5 
8.2 
0.126027 
0.084530 
0.670729 
26 
123.0 
45.4 
77.6 
0.1 
0.8041 
201 
5.5 
8.5 
0.126027 
0.081547 
0.647060 
27 
124.5 
46.1 
78.4 
0.1 
0.8563 
 
 
In addition to PFS, subjects will also be followed for the overall survival endpoint.   At the time of the PFS final analysis, which is 
anticipated to occur when approximately 87 deaths have been observed, an interim analysis for OS will take place.  After this  final 
analysis for PFS, there will be two more planned analyses for OS, one based on all deaths as of June 1 2017 and the final analysis 
based on all deaths as of November 1 2017. Table 8  presents the interim analysis plan for OS along with the power to detect a hazard 
ratio of 0.675 with type 1 error of 0.10.  The efficacy boundary is determined from the O’Brien Fleming spending function  while the 
futility boundary simply allows the study to continue while the estimated hazard ratio is less than 1 in favor of a survival benefit for 
demcizumab.  The rejection boun dary for OS may have to be adjusted using the O’Brien Fleming spending function for the number 
of deaths actually observed at times of the interim analyses (100% information = 131 deaths). 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 68 of 130 
CONFIDENTIAL 
 
19 December 2016 
Table 8: 
Summary of Power and Type 1 Error 
 
Interim 1 
PFS Final Analysis 
Interim 2 
Deaths as of June 1 2017 
Final Analysis 
Deaths as of Nov 1 2017 
Z-Statistic (reject the null) 
1.72 
1.52 
1.42 
Z-Statistic (reject the alt) 
0 
0 
1.42 
Events Total 
87 
112 
131 
Events Control 
34 
43 
49 
Events Treatment 
53 
69 
82 
Cumulative Power (HR=0.675) 
0.531 
0.713 
0.8 
Cumulative Type 1 Error (1-sided) 
0.043 
0.076 
0.1 
Cumulative Prob. of Stopping for Futility (Alt) 
0.036 
0.042 
0.201 
Cumulative Pro. of Stopping for Futility (Null) 
0.5 
0.577 
0.9 
 
The study will have 80 percent power to detect a hazard ratio of 0.675 with a type 1 error of 0.10 one-sided. The study followup for 
overall survival will stop for futility at either the OS analysis done at the time of the PFS analysis or the subsequent interim analysis 
for OS if the hazard ratio is greater than 1 suggesting that treatment with demcizumab may shorten survival.  The first analysis for OS 
will be based on all subjects who have died as of the data cutoff date for PFS.The final two analyses for OS will be based on all deaths 
on or prior to June 1 and November 1 2017.  The probability of stopping for futility at the first interim when there is no treatment 
benefit is 0.5.  The probability of stopping for futility at the first interim when demcizumab  has an overall suvival benefit described 
by a hazard ratio of 0.675 is 0.036.  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 69 of 130 
CONFIDENTIAL 
 
19 December 2016 
14.1 
Data Safety Monitoring Board 
A data safety monitoring board consisting of a Chairman, at least 2 medical oncologists and a 
statistician will meet quarterly to review the emerging data from the trial.  In addition to the 
planned Data Review meetings, the sponsor and/or DSMB may convene ad hoc meetings, should 
they be deemed necessary.  Specifically, the DSMB will review all adverse events (i.e., all 
Grades regardless of attribution to study drug) and safety data by treatment arm. 
14.2 
Study Stopping Rules 
These stopping rules apply to all subjects randomized on the study.  If two or more of the first 
10 subjects treated with demcizumab experience Grade 3-5 (per NCI CTCAE v. 4.03) heart 
failure and/or pulmonary hypertension, that is deemed at least possibly related to demcizumab, 
the study will be stopped.  
If after 10 subjects have been treated with demcizumab,  subjects experience greater than or 
equal to 15% above the rate in the control arm of Grade 3-5 (per NCI CTCAE v. 4.03) heart 
failure and/or pulmonary hypertension, that is deemed at least possibly related to demcizumab, 
the study will be stopped.   
During the trial, the proportion of subjects developing Grade ≥3 heart failure or pulmonary 
hypertension will be closely monitored by the DSMB on an ongoing basis.  In addition to the 
ongoing review of safety data by the DSMB, one formal joint interim safety analysis of the 
Grade >3 heart failure and Grade >3 pulmonary hypertension data from this trial and the ongoing 
companion trial in 1st line non-small cell lung cancer will occur after 60 demcizumab-treated 
subjects between the two studies have completed a minimum of 2 treatment cycles and the last of 
these 60 demcizumab subjects has been followed for 100 days.  Following review of these data, 
the DSMB will inform OncoMed in writing whether the incidence of >Grade 3 heart failure and 
the incidence of >Grade 3 pulmonary hypertension in the demcizumab-treated subjects is less 
than or greater than or equal to 15% above the incidence in the control arm.   
Table 9 presents the probability of exceeding the 15 percent threshold either at the formal interim 
or the final analyses of the trial. 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 70 of 130 
CONFIDENTIAL 
 
19 December 2016 
 
Table 9: 
Probability CHF Rate will Exceed 15 Percent over Control 
Control 
Rate 
Dem 
Rate 
Prob of exceeding 15 pct at 
Interim  
(67 subjects enrolled in 
demcizumab treated arm, 
67 subjects in the control 
arm) 
Prob of exceeding 15 pct 
at final  
(134 subjects with 
demcizumab, 134 
subjects with control) 
Prob of Not  
exceeding 15 pct at final 
Total Prob of exceeding 
15 pct 
Total 
Probability 
0.03 
0.03 
0.00016 
0.00000 
0.99984 
0.00016 
1.00000 
0.03 
0.06 
0.00877 
0.00016 
0.99108 
0.00893 
1.00001 
0.03 
0.09 
0.05897 
0.00502 
0.93603 
0.06399 
1.00002 
0.03 
0.12 
0.17202 
0.03042 
0.79758 
0.20244 
1.00002 
0.03 
0.15 
0.33041 
0.07915 
0.59047 
0.40956 
1.00003 
0.03 
0.18 
0.50000 
0.12501 
0.37501 
0.62501 
1.00002 
0.03 
0.21 
0.65292 
0.14233 
0.20478 
0.79525 
1.00003 
0.03 
0.24 
0.77491 
0.12838 
0.09673 
0.90329 
1.00002 
0.03 
0.27 
0.86330 
0.09702 
0.03969 
0.96032 
1.00001 
0.03 
0.30 
0.92226 
0.06359 
0.01416 
0.98585 
1.00001 
0.03 
0.33 
0.95869 
0.03694 
0.00438 
0.99563 
1.00001 
0.03 
0.36 
0.97958 
0.01926 
0.00116 
0.99884 
1.00000 
0.03 
0.39 
0.99067 
0.00907 
0.00026 
0.99974 
1.00000 
0.03 
0.42 
0.99609 
0.00386 
0.00005 
0.99995 
1.00000 
0.03 
0.45 
0.99852 
0.00147 
0.00001 
0.99999 
1.00000 
0.03 
0.48 
0.99950 
0.00050 
0.00000 
1.00000 
1.00000 
Note:  The sum of the probabilities in columns 3 to 6 adds up to 1.00. 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 71 of 130 
CONFIDENTIAL 
 
19 December 2016 
For continuous variables, descriptive statistics will include the number of non-missing values, 
mean, standard deviation, median, minimum, maximum, and possibly geometric mean and 
geometric standard error if applicable to biomarker data.  For categorical variables, descriptive 
statistics will include counts and percentages per category.  Statistics for time-to-event variables 
will be estimated by the Kaplan-Meier method. 
14.3 
Subject Populations for Analysis 
As noted above, 201 evaluable subjects will be enrolled in the trial.   
The Intent-to-Treat (ITT) Population comprises all subjects who receive at least one partial or 
complete dose of demcizumab or placebo.  All baseline characteristics and demographic, 
efficacy, immunogenicity, and biomarker data will be analyzed using the ITT Population. 
The Per Protocol Population (PP) is comprised of all randomized subjects who received at least 
one dose of study drug and had at least one post baseline tumor assessment.  All efficacy data 
will be analyzed using the PP population as well as the ITT Population. 
The Safety Population comprises all subjects who receive at least one partial or complete dose of 
demcizumab or placebo and who have at least one post-dosing safety evaluation.  All safety 
endpoints will be summarized using the Safety Population. 
The Pharmacokinetic (PK) Population comprises all subjects who receive at least one partial or 
complete dose of demcizumab or placebo and who provide adequate PK samples, as defined by 
the PK specialist, to calculate the PK parameters.  Subjects with protocol violations will be 
assessed on a subject-by-subject basis for inclusion in the PK Population.  PK analysis will be 
conducted using the Pharmacokinetic Population. 
Missing values will not be imputed. 
14.4 
Demographics and Baseline Characteristics 
Demographic and baseline characteristics will be analyzed using the Intent-to-Treat Population.  
Quantitative and/or categorical summaries will be presented for demographics, medical history, 
and other baseline characteristics.  For continuous variables, data will be summarized by sample 
size, mean, standard deviation, median, minimum, and maximum.  For categorical variables, data 
will be summarized as frequency counts and percentages.  Medical history will also be displayed 
by subject in listing formats. 
14.5 
Treatment Exposure 
Treatment exposure will be summarized as duration on treatment and extent of exposure to 
demcizumab in Arms 2 and 3.  Duration of exposure will be summarized quantitatively in days 
using sample size, mean, standard deviation, median, minimum, and maximum. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 72 of 130 
CONFIDENTIAL 
 
19 December 2016 
Measures of extent of exposure include the total number of doses per subject, cumulative dose 
per subject, dose intensity and compliance.  Compliance will be summarized as the number of 
subjects who had dose(s) withheld or delayed.  The reasons for dose(s) withheld or delayed will 
also be summarized. 
14.6 
Endpoints 
14.6.1 
Safety Endpoints 
Safety endpoints include AEs; SAEs; physical examination; vital signs; clinical laboratory 
testing including assessment of BNP every 14 days; electrocardiograms with assessment of PR 
interval, QRS duration, and QTc interval; transthoracic doppler echocardiograms with left 
ventricular ejection fraction and peak tricuspid velocity determination; and anti-demcizumab 
testing.  Safety endpoints will be analyzed by treatment arm using the Safety Population. 
14.6.1.1 
Adverse Events 
All reported adverse events will be mapped to standard Medical Dictionary for Regulatory 
Activities (MedDRA) coding terms, grouped by system organ class and preferred terms and 
tabulated by treatment arm.  The incidence of adverse events in each treatment arm will be 
tabulated by seriousness, severity, and relationship to study drug. 
14.6.1.2 
Clinical Laboratory Assessments and Vital Signs 
Clinical laboratory data (hematology, serum chemistry, and urinalysis with microscopic analysis) 
and vital signs will be summarized by treatment arm using descriptive statistics of the reported 
values and change from baseline values at the point of each subject’s minimum value/change, 
maximum value /change and the last value/change.  In addition, the frequency counts and 
percentages of subjects shifting from “low,” or “normal,” at baseline to “high” post baseline or 
“high” or “normal” at baseline to “low” post baseline for each treatment group will also be 
provided at the same time points. The high and low post baseline categories will be further 
classified by NCI CTC grade if available.  All laboratory and vital sign data will be presented in 
listings and special attention will be given to any unexpected abnormal results. 
14.6.1.3 
BNP Assessment 
The proportion of subjects with at least two consecutive BNP assessments above 100 pg/mL or 
at least one BNP assessment ≥200 pg/mL, the proportion of subjects who had their treatment 
held due to a BNP ≥300 pg/mL and the proportion of subjects who have a BNP elevation 
≥400 pg/mL will be summarized by treatment group. 
Among the subjects in the demcizumab groups with two BNP measurements above 100 pg/mL 
or one ≥200 pg/mL, the use of ACE inhibitors and carvedilol will be described with simple 
descriptive statistics and the proportion of subjects with an elevation to ≥400 pg/mL will also be 
summarized along with the total amount of follow-up time both preceding and following the 
initiation of ACE inhibitors or carvedilol. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 73 of 130 
CONFIDENTIAL 
 
19 December 2016 
14.6.1.4 
ECOG and Physical Examination 
ECOG performance status at baseline and follow-up and physical examination data at baseline 
will be listed by subject for each treatment arm.  Changes in ECOG performance status scores 
from baseline will be summarized by treatment group at selected scheduled time points using 
shift tables. 
14.6.1.5 
ECG and Doppler echocardiogram 
An electrocardiogram with assessment of PR interval, QRS duration, and QTc interval will be 
obtained every 28 days and a transthoracic doppler echocardiogram with left ventricular ejection 
fraction, and peak tricuspid velocity determination will be obtained every 28 days.  The 
maximum change in PR interval (increase), QRS duration (increase) and QTc interval (increase) 
will be summarized by treatment arm. 
14.6.2 
Immunogenicity Endpoints 
Immunogenicity endpoints will be analyzed using the ITT Population.  The incidence of anti-
demcizumab antibody development in each treatment arm will be summarized by frequency 
counts and percentages.  For subjects with a positive result for an anti-demcizumab antibody, the 
incidence of neutralizing capability development will be further summarized by standard 
quantitative methods for each treatment arm.  In addition, the impact of positive results on safety 
and biologic activity will be assessed. 
14.6.3 
Pharmacokinetic Endpoints  
Peak and trough concentrations will be summarized with simple descriptive statistics. 
Demcizumab concentration data from this study will be also included in a population 
pharmacokinetic analysis encompasses all studies in which pharmacokinetic sampling was 
conducted, to estimate the individual PK parameters (i.e., half-life, volume of distribution, 
clearance etc.) and to analyze the inter-subject variability and factors that may contribute to the 
inter-subject variability of the PK of demcizumab. 
14.6.4 
Efficacy Endpoints 
Efficacy endpoints include best overall response, confirmed response, time to progression, 
duration of response and survival.  Efficacy endpoints will be analyzed using the ITT Population. 
14.6.4.1 
Best Overall Response 
The best overall response is defined as the best response recorded from the start of the treatment 
until disease progression (see detailed definition in Appendix D) in the following order of 
importance: 
 Complete Response (CR) 
 Partial Response (PR) 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 74 of 130 
CONFIDENTIAL 
 
19 December 2016 
 Stable Disease (SD) 
 Progressive Disease (PD) 
 Not Evaluable (NE) 
The number and proportion of subjects achieving their best overall response will be summarized 
for each dose group and for the pooled demcizumab arms. 
The confirmed response rate is the number of subjects per treatment arm who have either a 
confirmed CR or a confirmed PR (according to RECIST criteria) divided by the number of 
subjects randomized to the respective arms.  These proportions and their 95% confidence 
intervals will be displayed for each treatment arm as well as for the pooled demcizumab arms.  
The p-value for equality between  the pooled demcizumab treatment arms and control will be 
calculated  using a logistic regression model with treatment performance status and region as 
factors in the model. A similar comparison will be made between each individual demcizumab 
arm and  control   
14.6.4.2 
Clinical Benefit Rate 
The Investigator-assessed RECIST clinical benefit rate (i.e., the rate of complete response + 
partial response + stable disease) will be calculated for the pooled demcizumab arms and will be 
compared with control.  In addition, the rates in each individual demcizumab arm will also be 
compared with control. 
14.6.4.3 
Progression-Free Survival and Duration of Response 
The primary endpoint, PFS based on the Investigator assessment of tumor response, is defined as 
the number of days from randomization until death or disease progression as defined by RECIST 
criteria for the ITT Population.  The Kaplan-Meier method will be used to estimate the 
proportion of subjects without progression or death over time and the median progression-free 
survival time in the pooled demcizumab arms as well as each individual arm of the trial.  The 
95% confidence intervals for median progression-free survival time will also be calculated for 
the pooled demcizumab arms as well as each treatment arm.  The p-values for the demcizumab 
treatment effects (pooled versus control as well as each individual demcizumab arm versus 
control)  will be generated using a stratified Cox proportional hazards model.  The stratification 
factors will be performance status (0 or 1), region (United States/ Canada or Europe/Australia) 
and CA19-9 (0 – ULN, >ULN – 59ULN, >59ULN).   Subjects who have not experienced death 
(within 56 days of the last tumor assessment) or progression by their last contact will be censored 
at the time of their last radiographic response assessment and the number and percentage of these 
subjects will be displayed.  In addition subjects who receive non protocol therapy will be 
censored at the point they start this treatment.  Radiotherapy and surgery directed at a disease site 
will be considered non protocol therapy.  Bisphosphonates and hormones will not be considered 
non protocol therapy.  If there is a disparity in discontinuation rates between treatment arms or in 
the types of censoring or in the use of non protocol therapy, sensitivity analyses will be 
performed to assess the impact. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 75 of 130 
CONFIDENTIAL 
 
19 December 2016 
In addition, for subjects who died or progressed after an extended lost to follow-up period 
(greater than 17 weeks from the previous assessment), PFS will be right censored at the date of 
the last adequate assessment prior to the lost to follow-up period.  Subjects who do not have any 
tumor assessments will be treated as censored at Day 0. 
PFS based on the IRF (optional) assessment of tumor response will be similarly defined with 
performance status and CA19-9 (0 – ULN, >ULN – 59ULN, >59ULN) being the stratification 
factors.  The optional IRF assessment will be performed if the Investigator-assessed efficacy data 
show a sufficiently positive trend in favor of one or both of the demcizumab arms. 
In addition to the log rank test, the Wilcoxon test will also be used as a sensitivity analysis to 
evaluate the impact of treatment on progression free survival. 
To evaluate the impact of the second course of demcizumab therapy, a cox regression analysis 
will be used with a time dependent covariate to capture the effect of the second course of 
demcizumab.  The two demcizumab arms will be pooled and compared with control.  A time-
dependent variable to capture the effect of the second course of demcizumab will be used.  The 
variable will be zero unless a subject has started a second course of demcizumab in which case 
the variable will assume the value of 1.  A standard variable will also be included in the model to 
capture the randomized assignment of subjects to control or demcizumab (pooled). 
14.6.5 
Continuous Variable Assessment of Tumor Length 
The tumor length will be calculated as the sum of the longest diameters for the target lesions (as 
defined by RECIST criteria and determined by the Investigator and the IRF (optional)).  The data 
will be displayed graphically with waterfall plots.  Summary statistics including mean, standard 
deviation, median, minimum, and maximum for tumor length will be presented for baseline, 
9 weeks post-baseline, and 18 weeks post-baseline.  These summary statistics will also be 
presented for differences from baseline at 9 and 18 weeks post-baseline.  Along with the 
summary statistics, the 95% confidence intervals of the mean tumor length for each treatment 
arm and the pooled demcizumab arms at each of the three timepoints will also be presented.  An 
ANCOVA model will be used to test the hypothesis that there is no difference between treatment 
arms as well as no difference between the pooled demcizumab arms and control with regard to 
changes from baseline tumor length at scheduled tumor assessments.  Treatment and ECOG PS 
and region will be factors in the model and baseline tumor length will be used as a covariate.  
Missing values will not be imputed. 
In the event that the parametric assumptions are not met, the p-value will be generated using a 
nonparametric test utilizing ranks.  This nonparametric test will be performed at scheduled tumor 
assessments, using the log of (tumor length at week t divided by tumor length at baseline) as the 
endpoint.  In the case of complete response when the outcome variable is undefined, the best 
possible rank will be assigned.  In the case of death or withdrawal due to adverse event, the worst 
possible rank will be assigned. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 76 of 130 
CONFIDENTIAL 
 
19 December 2016 
In addition, the rate of change in tumor volume at progression (sum of the longest diameters 
(SLD) at progression – SLD at nadir)/SLD at nadir as determined by both the Investigator and 
the IRF (optional) will be compared between thearms of the study as well as between the pooled 
demcizumab arms and control. 
14.6.6 
Duration of Response 
The Investigator and IRF (optional) assessed duration of response are defined as the time from 
the first partial or complete response to the time of death or disease progression for subjects with 
a confirmed response.  The Kaplan-Meier method will be used to estimate the duration of 
response.  The 95% confidence intervals for duration of response will also be calculated for the 
pooled demcizumab arms as well as each treatment arm.  The p-value for treatment effect 
(pooled versus control and each demcizumab arms versus control) will be generated using a Cox 
proportional hazards model.  Subjects who have not experienced death or progression by their 
last contact will be censored at the time of their last radiographic response assessment.  
14.6.6.1 
Sites of Progression 
The sites of progression as determined by the Investigator and by the IRF (optional) will be 
classified according to organ type and compared between the arms pooled demcizumab arms and 
control as well as the individual demcizumabarms versus control using a chi-square test.  If a 
subject has a new site of disease, that site will be used as the organ site. If a subject has no new 
site of disease then the organ site will be classified as existing tumor. Two chi-square tests will 
be performed, one using the classification existing organ site versus other and the second using 
the full classification described above. 
14.6.7 
Overall Survival 
A comparison of the overall survival between the pooled demcizumab arms and control as well 
as each individual demcizumab arm versus control will be performed.  Overall survival is 
defined as the number of days from randomization until death occurs.  No treatment cross-over is 
permitted in the study.  The Kaplan-Meier method will be used to estimate both the survival 
curves and the median survival time.  The 95% confidence intervals for median survival times 
will also be calculated.  A p-value for treatment effect will also be generated using a stratified 
Cox proportional hazards model.  The stratification factors will be performance status and CA19-
9 (0 – ULN, >ULN – 59ULN, >59ULN).  Subjects who have not experienced death by their last 
contact date will be censored at that time and the number and percentage of these subjects will be 
displayed.  If there is a disparity in discontinuation rates between treatment arms, a sensitivity 
analysis will be performed to assess the impact.In addition, a robust test procedure that  
adaptively weights which time points receive the greatest weights in the construction of the test 
(Ref 19) will be applied to the OS data.  This test is based on a weighted Kaplan Meier curve 
differences and the weighting is data dependent.  To supplement the model based hazard ratio 
estimate, we will calculate the difference in the area under the Kaplan Meier curves between the 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 77 of 130 
CONFIDENTIAL 
 
19 December 2016 
two arms restricted up to the time point T, which is the minimum of the two largest observed 
death times from the two arms combined. Landmark Survival 
The Kaplan Meier estimates of survival at 6, 12, 18 and 24 months will be compared between the 
pooled demcizumab arms and control as well as the individual demcizumab arms versus control 
using a simple Z test.  Greenwood’s formula for the variance of the survival estimate will be 
used to construct the Z-test. Exploratory Endpoints 
Exploratory endpoints include blood markers (see Section 11.0).  These endpoints will be 
analyzed using the Intent-to-Treat Population.  The correlation of changes in these endpoints 
with tumor response (best response and PFS) will be explored. 
14.7 
Termination Criteria 
Randomization will be terminated when at least 201 subject have been randomized. 
Randomization may be extended beyond 201 subjects to ensure that 201 evaluable subjects are 
enrolled.  All ongoing subjects will continue to be dosed until disease progression, subject 
withdrawal, or the Investigator withdraws subjects from the study. 
14.8 
Deviation Reporting 
The following protocol deviations will be recorded and summarized for the Intent-to-Treat 
population in the final report: 1) randomization violations, 2) dosing violations, 3) concomitant 
therapy violations, and 4) continuation of therapy when treatment should have been 
discontinued. 
15.0 
DIRECT ACCESS TO SOURCE DATA/DOCUMENTATION 
By participating in this trial, the investigator(s)/institution(s) agree to permit trial-related 
monitoring, audits, IRB/IEC(s) review by OncoMed and its representative and regulatory 
inspection(s) by providing direct access to all primary source documents, such as medical 
records, CT scans, etc. 
16.0 
ETHICAL CONSIDERATIONS 
This study will be conducted according to international standards of Good Clinical Practice (ICH 
guidance E6). 
17.0 
INVESTIGATOR REQUIREMENTS 
17.1 
Informed Consent 
A sample informed consent form will be provided.  OncoMed must review any proposed 
deviations from the sample informed consent form prior to submission to the IRB/IEC.  The final 
IRB/IEC-approved document must be provided to OncoMed for regulatory purposes. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 78 of 130 
CONFIDENTIAL 
 
19 December 2016 
The informed consent document must be signed and dated by the subject or the subject’s legally 
authorized representative before his/her participation in the study.  Documentation is required in 
each subject’s record that informed consent was obtained prior to participation in the study.  A 
copy of the informed consent document must be provided to the subject or the subject’s legally 
authorized representative. 
Signed consent forms must be kept in each subject’s study file and must be available for 
review/verification by study monitors at any time. 
17.2 
Institutional Review Board/Ethics Committee Approval 
This protocol, the informed consent documents, and relevant supporting information must be 
submitted to the IRB or IEC for review and must be approved before the study is initiated.  The 
study will be conducted in accordance with all regulatory requirements and the IRB or IEC 
requirements. 
The Principal Investigator is responsible for keeping the IRB or IEC apprised of the progress of 
the study and of any changes made to the protocol as deemed appropriate.  The IRB or IEC must 
be updated at least once a year or in accordance with local requirements.  The Principal 
Investigator must also inform the IRB or IEC of any significant adverse events. 
Investigators are required to follow their respective IRB or IEC requirements for the reporting of 
Serious Adverse Events and written safety reports to the IRB or IEC.  Investigators must 
immediately forward to their IRBs or IECs any updates provided by OncoMed (e.g., Investigator 
Brochure, safety amendment, etc.) 
17.3 
Study Monitoring 
Site visits will be conducted on a regular basis by an authorized OncoMed representative 
(e.g., Clinical Research Associate [CRA]) to inspect study data, subjects’ medical records, and 
electronic data capture (EDC) fields in accordance with current GCPs.  During the site visit, the 
OncoMed CRA or representative will review the following: 
 Completeness of subject records 
 Accuracy of entries in the EDC fields 
 Adherence to the protocol and to GCP 
 Adherence to specifications for study drug storage, dispensing, and accountability 
The OncoMed CRA or representative will be responsible for reviewing completed EDC fields 
and clarifying and resolving any data queries. 
The CRA will also review regulatory study documents during site visits.  The investigator and 
key study personnel must be available to assist the OncoMed monitor or representative during 
these visits. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 79 of 130 
CONFIDENTIAL 
 
19 December 2016 
The Principal Investigator will permit authorized representatives of OncoMed and any regulatory 
authority to inspect facilities and records relevant to this study. 
17.4 
Auditing Procedures 
A representative of OncoMed may conduct an audit of the clinical research activities to ensure 
accordance with internal standard operating procedures (SOPs) and to evaluate compliance with 
the principles of GCP.  Any regulatory authority may also conduct an inspection during the study 
or after its completion.  If an inspection is requested by a regulatory authority, the investigator 
must inform OncoMed of this immediately. 
17.5 
Data Collection 
The data will be reported by the site via an internet-based EDC system.  The EDC screens should 
be completed in accordance with instructions from OncoMed. 
The EDC screens should be completed by examining personnel, the study coordinator, or 
designee.  The EDC screens must be reviewed by the investigator.  The investigator will ensure 
that all data is completely and accurately recorded on the EDC screens. 
17.6 
Investigational Medicinal Product Accountability 
All IMP (demcizumab and placebo) required for completion of this study will be provided by 
OncoMed or its agent.   
Accurate records of all IMP dispensed from and returned to the pharmacy should be documented 
by completing the Drug Accountability Log. 
Sites will destroy and document destruction on the Investigational Drug Product Return or 
Destruction Form, or return all unopened, unused, and expired vials to the drug distribution 
center along with a completed Investigational Drug Product Return or Destruction Form Sites 
must have appropriate processes or SOPs and capabilities, in order to destroy study drug. 
All IMP Accountability Forms will be provided by OncoMed.  Upon agreement by OncoMed, 
the site may use its own IMP Accountability Log if it contains all of the information required on 
OncoMed’s log. 
17.7 
Disclosure of Data and Publication 
Subject medical information obtained by this study is confidential, and disclosure to third parties 
other than those noted below is prohibited. 
Upon the subject’s permission, medical information may be given to his or her personal 
physician or other appropriate medical personnel responsible for his/her welfare. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 80 of 130 
CONFIDENTIAL 
 
19 December 2016 
Data generated by this study must be available for inspection upon request by representatives of 
any regulatory authority, auditors, OncoMed representatives, and the local IRB or IEC for each 
study site. 
OncoMed commits to publish the study results.  The manuscript will include all subjects from all 
sites.  The Investigators will participate in writing and reviewing the manuscript.  OncoMed will 
make the final decision on all presentations of study results and submissions of abstracts and 
manuscripts working in good faith with the Investigators. 
17.8 
Retention of Records 
Regulations require that records and documents pertaining to the conduct of this study and the 
distribution of investigational drug, including consent forms, laboratory test results, study 
medication inventory records, and regulatory documents, must be retained by the Principal 
Investigator for 2 years after marketing application approval.  If no application is filed, these 
records must be kept for 2 years after the study is discontinued and the applicable regulatory 
authorities are notified.  OncoMed will notify the Principal Investigator of these events. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 81 of 130 
CONFIDENTIAL 
 
19 December 2016 
18.0 
REFERENCES 
1. 
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with 
Abraxane plus gemcitabine. N Engl J Med 2013;369:1691-1703. 
2. 
Clarke MF, Fuller M. Stem cells and cancer: Two faces of Eve. Cell 2006;124:1111–5. 
3. 
Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea-A paradigm shift. Cancer Res 
2006;66:1883–90. 
4. 
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells 
promote radioresistance by preferential activation of the DNA damage response. Nature 
2006;444(7120):756–60. 
5. 
Dylla SJ, Beviglia L, Park I, Raval J, Ngan L, Pickell K. Colorectal cancer stem cells 
(CoCSC) are enriched in residual xenogeneic tumors following chemotherapy. 
PloS ONE. 2008:3;e2428. 
6. 
Besseyrias V, Fiorini E, Strobl LJ, Zimber-Strobl U, Dumortier A, Koch U, et al. 
Hierarchy of Notch-Delta interactions promoting T cell lineage commitment and 
maturation. J Exp Med 2007;204(2):331–43. 
7. 
Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 
signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 
2007; 445 (7129):776–80. 
8. 
Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of 
Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 
2006;444(7122):1083–7. 
9. 
Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. 
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. 
Nature 2006;444 (7122):1032–7. 
10. 
Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghanesh P. 
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: 
results of secondary end points analyses. Br J Cancer 2008;99:6-13. 
11. 
Murtaugh LC, Stanger BZ, Kwan KM, Melton DA. Notch signaling controls multiple 
steps of pancreatic differentiation. Proc Natl Acad Sci (USA) 2003;100:14920–5. 
12. 
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-
mesenchymal transition phenotype of gemcitabine resistant pancreatic tumor cells is 
linked with activation of the Notch signaling pathway. Cancer Res 2009;69:2400–7. 
13. 
Yen WC, Fischer MM, Hynes M, Wu J, Kim E, Beviglia L, et al. Anti-DLL4 Has Broad 
Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling 
in Both Tumor and Vasculature Cells, Clin Cancer Res 2007;18(19); 5374–86. 
14. 
Radtke F, Fasnacht N, and MacDonald HR. Notch signaling in the immune system. 
Immunity 2010;32:14-27. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 82 of 130 
CONFIDENTIAL 
 
19 December 2016 
15. 
Mathieu M, Cotta-Grand N, Daudelin JF, et al. Notch signaling regulates PD-1 
expression during CD8(+) T-cell activation. Immunol Cell Biol 2013;1:82-8. 
16. 
James PA, Oparil S, and Carter BL. 2014 evidence-based guideline for the management 
of high blood pressure in adults: report from the panel members appointed to the Eighth 
Joint National Committee (JNC 8). JAMA. 2014;311:507-20. 
17. 
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and 
treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and 
treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. 
Developed in collaboration with the Heart Failure Association of the ESC (HFA) and 
endorsed by the European Society of Intensive Care Medicine (ESICM).  Eur J Heart 
Failure 2008;10:933-89. 
18. 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). 
Eur J Cancer 2009:45:228–47 
19. 
Uno H, Tian L, Claggett B, Wei LJ. A versatile test for equality of two survival functions 
based on weighted differences of Kaplan–Meier curves. Statist. Med. 2015, 34 3680–
3695 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 83 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX A: 
STUDY SCHEMA 
1st Line Metastatic Pancreatic Ductal Adenocarcinoma:  
1:1:1 Randomization (n = 201) 
 
 
1st line 
Metastatic 
Pancreatic 
Ductal
Adenocarcinoma
(N=201)
Abraxane, 
Gemcitabine
+
Placebo
for 3 Cycles
1:1:1
Abraxane, 
Gemcitabine
for 3 Cycles
Abraxane, 
Gemcitabine
+
Placebo
for 3 Cycles
Abraxane,
Gemcitabine
+
Demcizumab
for 3 Cycles
Abraxane,
Gemcitabine
for 3 Cycles
Abraxane, 
Gemcitabine
+
Placebo
For 3 Cycles
Abraxane,
Gemcitabine
+
Demcizumab
for 3 Cycles
Abraxane,
Gemcitabine
for 3 Cycles
Abraxane, 
Gemcitabine
+
Demcizumab
for 3 Cycles
Abraxane,
Gemcitabine
Until 
Progressive 
Disease
Abraxane, 
Gemcitabine
Until 
Progressive 
Disease
Abraxane,
Gemcitabine
Until
Progressive 
Disease
ARM 1
ARM 3
ARM 2
If a drug cannot be administered within the specified time window ( See Section 12.0) , the missed dose cannot be administered at a later time point. 
Instead, the drug is to be administered until the next scheduled dose.


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 84 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX B: 
SCHEDULE OF ASSESSMENTS 
Day(s) 
-28  
to 0 
0 
7 
14 
21 
28 
35 
42 
49 
56 
63 
70 
77 
84 
91 
98 
105r 
Termination
Visit 
Follow-up 
after 
termination 
visit 
Informed consenta 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abraxane®b 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
Xr 
 
 
 
Gemcitabineb  
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
X 
 
X 
X 
Xr 
 
 
 
Demcizumab or placebob 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
 
 
 
 
 
Past medical history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examc 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Vital signs d,e 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Xs 
 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
ECOG performance status 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
CBC w/diff, plts 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Serum chemistryf 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
INR/aPTT 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BNPg 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Xt 
 
Anti-demcizumab antibody 
 
Xu 
 
 
 
 
 
 
 
Xu 
 
 
 
 
 
 
 
Xu 
 
Urinalysis with 
microscopic analysis 
X 
 
 
 
 
X 
 
 
 
Xy 
 
 
 
 
 
 
 
Xt 
 
ECGh 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
Transthoracic doppler 
echocardiogram with LVEF 
and peak tricuspid velocity 
determinationi 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
Xt 
 
Tumor marker CA 19-9 
X 
 
 
 
 
 
 
 
 
Xq 
 
 
 
 
 
 
 
Xq 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 85 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX B: 
SCHEDULE OF ASSESSMENTS (CONT’D) 
Day(s) 
-28 
to 0 
0 
7 
14 
21 
28 
35 
42 
49 
56 
63 
70 
77 
84 
91 
98 
105r 
Termination
Visit 
Follow-up 
after 
termination 
visit 
Serum pregnancy testj 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
X 
Chest, abdomen, and pelvis 
radiographic evaluationk 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
Xv 
 
CT pulmonary angiogram  
(if applicable)aa 
 
If pulmonary hypertension is diagnosed, 
……………..perform CT pulmonary angiogram (or other appropriate study) to rule out pulmonary embolism………………
 
Concomitant medsl 
 
X 
…………………………………………………………………………………………………………………. X 
 
Adverse event evaluationl 
 
X 
…………………………………………………………………………………………………………………. X 
 
Peripheral neuropathy 
assessment 
X 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
Pharmacokinetics 
 
Xp 
 
Xp 
 
 
 
 
Xp
 
Xp 
 
 
 
 
 
X 
 
Blood for biomarkersm 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
 
 
 
 
 
X 
 
Optional Pharmacogenomicsn 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colonoscopy and/or upper GI 
endoscopyo 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Head CT or MRI 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FFPE (if tissue blocks 
available)w 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Survival data including date 
and cause of deathx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xx 
Subsequent anti-cancer 
therapiesy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Response assessment dataz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 86 of 130 
CONFIDENTIAL 
 
19 December 2016 
NOTES TO APPENDIX B 
a. 
Written informed consent is required before performing any study-specific tests or procedures and may be obtained at any time prior to such tests or procedures. Results of 
standard of care tests or examinations performed prior to obtaining informed consent and within 28 days prior to Day 0 may be used for screening assessments rather than 
repeating such tests.b. 
Demcizumab or placebo and gemcitabine and Abraxane® must be dosed as described in Section 8.0. Dosing of gemcitabine, Abraxane®, and 
demcizumab or placebo must be administered within ± 2 days of the Study Day listed in the protocol.  If a drug cannot be given within this 2 day window, then the dose of that 
drug is permanently missed.  
c. 
A full physical examination will be done at screening.  Subsequently, an abbreviated physical examination will performed at Day 0, every other week while on treatment and at 
treatment termination.  The abbreviated physical examination must include respiratory rate, auscultatory examination of the heart and lungs, abdominal examination, and 
assessment for the presence or absence of edema and/or ascites.  A more complete physical examination should be conducted when clinically indicated. 
d. 
On the day of demcizumab or placebo dosing, pre-infusion, 15 minutes after start of infusion, end of infusion, and 15 minutes post infusion on the days of dosing. 
e. 
Vitals obtained once at the visits where demcizumab or placebo is not administered (Study Days 7, 21, 35, 49 63, 77, 84, 91, 98 and 105). 
f. 
Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, potassium, total protein, AST (SGOT), 
ALT (SGPT), sodium 
g. 
BNP measured using an Alere Triage POC device (or if approved by OncoMed the site’s laboratory). 
h. 
A 12-lead ECG must be performed and must include assessment of the PR interval, QRS duration, and QTc interval. 
i. 
A doppler echocardiogram with left ventricular ejection fraction and peak tricuspid velocity determination to be repeated every 28 days while subjects remain on therapy. 
j. 
Serum pregnancy test (women of childbearing potential only) must be obtained within 7 days prior to randomization, every 56 days while on study, at the termination visit and 
56 and 112 days following the termination visit 
k. 
Conventional CT, Spiral CT, or MRI of the chest, abdomen, and pelvis performed as outlined by RECIST 1.1 (see Appendix D).  Note:  The same radiographic technique of 
each region must be used consistently throughout the study. 
l. 
To be collected for 30 days after treatment termination.. 
m. A predose sample of a total of 9 mL of blood will be drawn on Days 0, 21, 35, 49 and 63 and at treatment termination, unless one has been obtained during the prior 14 days 
for subjects continuing on study drug to evaluate changes in plasma proteins (4 mL) (e.g., VEGF, βFGF, SDF1, PLGF, SCF, etc.),  and Notch-related gene expression of 
mRNA (5 mL) as described in Section 11.0.  Instructions for the collection, handling, storage, and shipment are provided in the Study Reference Binder. 
n. 
Pharmacogenomics:  For subjects who sign the optional Pharmacogenomics Informed Consent only, a blood sample (10 mL) will be collected at Day 0 (where local 
regulations permit).  Analysis of genes relevant to Notch/DLL4 target or pathway genes may be performed (e.g., FBW7 and PTEN).  Instructions for the collection, handling, 
storage, and shipment of these samples are provided in the Study Reference Binder. 
o. 
Colonoscopy and/or upper gastrointestinal endoscopy to rule gastrointestinal involvement in subjects having symptoms suggestive of possible gastrointestinal involvement. 
p. 
Plasma samples for PK analysis to be obtained at the end of the demcizumab or placebo infusion on Days 0, 56, 70, 168 and 224; prior to the demcizumab infusion on Days 0, 
14, 56, 70, 168, 182, 224 and 238 (prior to the paclitaxel infusion) and at treatment termination. Instructions for the collection handling, storage, and shipment of these samples 
are provided in the Study Reference Binder.  
q. 
If elevated at baseline. 
r. 
As long as the subject has stable disease or a response, the subject may continue to be dosed weekly for 3 weeks followed by a week of rest for gemcitabine and Abraxane® and 
will undergo the tests designated for Study Days 84, 91, 98, and 105.  In addition, 1) every 8 weeks the subject will have a conventional CT, spiral CT, or MRI of the chest, 
abdomen, and pelvis performed as outlined by the RECIST criteria 1.1 (see Appendix D), 2) every 8 weeks the subject will have a CA 19-9 level obtained, 3) a urinalysis with 
microscopic analysis  will be performed every 56 days and 4) every 4 weeks the subject will have a transthoracic doppler echocardiogram with LVEF and peak tricuspid 
velocity determination. 5) A second course of demcizumab or placebo once every 2 weeks for 70 days will be given starting on Day 168, 6) plasma for pharmacokinetics will 
be obtained prior to demcizumab or placebo infusion on Day 168, 182, 224 and 238, and at the end of demcizumab or placebo infusion on Day 168 and 224. Note:  The same 
radiographic technique of each region that was used at baseline must be used throughout the study. 
s. 
Any subject with demcizumab- induced or -exacerbated hypertension will continue to have their BP monitored once every 2 weeks for 8 weeks.  If the BP is not 
<150/90 mmHg at the end of the 8-week period, then the BP will continue to be monitored once every 2 weeks until it is <150/90 mmHg for a 4-week period. 
t. 
Unless done within last 28 days. If a subject has a BNP of ≥400 pg/mL and/ or a diagnosis of pulmonary hypertension or heart failure at the time of termination, all subsequent 
standard of care BNP data until the value is <200 pg/mL and all subsequent standard of care LVEF and PTV values until they normalize will be collected and entered into the 
database.  
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 87 of 130 
CONFIDENTIAL 
 
19 December 2016 
NOTES TO APPENDIX B CONT’D 
u. 
Serum sample for immunogenicity to be obtained at baseline, every 8 weeks (prior to demcizumab or placebo infusion) while the subject is on study and at treatment 
termination. Instructions for the collection, handling, storage, and shipment are provided in the Study Reference Binder.  
v. 
Perform tumor assessment at screening (Study Days -28 to -8), every 8 weeks thereafter until disease progression, and at the termination visit (unless performed within 7 days 
of termination or at a prior response evaluation that documented progressive disease). The schedule of every 8 weeks is to be maintained throughout the study and will not be 
shifted if there are dose holds. 
 
Screening assessments should include CT scans of the chest, abdomen, and pelvis, as well as MRI of the brain.  CT scan of the neck or bone scan should be performed if 
clinically indicated.  A documented standard-of-care tumor assessment performed within Study Days -28 to -8 may be used for the screening assessment provided it meets 
protocol requirements.  Alternative imaging modalities may be used as outlined in Section 10.0. Subsequent tumor assessments must include imaging of chest and abdomen, as 
well as all other known sites of disease.  The same imaging methods used at screening must be used throughout the study.  Response assessments will be performed by the 
investigator according to RECIST v1.1 (Appendix D). 
w. If available, archival FFPE tumor specimens obtained at the time of surgical resection or from a core biopsy will be collected. Analysis of candidate genes and/or proteins 
relevant to the Notch pathway may be performed (e.g., DLL4, Notch1, Hey 1, FBW7, etc.).  Archived FFPE specimens may be obtained during screening or post-screening, as 
long as the trial is active. Instructions for the collection, handling, storage, and shipment of these samples are provided in the Study Reference Binder.  
x. 
Once a subject has completed the termination visit, overall survival follow-up will be performed every three months ± 1 week for up to 5 years to determine the subject’s status 
and ultimately the date and cause of death. Follow-up may be conducted through telephone calls, review of medical records, and/or clinic visits.  In addition, the site may check 
public data sources to get this information, if needed (e.g., obituaries). 
y. 
Subsequent anti-cancer therapies, including systemic therapies, surgery (resection of metastatic disease), and radiation therapy will be collected through telephone calls, review 
of medical records, and/or clinic visits on the same schedule as for survival data (see note aa.). 
z. 
Response assessment data (i.e., progressive disease or no progression of disease) will continue to be collected (based on standard-of-care radiographs) on subjects who have 
not progressed at the time of the termination visit. For these subjects, copies of the standard-of-care radiographs may be provided to the Sponsor in a de-identified manner.  
These data and radiographs will continue to be collected until the subject starts new anti-cancer treatment or develops progressive disease, whichever occurs first. 
aa. A CT pulmonary angiogram (CTPA) should be performed if pulmonary hypertension is diagnosed (i.e., the subject has a peak tricuspid velocity >3.4 m/s on Doppler 
echocardiogram, has been seen by a cardiologist and was diagnosed with clinically significant pulmonary hypertension) to determine if pulmonary embolism might be the 
cause of the pulmonary hypertension. An MR angiogram or VQ scan may be performed instead per local or country standards or if the subject has a contrast allergy. 
 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 88 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX C: 
ECOG PERFORMANCE STATUS CRITERIA 
 
ECOG Performance Status Scale 
Grade 
Descriptions 
0 
Normal activity.  Fully active, able to carry on all pre-disease performance without 
restriction. 
1 
Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and 
able to carry out work of a light or sedentary nature (e.g., light housework, office work). 
2 
In bed <50% of the time.  Ambulatory and capable of all self-care, but unable to carry out 
any work activities.  Up and about more than 50% of waking hours. 
3 
In bed >50% of the time.  Capable of only limited self-care, confined to bed or chair more 
than 50% of waking hours. 
4 
100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally confined to 
bed or chair. 
5 
Dead 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 89 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX D: 
RECIST CRITERIA 1.1 
Response Evaluation Criteria in Solid Tumors (RECIST) Quick Reference 
ELIGIBILITY 
· 
Only subjects with measurable disease at baseline should be included in protocols where 
objective tumor response is the primary endpoint. 
Measurable Disease – the presence of at least one measurable lesion.  If the measurable 
disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by 
cytology/histology. 
Measurable Lesions – lesions that can be accurately measured in at least one dimension 
with the minimum size of: 
· 
10 mm by CT scan or MRI (no less than double the slice thickness and a 
minimum of 10 mm). 
· 
10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measureable). 
· 
15 mm for nodal disease in short axis 
· 
20 mm by chest X-ray (if clearly defined and surrounded by aerated lung) 
· 
Malignant lymph node: 15 mm in short axis when assessed by CT scan (CT scan 
slice thickness no greater than 5 mm).  At baseline and in follow-up only the short 
axis is to be followed. 
Non-Measurable Lesions – all other lesions, including small lesions (longest diameter 
<10 mm or pathological lymph nodes with >10 to <15 mm short axis) ) as well as truly 
non-measurable lesions.  Lesions considered truly non-measurable include 
leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast disease, 
lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly 
identified by physical examination that is not measurable by reproducible imaging 
techniques, and nodal disease that is 10 to < 15 mm in short axis. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 90 of 130 
CONFIDENTIAL 
 
19 December 2016 
Special Considerations Regarding Lesion Measurability:  Bone lesions, cystic lesions, and 
lesions previously treated with local therapy require particular comment: 
Bone lesions: 
· 
Bone scan, PET scan or plain films are not considered adequate imaging techniques to 
measure bone lesions.  However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
· 
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, 
that can be evaluated by cross sectional imaging techniques such as CT or MRI can be 
considered as measurable lesions if the soft tissue component meets the definition of 
measurability described above. 
· 
Blastic bone lesions are non-measurable. 
Cystic lesions: 
· 
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
definition, simple cysts. 
· 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above.  However, if noncystic 
lesions are present in the same subject, these are preferred for selection as target lesions. 
Lesions with prior local treatment: 
· 
Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-
regional therapy, are usually not considered measurable unless there has been demonstrated 
progression in the lesion.  Study protocols should detail the conditions under which such 
lesions would be considered measurable. 
Measurement of Lesions 
· 
All measurements should be taken and recorded in metric notation, using calipers if clinically 
assessed.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 28 days before the beginning of the treatment. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 91 of 130 
CONFIDENTIAL 
 
19 December 2016 
Methods of Measurement 
· 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and at each subsequent response assessment.  
Imaging based evaluation should always be done rather than clinical examination unless the 
lesion(s) being followed cannot be imaged but are assessable by clinical examination. 
· 
For the case of skin lesions, documentation by color photography, including a ruler to 
estimate the size of the lesion, is recommended. 
· 
CT is currently the best currently available and reproducible method to measure target 
lesions selected for response assessment.  The CT scan slice thickness should be 5 mm or 
less.  When the CT scans have a slice thickness that is greater than 5 mm, the minimum size 
for a measurable lesion should be twice the slice thickness.  MRI is also acceptable.  Please 
see Appendix II (Ref 13) for more details concerning the use of CT scan and MRI. 
· 
Lesions on chest X-ray are acceptable as measurable lesions when they are clearly defined 
and surrounded by aerated lung.  However, CT is preferable. 
· 
Ultrasound (US) should not be used to measure tumor lesions.  The utilization of endoscopy 
and laparoscopy for objective tumor evaluations not advised. 
· 
FDG-PET can be used to determine a new lesion if the lesion was absent at baseline on FDG-
PET 
· 
Tumor markers alone cannot be used to assess response.  If markers are initially above the 
upper normal limit, they must normalize for a subject to be considered in complete response 
when all lesions have disappeared. 
· 
Cytology and histology can be used to differentiate between PR and CR in rare cases (e.g., 
after treatment to differentiate between residual benign lesions and residual malignant lesions 
in tumor types such as germ cell tumors). 
Baseline Documentation of “Target” and “Non-Target” Lesions 
· 
All measurable lesions up to a maximum of two lesions per organ and 5 lesions in total, 
representative of all involved organs should be identified as target lesions and recorded and 
measured at baseline. 
· 
Target lesions should be selected on the basis of their size (lesions with the longest diameter) 
and be representative of all involved organs, but in addition should lend themselves accurate 
repeated measurements. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 92 of 130 
CONFIDENTIAL 
 
19 December 2016 
· 
A sum of the longest diameter (LD) for all target lesions will be calculated and reported as 
the baseline sum diameters.  The baseline sum diameters will be used as reference by which 
to characterize the objective tumor.  If lymph nodes are to be included in the sum, then as 
noted above, only the short axis is added to the sum. 
· 
If a target lesion becomes too small to measure, a default value of 5 mm is assigned.  If the 
lesion disappears, the measurement is recorded at 0 mm. 
· 
If extranodal target lesions fragment, the LDs of the fragmented portion are added in the 
sum.  If targets lesions coalesce and cannot be distinguished, the LD of the coalesced lesion 
is added to the sum. 
· 
For a patient with SD or PR, a lesion which disappears and then reappears will continue to be 
measured and added to the sum.  Response will depend upon the status of the other lesions.  
For a patient with CR, reappearance of a lesion is considered PD. 
· 
New lesions should be unequivocal and not attributable to differences in scanning technique 
or findings which may not be tumor.  If a new lesion is equivocal, repeat scans are needed to 
confirm.  If confirmed, PD is assessed from the date of the first scan. 
· 
All other lesions (or sites of disease) should be identified as non-target lesions and should 
also be recorded at baseline.  Measurements of these lesions are not required, but the 
presence or absence of each or in rare case unequivocal progression should be noted at each 
subsequent response assessment. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 93 of 130 
CONFIDENTIAL 
 
19 December 2016 
RESPONSE CRITERIA 
Evaluation of Target Lesions 
* Complete Response (CR): 
Disappearance of all target lesions.  Any pathological lymph node (whether target 
or nontarget) must have reduction in short axis to <10 mm 
* Partial Response (PR): 
At least a 30% decrease in the sum of the diameters of target lesions, taking as 
reference the baseline sum diameters 
* Progressive Disease (PD): 
At least a 20% increase in the sum of the diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm.  The appearance of one or more 
new lesions is also considered progression. 
* Stable Disease (SD): 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
PD, taking as reference the smallest sum diameters while on study. 
 
Evaluation of Non-Target Lesions 
* Complete Response (CR): 
Disappearance of all non-target lesions and normalization of tumor marker level. 
All lymph nodes must be non-pathological in size (i.e., < 10 mm short axis) 
* Non-CR/Non-PD 
Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits 
* Progressive Disease (PD): 
Unequivocal progression of the existing non-target lesions.  The appearance of 
one or more new lesions is also considered progressive disease. 
(1) Although a clear progression of “non target” lesions only is exceptional, in such circumstances, the opinion of 
the Investigator should prevail. 
 
Evaluation of Overall Response 
The overall response is assessed according to the following table. 
Target lesions 
Non-Target lesions 
New Lesions 
Overall response 
CR 
CR 
No 
CR 
CR 
Non-CR/Non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all evaluated 
No 
PR 
SD 
Non-PD or not all evaluated 
No 
SD 
Not all evaluated 
Non-PD  
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 94 of 130 
CONFIDENTIAL 
 
19 December 2016 
· 
Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as having 
“symptomatic deterioration”.  Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
· 
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy) to confirm the complete 
response status.  If described in the clinical protocol, FDG-PET may be used to upgrade a 
response to a CR in a manner similar to a biopsy in cases where a residual radiographic 
abnormality is thought to represent fibrosis or scarring. 
Confirmation 
Confirmation of response is not required in this randomized study since the control arm serves as 
an appropriate means to interpret the data. 
REPORTING OF RESULTS 
· 
All subjects included in the study must be assessed for response to treatment, even if there 
are major protocol treatment deviations or if they are ineligible.  Each subject will be 
assigned one of the following categories:  1) complete response, 2) partial response, 3) stable 
disease, 4) progressive disease, 5) inevaluable for response:  specify reason such as early 
death from malignant disease, early death from toxicity, tumor assessments not 
repeated/incomplete, or other (specify). 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 95 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX E: 
NEW YORK HEART ASSOCIATION CLASSIFICATION 
NYHA 
Class 
Symptoms 
I 
Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no 
shortness of breath when walking, climbing stairs etc. 
II 
Mild symptoms (mild shortness of breath and/or angina) and slight limitation during 
ordinary activity. 
III 
Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. 
walking short distances (20-100 m).  Comfortable only at rest. 
IV 
Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 96 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX F: 
SAMPLE INFORMED CONSENT 
PROTOCOL M18-006:  YOSEMITE:  A 3-Arm Phase 2 Double-Blind Randomized Study of 
Gemcitabine, Abraxane® Plus Placebo versus Gemcitabine, Abraxane® plus 1 or 2 Truncated 
Courses of Demcizumab in Subjects with 1st-line  Metastatic Pancreatic Ductal Adenocarcinoma 
Principal Investigator:  _____________________________________________ 
Before you decide whether or not to take part in this research study, it is important for you to 
understand the purpose of the study, what risks may be involved, and what is expected of you 
during the study.  If you have any questions that are not answered or if there are words that you 
do not understand in this consent form, a member of the research team will give you further 
information.  Once you understand the purpose of this study, and if you decide to volunteer to 
participate in the study, you will be asked to sign this consent form. 
You are being asked to participate in this research study because you have been diagnosed with 
1st-line Metastatic Pancreatic Ductal Adenocarcinoma. 
PURPOSE AND BACKGROUND 
Current cancer therapies often produce an initial reduction in tumor size but may not have long-
term benefits.  One possible explanation for this is the presence of a specific type of cancer cell 
known as a cancer stem cell.  Cancer stem cells represent a small part of the tumor but are 
believed to be responsible for much of the growth and spread of the cancer.  Cancer stem cells 
may also be more resistant to traditional types of therapy, such as chemotherapy and radiation 
therapy. 
The purpose of this study is to compare the efficacy and safety of 1 or 2 truncated courses of a 
new experimental drug, demcizumab, when given in combination with gemcitabine and 
Abraxane® to gemcitabine and Abraxane (plus placebo).  The administration of Gemcitabine and 
Abraxane® is a standard treatment for subjects with pancreatic cancer.  You also may be given 
antiemetic therapy and/or hematopoietic growth factors and/or red blood cell/platelet 
transfusions, if your study doctor considers it appropriate 
Demcizumab is a humanized monoclonal antibody and was developed to target cancer stem 
cells.  Demcizumab may block the growth of cancer stem cells, the remaining cancer cells, and it 
may also prevent the growth of new blood vessels that tumors need to grow and spread. 
Demcizumab, used in this study, is experimental. That means that the United States Food and 
Drug Administration (FDA) has not approved it for use by the general public. This study is 
sponsored by OncoMed Pharmaceuticals, which is referred to as OncoMed or the Sponsor in this 
consent form. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 97 of 130 
CONFIDENTIAL 
 
19 December 2016 
WHAT IS EXPECTED FROM YOU? 
 When deciding whether to participate, consider whether you are able and willing: 
 To follow the study rules 
 To commit the time required to keep appointments 
 To tell the study doctor truthfully about your complete medical history 
 To report any new problems, illnesses, or changes in medication during the study 
PROCEDURES 
Up to 201 subjects will be enrolled at up to 65 centers in North America, Western Europe, and 
Australia.  Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your 
eligibility to take part in this study.   
If enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab 
(or placebo) once every 2 weeks for the duration defined by your treatment group stated in the 
next section.  Abraxane® and Gemcitabine will be administered on Days 1, 8 and 15 of each 
28-day treatment cycle and will continue until toxicity necessitates reducing or holding a dose). 
The treatment arms are defined in the next section. If your physician decides to delay treatment 
with one of the agents due to side effects, the other agents may still be administered as 
scheduled.  You will undergo assessments every 8 weeks to determine the status of your disease 
and for safety at every visit and through 30 days following the termination of study drug  
In addition to routine testing of blood and urine (for complete blood counts with differential and 
platelets, coagulation studies to determine how quickly your blood is clotting; serum chemistries; 
and B-type natriuretic peptide [BNP], which indicate how well your heart if working; creatinine 
clearance to measure your kidney function and urinalysis), special tests will be performed during 
the study at specific time points listed below. The samples for special tests will be sent to 
OncoMed Pharmaceuticals, 800 Chesapeake Dr., Redwood City, California, U.S.A, 94063 The 
special tests include the following: 
· 
Tumor markers:  These are substances that can be detected in higher than normal 
amounts in blood, urine, or body tissues for certain types of cancer.  The tumor marker 
level may indicate the extent of the cancer in your body and may show how you are 
responding to treatment.  For this study, only blood samples will be taken to check for 
tumor markers.  The tumor marker for pancreatic cancer is:  CA 19-9.  If your baseline:  
CA 19-9 tumor marker is not elevated, the test will not be repeated during the study. 
· 
Antibodies to demcizumab:  Antibodies are proteins produced by your body's immune 
system in response to a foreign substance.  In some cases, the development of antibodies 
to a treatment will not have any impact on the effectiveness of the treatment.  In other 
cases, the development of antibodies to a treatment can cause the treatment to be 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 98 of 130 
CONFIDENTIAL 
 
19 December 2016 
ineffective.  Blood will be drawn, , at baseline and then every 8 weeks, and at treatment 
termination, to determine if you are developing antibodies to demcizumab. .  The anti-
demcizumab antibody samples will be sent to ICON, ____________________________ 
____________. 
· 
Pharmacokinetic Analysis:  Blood samples will be obtained prior to your demcizumab (or 
placebo) infusion on Study Days 0, 14, 56, 70, 168, 182, 224 and 238, and at the end of 
the demcizumab infusion (prior to chemo infusion) on Days 0, 56, 70, 168, 224 and at 
treatment termination visit to determine how the demcizumab is distributed and 
eliminated from your body.  The PK samples will be sent to ICON, _________________ 
____________. 
· 
Biomarkers:  At specified time points blood samples will be obtained to assess whether 
the demcizumab is producing desired changes to the genes and proteins related to your 
cancer.  A predose sample of 9 mL of blood will be drawn on Study Days 0, 21, 35, 49 
and 63 and at treatment termination.   
· 
In addition, archival tumor tissue sections (formalin-fixed paraffin-embedded (FFPE)) 
will be collected if available for gene and protein testing of biomarkers related to your 
cancer.If you agree to have DNA testing on your FFPE tissue, you will sign a separate 
consent.  DNA testing of your tumor may help to identify biomarkers that could be used 
in the future to predict which patients are more likely to respond to demcizumab, 
gemcitabine and Abraxane treatment. 
In addition, you will have an ECG and doppler echocardiogram performed during screening, 
then every 28 days on study and at treatment termination.  Your Doppler echocardiograms may 
be sent to a Cardiologist at another hospital who may perform a central read on some of the 
doppler echocardiograms in this study.  Finally, you will have a head CT or MRI at baseline and 
CT scans and/or other radiographs performed every 56 days to assess the status of your tumor. A 
CT pulmonary angiogram (CTPA) (or MR angiogram or VQ scan if you have an allergy to the 
contrast dye) may be performed if you are diagnosed with pulmonary hypertension to see if you 
might have a pulmonary embolism. 
SCREENING 
If you volunteer to be in this study and you sign this informed consent form, you will be 
screened within 28 days before study entry to make sure that you are a suitable candidate.  No 
study-related tests will be performed prior to signing this informed consent form.  Results of 
your standard of care tests or examinations before signing this informed consent form and within 
28 days prior to Day 0 may be used for screening assessments rather than repeating such tests. 
Your doctor will: 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 99 of 130 
CONFIDENTIAL 
 
19 December 2016 
 Conduct a review of your physical health and medical history, including a review of any 
medications you are or have been taking.   
 Conduct a physical exam including height and weight will be performed, Peripheral 
neuropathy assessment and vital signs including your pulse, blood pressure, breathing 
rate and temperature will be measured.   
 Collect blood and urine samples for routine testing.   
 Collect blood for testing of tumor markers.  Approximately 3 tablespoons of blood will 
be taken at this visit.   
 Complete an electrocardiogram (ECG), doppler echocardiogram, and either a 
computerized tomography (CT) scan or magnetic resonance imaging (MRI) of your 
chest, abdomen, pelvis, and head.   
 Order a colonoscopy and/or upper gastrointestinal endoscopy if your tumor involves 
your esophagus, stomach, or intestinal tract or if you have symptoms that suggest that 
that your tumor may involve these areas, to ensure that your tumor does not currently 
involve your gastrointestinal tract.   
 Complete a serum pregnancy test within 7 days prior to the first dose of demcizumab if 
you are a female of childbearing potential, to ensure that you are not pregnant at the start 
of the study. 
TREATMENT PHASE 
Demcizumab (or Placebo) 
Once your doctor has evaluated the results of your screening tests to ensure that you meet the 
criteria for the study and are eligible to participate, you will be randomized in the study and 
assigned to a treatment arm. 
You will receive 3.5 mg/kg demcizumab or placebo as shown in the treatment arms, below. A 
placebo looks like the demcizumab, but does not contain any medication. Dosing of 
Gemcitabine, Abraxane® and Demcizumab or placebo must be done within ± 2 days of the Study 
Day listed in the protocol.  If a drug cannot be given within this 2 day window, then the dose of 
that drug is permanently missed.   
Demcizumab 3.5 mg/kg or placebo will be administered by IV infusion (prior to the 
administration of Abraxane® and Gemcitabine) once every 2 weeks for either one (1st course 
through Study Day 70) or two (2nd course begun on Study Day 168 and continued through Study 
Day 238) 70 day courses.  You will receive 6 doses of demcizumab or placebo during the 1st 
70 day course of treatment and an additional 6 doses of demcizumab or placebo during the 2nd 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 100 of 130 
CONFIDENTIAL 
 
19 December 2016 
70 day course of treatment (beginning on Day 168).  You will be randomly (by chance) assigned 
to one of the three treatment arms: 
Arm 1: 
 Abraxane® and gemcitabine plus placebo (3 cycles), then  
 Abraxane® and gemcitabine (3 cycles), then 
 Abraxane® and gemcitabine plus placebo (3 cycles), then 
  Abraxane® and gemcitabine until disease progression  
Arm 2: 
 Abraxane® and gemcitabine plus demcizumab (3 cycles), then 
 Abraxane® and gemcitabine (3 cycles), then 
 Abraxane® and gemcitabine plus placebo (3 cycles), then 
 Abraxane® and gemcitabine until disease progression 
Arm 3: 
 Abraxane® and gemcitabine plus demcizumab (3 cycles), then 
 Abraxane® and gemcitabine (3 cycles), then 
 Abraxane® and gemcitabine plus demcizumab (3 cycles), then  
 and then Abraxane® and gemcitabine until disease progression 
You will have an equal chance of being assigned to Arm 1, Arm 2 or Arm 3. Neither you nor 
your doctor will know which treatment arm you have been assigned, or whether you are 
receiving demcizumab or placebo.   
Abraxane® 
Abraxane® must be administered after the demcizumab, but before gemcitabine administration 
on days when three drugs are given.  Abraxane® should be administered by IV infusion at a 
starting dose of 125 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.  The 
dose of Abraxane may be reduced over time if necessary to reduce toxicity. 
Gemcitabine 
Gemcitabine must be administered after the administration of demcizumab and Abraxane®. 
Gemcitabine should be administered by IV infusion at a starting dose of 1000 mg/m2 
over 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 101 of 130 
CONFIDENTIAL 
 
19 December 2016 
30 minutes once weekly for 3 weeks (or until toxicity necessitates reducing or holding a dose), 
followed by a week of rest every 28 days.  The dose of gemcitabine may be reduced over time if 
necessary to reduce toxicity. 
Study Day 0:  This is considered your randomization visit where you will start your study 
treatment.  This visit will take approximately (3) hours.  The following assessments will be done 
prior to the infusion of demcizumab or placebo, Abraxane®, and Gemcitabine:  abbreviated 
physical examination including weight; Peripheral neuropathy assessment review of medications 
you are taking, including any changes in medication since the screening visit; changes in your 
medical status; and vital signs.  Approximately 4 tablespoons of blood will be drawn for routine 
tests, antibody testing, pharmacokinetic testing (before and after your infusion) and biomarkers. 
Study drug will be administered and you will be monitored for at least 15 minutes after the 
demcizumab (or placebo) has been stopped.  Abraxane® will then be administered, followed by 
Gemcitabine. 
 Study Days 7, 14, 21, 28, 35, 42, and 49:  demcizumab or placebo will be given on Days 14, 
28 and 42 only, Abraxane®, and Gemcitabine will be given on Study Days 7, 14, 28, 35 and 
42 only.  The following assessments will be obtained weekly: weight; review of the 
medications you are taking and any changes in medication since the previous visit; changes 
in your medical status or new health problems since the previous study visit; and vital signs.  
An abbreviated physical examination will be performed on the days that your receive 
demcizumab or placebo, and also your BNP will be measured those days. At Day 28 only,  
Peripheral neuropathy assessment 
Blood will be taken for routine testing.  On Day 28, blood will be taken before the infusion of 
demcizumab (or placebo), for pharmacokinetic testing.  At Day 21, Day 35 and Day 49, blood 
will also be obtained for biomarkers.  Approximately 3 tablespoons of blood will be drawn on 
Study Days 7, 14, 21, 28, 35, and 42. 
 At Day 28 only, a urine specimen will be obtained for routine testing. On Day 28, an ECG 
and doppler echocardiogram will be done.  
Study Day 56:  The following assessments will be obtained on Day 56:  weight; review of 
medications you are taking and any changes in medication since the previous visit; changes in 
your medical status or new health problems since the previous study visit; and vital signs and 
abbreviated physical exam BNP measured, urine specimen for routine testing, Peripheral 
neuropathy assessment. 
Blood will be obtained for routine testing, pharmacokinetics, immunogenicity and if you are a 
female of child-bearing potential for a serum pregnancy test. Approximately 3 tablespoons of 
blood will be drawn during this visit. An ECG and doppler echocardiogram will be done. Tumor 
marker:  CA 19-9 (if elevated at baseline) will be done, In addition, on Day 56, you will undergo 
a CT scan or MRI of the chest, abdomen, and pelvis, to assess whether your cancer has 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 102 of 130 
CONFIDENTIAL 
 
19 December 2016 
improved, progressed, or is stable.  If the CT scan or MRI shows that you have stable or 
improved disease, you may continue to receive demcizumab, Abraxane®, and Gemcitabine 
If the CT scan or MRI shows disease progression, you will be taken off the study and will 
undergo assessments listed under Treatment Termination.  At this point, your study doctor 
will discuss alternate treatment options. 
Study Days 63 and 70:  demcizumab or placebo, will be given on Day 70 only, Abraxane®, and 
Gemcitabine will be given on Day 63 and 70. The following assessments will be obtained prior 
to the infusion of drug: weight; review of the medications you are taking and any changes in 
medication since the previous visit; changes in your medical status or new health problems since 
the previous study visit; and vital signs.  An abbreviated physical examination will be performed 
on the day that your receive demcizumab (or placebo). 
Blood will be taken for routine testing, blood will also be taken for biomarkers on day 63, and 
blood will also be taken for pharmacokinetics on day 70. Approximately 3 tablespoons of blood 
will be drawn on Study Days 63 and 70. BNP will be also measured 
Study Day 77:  The following assessments will be obtained: weight; review of the medications 
you are taking and any changes in medication since the previous visit; changes in your medical 
status or new health problems since the previous study visit; and vital signs.  Approximately 3 
tablespoons of blood will be taken for routine testing. An abbreviated physical examination will 
be performed 
Study Days 84, 91 and 98:  Abraxane®, and Gemcitabine.  The following assessments will be 
obtained:  weight; review of the medications you are taking and any changes in medication since 
the previous visit; changes in your medical status or new health problems since the previous 
study visit; Peripheral neuropathy assessment (Day 84 only) ,and vital signs.  An abbreviated 
physical examination will be performed on Days 84 and 98 only, and BNP measured on Days 84 
and 98 only. 
Blood will be taken for routine testing.  On Study Day 84 only, blood will also be obtained for 
testing for antibody formation to demcizumab.  Approximately 3 tablespoons of blood will be 
drawn on Study Days 84, 91, and 98. 
On Day 84 only an ECG and doppler echocardiogram will be done. 
Study Day 105:  The following assessments will be obtained  weight; review of the medications 
you are taking and any changes in medication since the previous visit; changes in your medical 
status or new health problems since the previous study visit; and vital signs. 
Approximately 3 tablespoons of blood will be taken for routine testing. 
As long as your disease is stable or shows a response, you may continue to be treated.  You will 
undergo the tests listed for Study Days 84, 91, 98, and 105.  In addition, every 8 weeks you will 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 103 of 130 
CONFIDENTIAL 
 
19 December 2016 
undergo a CT scan or MRI of the chest, abdomen, and pelvis, to assess whether your cancer has 
improved, progressed, or is stable. 
In addition, every 8 weeks blood will be obtained for tumor markers, if applicable and if you are 
a female of child-bearing potential for a serum pregnancy test.  You will also have a doppler 
echocardiogram every 4 weeks. 
TERMINATION VISIT 
When your tumor has progressed or you are going to be removed from the study for another 
reason the following assessments will be performed:  abbreviated physical exam with weight; 
review of medications you are taking and any changes in medication since the previous visit; 
changes in your medical status or new health problems since the previous study visit; Peripheral 
neuropathy assessment and vital signs. 
Blood samples will be obtained for routine testing (including BNP), antibody formation to 
demcizumab, pharmacokinetic testing, and biomarkers unless obtained within the previous 14 
days.  Blood will also be obtained for tumor marker testing if applicable and for BNP unless 
obtained within the previous 28 days. In addition, if you are a female of child-bearing potential, 
blood will be obtained for a serum pregnancy test.  A urine specimen will be obtained unless one 
was obtained within 28 days of treatment termination.  An ECG will be done and a doppler 
echocardiogram will be performed.  A repeat CT scan or MRI of the chest, abdomen, and pelvis 
will be obtained unless performed within 7 days of termination visit. 
Approximately 3 tablespoons of blood will be drawn during this visit. 
FOLLOW-UP AFTER TERMINATION VISIT 
If your blood pressure was too high at the Termination visit (greater than 150/90 mmHg), your 
blood pressure will be determined every 2 weeks until your blood pressure is less or equal to 
150/90 mmHg for a 4-week period. 
If you are a female of child-bearing potential, you will have a serum pregnancy test done 56 and 
112 days after your termination visit. 
You will be contacted every 3 months for up to 5 years by the clinic study staff to check on your 
condition. This contact may be by telephone or medical record review.  Information regarding 
any anti-cancer therapies that you receive will also be collected through telephone calls, review 
of medical records, and/or clinic visits. 
In addition, if your tumor has not progressed at the time of your Termination visit, your tumor 
response outcome will continue to be followed until you begin receiving alternative anti-cancer 
treatment or your tumor progresses, whichever occurs first, and a copy of the corresponding 
radiographs (e.g., CT scans and/or MRIs) may be provided to OncoMed, the Sponsor of the trial.  
If you have a BNP greater than 400 pg/mL and/or a diagnosis of pulmonary hypertension or 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 104 of 130 
CONFIDENTIAL 
 
19 December 2016 
heart failure at the time of termination, all subsequent standard of care BNP data will be 
collected until the value is less than or equal to 200 pg/mL and all subsequent standard of care 
left ventricular ejection fraction (LVEF) and peak tricuspid velocity (PTV) values will be 
collected until they normalize.  LVEF and PTV are tests that provide information on how your 
heart is functioning.  Below is a table that summarizes the treatment and tests that will be 
performed through Day 105.  Similar testing will continue to be performed after Day 105 until 
you are removed from the study. 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 105 of 130 
CONFIDENTIAL 
 
19 December 2016 
Day(s) 
-28 
to 0 
0 
7 
14 
21 
28 
35 
42 
49 
56 
63 
70 
77 
84 
91 
98 
105 
Termination 
Visit 
Follow-up 
after 
termination 
visit 
Informed consent 
Past medical history/ 
height/INR/aPTT 
Serum pregnancy test 
Head CT or MRI 
FFPE (if tissue blocks available) 
Colonoscopy and/or upper GI 
endoscopy (in subjects having 
symptoms of possible 
gastrointestinal involvement) 
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Abraxane/ Gemcitabine 
  
X 
X 
X 
  
X 
X 
X 
  
X 
X 
X 
  
X 
X 
X 
  
  
  
Demcizumab or placebo 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
  
  
  
  
  
  
Physical exam 
X 
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
Weight and vital signs/ ECOG 
performance status 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
Concomitant meds/ Adverse event 
evaluation 
  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
CBC w/diff, plts/ Serum 
Chemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
BNP 
X 
  
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
X 
  
Peripheral neuropathy assessment 
X 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
Anti-demcizumab antibody/ ECG/ 
Transthoracic doppler 
echocardiogram  
X 
  
  
  
  
X 
  
  
  
X 
  
  
  
X 
  
  
  
Xt 
  
Urinalysis  
X 
  
  
  
  
X 
  
  
  
X 
  
  
  
  
  
  
  
X 
  
Tumor marker CA 19-9 
Chest, abdomen, and pelvis 
radiographic evaluation 
X 
  
  
  
  
  
  
  
  
X 
  
  
  
  
  
  
  
X 
  
Blood for biomarkers 
  
X 
  
  
 X 
 X 
  
X  
 X 
  
  
  
  
  
  
X 
  
Pharmacokinetics 
  
X  
  
X  
  
  
  
  
X 
  
 X 
  
  
  
  
  
 X 
  
Optional Pharmacogenomics 
  
X 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Survival data including date and 
cause of death) 
Subsequent anti-cancer therapiesy 
Response assessment data 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
X 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 106 of 130 
CONFIDENTIAL 
 
19 December 2016 
POSSIBLE RISKS AND DISCOMFORTS 
You may have side effects while you are in the study, but you will be carefully checked by the 
study doctor for any problems.  There may be risks or side effects of the study treatment that are 
unknown at this time.  You should tell the study doctor/staff about anything that is bothering you 
or any side effects you have, even if you do not think they are related to the study drug.  
The following is a list of the most medically significant or most common side effects reported in 
completed studies of demcizumab, Abraxane® and/or gemcitabine. In some cases, side effects 
can be serious, long-lasting, or can cause death.  Some side effects go away soon after you stop 
the study treatment/therapy and some may never go away.  The study doctor may alter the 
dosage regimen of one or more of these drugs (if allowed by the study) or give you medicines to 
help lessen the side effects.  This is not a complete list of all side effects that may occur.  For 
more information about risks and side effects, please ask the study doctor.   
Demcizumab 
The following are the side effects that were observed in >10% (common) and 5-10% (less 
common) of the 55 patients treated in the initial single-agent study of demcizumab and were 
considered to be possibly related to demcizumab. 
Common (occurred in >10% of patients who received demcizumab) 
Hypertension, fatigue, anemia, diarrhea, headache, nausea, decreased protein in the blood and 
shortness of breath 
Less Common (occurred in 5-10% of patients who received demcizumab) 
Low sodium in blood, dizziness, weight loss, heart failure, laboratory values indicating a 
decrease in liver or kidney function, decreased white blood count in the blood, abdominal pain, 
chills, fever, insomnia and cough 
The following are the side effects that were observed in >10% (common) and 5-10% (less 
common) of the 99 patients treated in the 4 studies of demcizumab plus chemotherapy and 
were considered to be possibly related to demcizumab. 
Common (occurred in >10% of patients who received demcizumab and chemotherapy) 
Fatigue, nausea, hypertension, swelling of tissue due to increased fluid, diarrhea, appetite 
decreased, increased BNP (suggesting possible early damage to the heart), anemia, decreased 
platelet count in the blood, decreased white blood count in the blood, shortness of breath, 
headache, increased pressure in the lungs, constipation and rash. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 107 of 130 
CONFIDENTIAL 
 
19 December 2016 
Less Common (occurred in 5-10% of patients who received demcizumab and 
chemotherapy) 
Change in taste, hair loss and laboratory values indicating a decrease in liver function 
The majority of the side effects observed in these studies were mild to moderate.  The most 
common adverse event across these studies that was clearly related to demcizumab was 
hypertension which occurred in 14-60% of the patients. Thus, if you participate in this study, 
your blood pressure will be checked frequently and, if necessary, you will be treated with 
medication(s) to lower your blood pressure.  If your increased blood pressure is not controlled by 
medications, administration of demcizumab will be discontinued. 
In addition, in these studies, 7 patients developed serious bleeding in the gastrointestinal tract.  
Two patients died as a result of this bleeding.  Because of that, you will not be treated in this 
study if you have tumor in one or more locations that carries an increased risk for bleeding.  
If you participate in the study, your hemoglobin (a measurement of the amount of red blood 
cells) will be tested regularly.  If your hemoglobin decreases, your physician will look carefully 
for the reason.  If you develop active significant bleeding, administration of demcizumab will be 
discontinued. 
One patient in the single-agent study died as a result of complications relating to a tumor within 
the brain.   As a result, if you choose to participate in this study, prior to treatment you will have 
a scan of the brain to ensure that there is no tumor within the brain.  Patients who have a tumor 
within the brain will not be able to participate in the study. 
Finally, approximately 40% of patients treated in these trials developed rises in a laboratory test 
(BNP) suggesting possible early damage to their heart.  In addition, approximately 5-10% of the 
patients had symptoms of heart failure (such as shortness of breath and/or extra fluid in their 
legs).  These patients typically improved after discontinuation of demcizumab and treatment with 
medications to reduce their symptoms.  In addition, the heart failure typically developed in 
patients who received demcizumab for at least 3 months.  Also, an increase in the blood pressure 
in the lungs which can also result in heart failure has been observed in some patients that were 
typically treated for more than 3 months.  As a result, demcizumab will not be given on an 
ongoing basis in this study. Instead, a shortened regimen of 6 doses over 70 days will be 
administered either once or twice during your time on study.  Approximately 50 patients have 
received this type of shortened treatment schedule, and none have developed serious heart failure 
or increased blood pressure in the lungs.  However, it is anticipated that heart failure and /or 
increased blood pressure in the lungs will likely still occur in some patients receiving this 
shortened duration of treatment with demcizumab.  Finally, no patients have been previously 
treated with a 2nd 70-day course of demcizumab that some patients will be receiving in this 
study, so the risks of this approach are unknown. 
You will not be treated in this study if you have an elevated BNP value, evidence of heart failure 
or evidence of disease in the vessels in your heart, or have a significant decrease in the amount of 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 108 of 130 
CONFIDENTIAL 
 
19 December 2016 
blood your heart is pumping on Doppler echocardiogram. Your heart and lung function will be 
watched closely while you are on study using blood tests and echocardiograms. If these side 
effects are noted, you will be referred to a heart specialist who may be able to treat the side 
effects with drugs.  If further increases in your BNP occur or the amount of blood your heart is 
pumping declines further, your demcizumab therapy will be discontinued.   
As with all antibody treatments, there is the possibility of an allergic reaction, such as fever, 
chills, rash, and/or hives associated with the infusion of demcizumab.  Rarely, a severe or serious 
allergic reaction can occur during or following the administration of an antibody. 
Not enough patients have yet been treated with demcizumab to fully understand the side effects 
that may be associated with this antibody.  It is possible that you may receive a lower dose of 
gemcitabine and/or Abraxane® than you would have received if you were not participating on 
this study due to additional toxicities caused by demcizumab. 
The following side effects have been observed in other drugs that have an anti-angiogenic effect 
(drugs that prevent the growth of new blood vessels that tumors need to grow and spread) and in 
other drugs that may inhibit the growth of cancer stem cells.  It is not known if the administration 
of demcizumab will result in any of these findings: 
· 
Gastrointestinal perforation sometimes associated with intra-abdominal abscess 
· 
Diarrhea, weight loss, constipation, vomiting, abdominal pain, nausea, and fever 
· 
Wound healing complications 
· 
Hemorrhage including minor bleeding events such as nose bleeds or more serious, 
sometimes fatal bleeding events 
· 
Arterial or venous thromboembolic events, including cerebral (brain) infarction, transient 
ischemic attacks (TIAs), myocardial infarction (MI), angina, and other sometimes fatal 
events 
· 
Hypertension including episodes of severe increased blood pressure 
· 
Neutropenia and/or infection 
· 
Proteinuria (loss of protein through your kidneys) 
· 
Congestive heart failure 
· 
Diarrhea 
· 
Rashes 
· 
Somnolence (sleepiness) 
· 
Fatigue 
∙ 
Prolonged QT interval (irregular heart rhythm) 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 109 of 130 
CONFIDENTIAL 
 
19 December 2016 
Abraxane® 
Very common (a 10% or more chance that this will happen): 
 anemia (a decrease in the number of red blood cells (which may make you feel weak 
or tired)  
 low number of white blood cells with or without fever (that may make it easier get 
infections)  
 a decrease in the number platelets, the cells that help your blood to clot (which may 
lead to unusual bleeding or bruising under the skin)  
 constipation  
 diarrhea  
 nausea  
 vomiting  
 stomach pain  
 pain, swelling or sores on the inside of the mouth 
 neuropathy, a disorder of the nerves which can cause tingling or numbness, with 
weakness, or decreased sensation or movement  
 dizziness  
 headache  
 feeling tired or weak 
 pain (including muscle, joints, bone, and chest pain)  
 swelling caused by fluid held in the tissues, especially of the ankles, feet or fingers  
 fever  
 chills  
 decreased appetite  
 change in taste  
 weight loss  
 difficulty sleeping  
 depression  
 cough  
 shortness of breath  
 hair loss  
 rash, possibly red, bumpy or generalized  
 itchiness 
 changes in nails, including discoloration or separation from nailbed  
 abnormal liver function test results  
 dehydration (loss of water and minerals in the body)  
 nose bleed  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 110 of 130 
CONFIDENTIAL 
 
19 December 2016 
Common (between a 1% to less than 10% chance that this will happen): 
 bone marrow depression which is a severe reduction of red or white blood cells and 
platelets (at nearly the same time) which can cause weakness, bruising, or make 
infections more likely  
 infections, including pneumonia or of the lung, mouth, gallbladder, urinary tract, nail, 
or hair follicle, (which may be bacterial, fungal or viral)  
 a very severe infection of the blood which may include a decrease in blood pressure  
 inflammation of the lung passages  
 thickening, inflammation or scarring in the lungs which may cause breathlessness, 
cough  
 inflammation of the bowel causing abdominal pain or diarrhea  
 blockage of the intestine  
 trouble swallowing  
 indigestion or upset stomach  
 abnormal chemistry or electrolyte blood test results  
 abnormal kidney function test results  
 acute kidney failure  
 blood in the urine  
 lack of muscle coordination  
 muscle weakness  
 anxiety  
 nasal congestion  
 mouth or throat pain  
 dry mouth, nose, and throat  
 coughing up blood or bloody sputum  
 blood clot in the lungs or in deep vein  
 fluid in the chest cavity  
 red or flushed skin  
 dry skin  
 hand-foot syndrome, involving reddening, swelling, numbness and peeling of palms 
and soles of feet  
 high blood pressure  
 low blood pressure  
 faster heart beat  
 watery eyes  
 changes in vision or blurry vision  
 infusion site reactions (described as discomfort, bleeding or bruising/swelling at the 
needle site, and in some instances infection or leaking of IV fluid outside of blood 
vessel into the surrounding tissue)  
 localized swelling due to build up of lymph fluid  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 111 of 130 
CONFIDENTIAL 
 
19 December 2016 
Uncommon (between a 0.1 to less than 1% chance that this will happen):  
 a decrease in the heart’s ability to pump blood to all parts of the body and possibly 
heart failure  
 irregular or slow heart beat  
 stopping of the heart  
 allergic reaction (may include skin inflammation, rash, trouble breathing, trouble 
speaking, fever), sometimes fatal  
 syndrome involving abnormal blood clotting, with decreased platelets, bruising 
(including tiny red or purple spots under the skin) and possibly leading to blood clots  
 edema/swelling and cyst formation of the macular area of the retina  
 irritation and redness of the thin membrane covering the eye  
 inflammation of the cornea  
 too much fluid in the body  
 feeling unwell  
 sleepiness  
 scaly or peeling skin  
 hives  
 a loss of nerve function in the muscles of the face  
Additional side effects observed during post-marketing surveillance of Abraxane, not otherwise 
noted above include:  
 a loss of nerve function in the muscles of the face or the eyes  
 lack of movement in the vocal cords with possible voice changes  
 skin sensitivity to sunlight  
 potentially life threatening skin rash with skin blistering  
 skin or tissue damage from prior radiation therapy can become damaged again, when 
a person receives chemotherapy after having had radiation therapy. This is referred to 
as radiation recall and may involve redness, peeling, pain, and swelling.  Skin 
changes have been noted to range from mild redness to tissue death. Radiation recall 
may also occur in the lungs and other internal organs.  
Abraxane®  in Combination with Gemcitabine  
In subjects with metastatic pancreatic cancer, who received the combination of Abraxane® and 
gemcitabine, there may be an increase of blood infections. Contact your study doctor 
immediately if you develop a fever. Your study doctor will evaluate if your fever is an early sign 
of a serious infection, which may require treatment. 
A particular lung illness, known as pneumonitis (thickening, inflammation or scarring in the 
lungs with breathlessness, or cough), appears to occur more often (4%) when the two drugs are 
given together. This lung illness requires early detection and treatment as it may be life-
threatening or even fatal. Therefore, it is important that you promptly tell your study doctor if 
you have worsening shortness of breath, difficulty breathing, fever, or a dry cough (not 
productive), for further evaluation and possible treatment. 
In addition, acute renal or kidney failure and hemolytic uremic syndrome (a syndrome involving 
abnormal blood clotting, with decreased platelets, bruising including tiny red or purple spots 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 112 of 130 
CONFIDENTIAL 
 
19 December 2016 
under the skin, and possibly leading to blood clots) have been reported commonly and 
uncommonly, respectively, in combination of Abraxane® with gemcitabine. 
Gemcitabine 
clinically important side effects of gemcitabine  
Very common (a 10% or more chance that this will happen): 
 blood and protein in the urine 
 fluid retention (swelling of the hands, feet or face) 
 difficulty breathing  
Uncommon (between a 0.1 to less than 1% chance that this will happen):  
 acute kidney failure (which can include hemolytic uremic syndrome) 
 severe hepatic toxicity (example: hepatic failure, hepatic veno-occlusive disease) 
 severe pulmonary toxicity (example: interstitial pneumonitis, pulmonary edema, adult 
respiratory distress syndrome 
Additional side effects observed during post-marketing surveillance of gemcitabine, not 
otherwise noted above include: 
 posterior reversible encephalopathy syndrome (a very rare condition known as 
posterior reversible encephalopathy syndrome has occurred when gemcitabine is 
given alone or in combination with other chemotherapy medications.  Therefore, you 
should tell your study doctor if you have one or more of the following symptoms; 
headache, abnormal shaking of body, sleepiness, increased blood pressure, feeling 
confused, abnormal vision including loss of vision, loss of muscle control or muscle 
weakness, numbness or tingling in extremities) 
 capillary leak syndrome (A very rare condition known as capillary leak syndrome that 
causes leaking of fluid outside of blood vessels has occurred when gemcitabine is 
given alone or in combination with other chemotherapy medications. Therefore, you 
should tell your study doctor if you have one or more of the following symptoms: 
fatigue; lightheadedness or fainting; pain in arms, legs, or stomach or all over body; 
swelling in face or body; difficulty breathing; low blood pressure) 
 pulmonary fibrosis (excess of fibrous tissue in the lung and a severe pulmonary 
toxicity) 
 vasculitis (an inflammation of the small blood vessels described as pain, heat, and 
redness to the affected part of the body) 
 gangrene (dying tissue due to lack of blood supply described as skin discoloration, 
severe pain, foul smelling leakage from a sore, and  may include swelling, and 
increased temperature to the affected region of the body) 
You should inform your study doctor if you are planning any dental work while on study, as 
some study subjects have an increased risk of bleeding. It may be advisable to use a soft-bristled 
tooth-brush and to be careful when using dental floss and toothpicks.  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 113 of 130 
CONFIDENTIAL 
 
19 December 2016 
Infusions: 
Demcizumab or placebo, Abraxane and Gemcitabine will be given as intravenous infusions.  
There may be minor discomfort from the needle in your arm.  Bruising, swelling and, in rare 
instances, infection and blood clot may occur at the infusion site. 
Blood Draws: 
During the course of this study, your blood will be drawn for laboratory tests (3-4 tablespoons 
will be collected at each blood draw).  The risks of drawing blood include some discomfort from 
the needle in your arm, bruising, swelling at the needle site and, in rare instances, infection or 
fainting. 
You will also be informed of any new significant side effects that develop during the course of 
this research study, or others regarding the use of demcizumab. 
Radiation exposure: 
– Risk relevant to the radiation exposure due to the following procedures: Radiographic 
evaluation:  Conventional CT, Spiral CT, or MRI of the chest, abdomen, and pelvis 
performed in screening, the same radiographic technique of each region must be used 
consistently throughout the study. Radiographic evaluation:  Conventional CT, Spiral CT, 
or MRI of the head performed in screening 
PREGNANCY 
Pregnancy Risk with study treatments 
There is a very high risk that demcizumab may be harmful to an unborn baby (embryo or fetus) 
or newborn child.  In addition, Abraxane® and gemcitabine can cause harm to an unborn child if 
given to a pregnant woman.  You cannot take part in this study if you are pregnant or breast-
feeding.  Because of the possible risks to an unborn child, if you are a female who can become 
pregnant, you will be asked to take a pregnancy test prior to starting study treatment.   It is 
important that both men and women take steps to prevent pregnancy through the use of adequate 
contraception (for example, a barrier or hormone method or abstinence) prior to study entry 
during the study and for 6 months after completion of the study. 
Females:  If you decide to take part in this study, you should avoid becoming pregnant while 
receiving the study treatment. You must commit to complete abstinence from heterosexual 
contact, or agree to use medical doctor-approved contraception throughout the study and for 6 
months following completion of the study without interruption.  If you become pregnant while 
on the study or within 6 months following completion of the study, you must tell the study doctor 
right away.  If this happens while you are on the study, the study treatment will be discontinued.   
The study doctor will follow you and your pregnancy to completion.    
Males:  If you have a partner of childbearing potential, you should avoid fathering a child while 
receiving study treatment and for 6 months after completion of the study. You must agree to 
complete abstinence from heterosexual contact or use a condom during sexual contact with a 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 114 of 130 
CONFIDENTIAL 
 
19 December 2016 
female of child bearing potential while receiving study treatment and within 6 months after 
completion of the study. If your partner becomes pregnant while you are receiving study 
treatment or within 6 months after completion of the study, you must tell the study doctor right 
away.  If your partner becomes pregnant while you are on study, you will remain on the study.  If 
your partner becomes pregnant during the study or within 6 months after completion of the 
study, you and/or your partner will be followed through the first well-baby visit or longer if any 
abnormality is present. 
POTENTIAL BENEFITS 
There is no guarantee that there will be any direct benefit to you if you take part in this research 
study.  The treatments you receive may be harmful.  It is possible that the information learned 
from this study may be helpful in the future to other people with cancer. 
SIGNIFICANT NEW FINDINGS 
Any significant new findings regarding demcizumab that become known during the course of 
this research study that might reasonably affect your willingness to participate in this study, will 
be provided to you in a timely manner. 
ALTERNATIVE TREATMENTS AND PROCEDURES 
If you decide not to participate in this study, you will continue to receive medical care to which 
you were entitled prior to your participation in this study.  Your doctor will discuss other options 
available to you.  Your choice not to participate in this study will not affect your medical care in 
any way. 
TERMINATION OF PATIENT PARTICIPATION 
Your participation in this research study may be terminated at any time for medical reasons or 
because the sponsor finds it necessary to limit or terminate this clinical trial.  Some reasons for 
termination include progression of your disease, any other illness that prevents further 
administration of demcizumab, unacceptable adverse events, or BNP and/or LVEF values, 
general or specific changes in your condition that make further treatment unacceptable in the 
opinion of your doctor, and protocol non-compliance. 
Your doctor may decide to hold or stop the demcizumab or placebo injections at any time during 
the study for safety reasons. 
If your doctor or the sponsor decides to withdraw you from the study, you will undergo the same 
assessments listed under Termination Visit.  In addition, your doctor will discuss with you 
alternate therapies for your disease. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 115 of 130 
CONFIDENTIAL 
 
19 December 2016 
COSTS AND COMPENSATION 
The cost of all “standard of care” assessments related to your participation in this study and your 
medical care will be billed to you and/or your insurance company.  These are tests that would 
normally be performed in subjects to evaluate their cancer.  Due to the investigational nature of 
this research study, insurance companies or government health care programs may limit their 
obligation to pay for experimental treatments and their consequences.  You may want to discuss 
this with your insurance company before agreeing to participate.  The cost of all non-standard of 
care assessments will be paid for by OncoMed. 
You will not be paid for participation in this study. 
COMPENSATION FOR RESEARCH-RELATED INJURY 
If you are physically injured as a direct result of demcizumab or a study procedure properly 
performed under the plan for this study and it is not due to a pre-existing medical condition or 
underlying disease, or your failure to follow the instructions provided by your doctor or another 
member of the study team, OncoMed will reimburse you for the reasonable medical expenses for 
medically necessary treatment of that injury which are not covered by another payor, your own 
insurance or health care program.  No other compensation is available from OncoMed if any 
injury occurs. 
CONFIDENTIALITY 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required 
by U.S. Law.  This Web site will not include information that can identify you.  At most, the 
Website will include a summary of the results.  You can search this website at anytime. 
HOW WILL YOUR CONFIDENTIALITY BE RESPECTED AND THE PRIVACY OF 
YOUR PERSONAL INFORMATION MAINTAINED? 
You have the right to control the use and disclosure of your personal information.  Basic 
personal information will be recorded including your name, contact details, gender, height, 
weight and racial origin (to be used only for clinical purposes), as well as information on your 
medical history, and clinical data collected about your participation in the study.  All this 
information will be used for research and clinical purposes only, including without limitation the 
pharmacokinetic and optional DNA research described in this consent form. 
The following people may also access these records: representatives of the FDA, other regulatory 
authorities, the Institutional Review Board/Independent Ethics Committee, OncoMed 
representatives and monitors, and OncoMed collaborators and licensees  


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 116 of 130 
CONFIDENTIAL 
 
19 December 2016 
All personnel accessing your records are required to respect your confidentiality at all 
times. 
To ensure privacy, your name and other identifying information will not be attached to records or 
samples released for research purposes.  Instead, you will only be identified by a code.  Only the 
study doctor and authorized personnel will be able to connect this code to your name, by a list 
that will be kept securely by the study site for 2 years after marketing application approval.  If no 
application is filed, these records must be kept for 2 years after the study is discontinued and the 
applicable regulatory authorities are notified.  Your date of birthmay also be recorded to help 
identify your study record. Your coded data will be forwarded to OncoMed and its service 
providers for activities related to the study e.g. laboratory analysis. It will be transferred into a 
computer database and processed to allow the results of this study to be analyzed and reported or 
published. If the results of the study are published, your identity will remain confidential, you 
will not be identified by name, picture, or by any other personally identifying information.. A list 
of companies to whom your coded information is transferred is available from OncoMed via 
your study doctor.  
EMEA: Under data protection law [identification of national law] your study site and OncoMed 
Pharmaceuticals shall be jointly responsible as ‘controllers’ for ensuring that your information is 
safeguarded. OncoMed has appointed [PPD local company name] as its ‘representative’ in your 
country to fulfill its obligations under this law.  
The information that we collect from you may be transferred to, and stored at, a destination 
outside the European Economic Area ("EEA"). It may also be processed by staff operating 
outside the EEA who work for us or for our representative. By participating in the research 
study, you agree to this transfer, storing or processing outside of the EEA. When transferring 
such information to countries outside of the EEA, that do not have the same protections as your 
country we will make sure that your information will be treated with a goodlevel of protection as 
required under your local data protection laws. 
APAC: Under data protection law [identification of national law] your study site shall be 
responsible for ensuring that your named personal information is safeguarded  
USA: Because of the research goals of this study, however, your study records cannot be kept 
completely confidential.  The sponsor of this study is OncoMed Pharmaceuticals.  
The study data may be transferred to other countries for processing, including countries not 
covered by data protection legislation similar in scope to the data protection legislation of your 
country, or at all. The laws of your state may provide further protection. 
CANADA: Under federal data protection law, The Personal Information Protection and 
Electronic Documents Act (PIPEDA) and regional specific regulations, your study site shall be 
responsible for ensuring that your information is safeguarded 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 117 of 130 
CONFIDENTIAL 
 
19 December 2016 
You have the right to access, through your study doctor, all the information collected about you 
and, if applicable, ask for corrections. But, in order to protect the scientific integrity of the study, 
the treatment you received in this study needs to remain unknown (i.e., blinded) until the study 
data is analyzed. Recipients of your information may be in countries that do not have data 
protection safeguards and rights. In such case, OncoMed and its authorized representatives, and 
regulatory authorities, shall anyway seek to maintain confidentiality within the limits of local 
laws in these countries and comply with the data export requirements of your country, including 
any requirements to ensure an adequate level of protection. 
If you should withdraw from the study, data collected prior to your withdrawal may still be 
processed along with other data collected as part of the study.  Normally no new information will 
be collected for the study database unless you specifically consent to such collection.  However, 
the law does require that any side effects you may suffer are documented and reported.  To 
complete the study findings, your long term health status may also be recorded (unless you 
object). ).  Following the end of the study, or after you have withdrawn from the study before its 
conclusion, your study doctor (or appointed delegate) may seek to establish your long term 
health status by accessing  your hospital records, or publicly available sources such as national 
registries, newspaper obituaries and social networking websites.  Attempts may also be made to 
contact you or your relatives to ascertain this information.  If you do not want this information 
about you to be collected, you may record your objection with your study doctor at any time.You 
have the right to require that any previously retained samples are destroyed.   


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 118 of 130 
CONFIDENTIAL 
 
19 December 2016 
WHAT WILL HAPPEN TO YOUR DATA? 
This clinical study may only be performed by collecting and using your medical information. 
Data protection laws give you the right to control the use of your personal information.  
Therefore, by signing this form you specifically authorize your information to be checked, 
transferred and processed as follows: 
 The authorized representatives of OncoMed, the Ethics Committee and regulatory 
authorities’ inspectors may review your medical information by direct access to your medical 
records. 
 Study data, including your coded medical information, may be used and shared for legitimate 
study and scientific purposes, including if you do not object, for future use in medical or 
pharmaceutical research. 
 
I agree to the use of my coded medical information for future research purposes. 
Signature:  _______________________________ 
 
I don´t agree to the use of my coded medical information for future research purposes.   
Signature:  _______________________________ 
 Study data may be transferred to other countries for processing, including countries not 
covered by data protection legislation similar in scope to the data protection legislation of 
your country, or at all. 
HAS THE STUDY RECEIVED MEDICAL OR ETHICAL APPROVAL? 
The Ethics Committee has given this study a positive opinion. 
You will be asked to review and sign a HIPAA (Health Insurance Portability and Accountability 
Act) Research Authorization Form requesting your authorization to collect, use, and disclose 
your medical information. 
OR IF SITE DOES NOT HAVE OWN HIPAA FORM: 
AUTHORIZATION TO USE AND DISCLOSE MY HEALTH INFORMATION 
I authorize (give permission to) insert name of study site to use and disclose (share) my health 
information solely for the purposes of this research study and research directly related to the use 
of demcizumab.  I understand that my health information that I am authorizing to be used and 
disclosed (Authorized Health Information) includes all health information about me that has been 
and will be created or received by (SITE) and that is in my medical records maintained by 
(SITE). 
I understand that I am free at any time to restrict the (SITE’s) use and disclosure of my 
Authorized Health Information, without penalty or other consequences.  However, I also 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 119 of 130 
CONFIDENTIAL 
 
19 December 2016 
understand that I may be denied participation in, or continued participation in, this research study 
if at any time I choose to restrict the (SITE’s) use and disclosure of Authorized Health 
Information that is necessary for the completion of this research study. 
AUTHORIZED PERSONS AND RECIPIENTS 
I authorize the following person(s) and groups of persons to request, receive, and use my 
Authorized Health Information:  representatives of the FDA, other regulatory authorities, the 
Institutional Review Board/Independent Ethics Committee, OncoMed representatives and 
monitors, and OncoMed collaborators and licensees.  I authorize (SITE) to disclose my 
Authorized Health Information to these persons and groups of persons. 
RE-DISCLOSURES TO THIRD PARTIES 
I understand that once (SITE) discloses my Authorized Health Information to the recipient(s) 
identified in the previous section Authorized Persons and Recipients, (SITE) cannot guarantee 
that the recipient(s) will not re-disclose my Authorized Health Information to other persons who 
may not be bound by this informed consent form. 
EXPIRATION DATE 
My authorization (permission) to use and disclose my Authorized Health Information will 
continue indefinitely, but that use and sharing will only be for the purposes described in this 
informed consent form. 
EFFECT OF MY REVOCATION OF AUTHORIZATION TO USE AND DISCLOSE 
AUTHORIZED HEALTH INFORMATION 
I understand that my authorization for (SITE) to use and disclose my Authorized Health 
Information will remain in effect until I withdraw my permission by sending my written notice 
of revocation (withdrawal of permission) to the Privacy Office listed in the Questions section.  
My written revocation will be effective immediately upon (SITE’s) receipt of my written notice, 
except that the revocation will not have any effect on any actions taken by (SITE) in relying on 
this authorization before it received my written notice of withdrawal of permission. 
QUESTIONS 
If you have any question about the study and/or its procedure or safety, you may contact 
Dr. (Name of Investigator) at (telephone number).  In the event of any injury, you may contact 
Dr. (name) at (telephone number).  You may also call (Name) at (telephone number) for 
information on experimental patients’ rights. 
If at any time during this research study you feel that you have not been adequately informed of 
your rights with respect to the privacy of your health information, or you feel that the privacy of 
your health information has not been adequately protected, you may contact or visit (Site’s) 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 120 of 130 
CONFIDENTIAL 
 
19 December 2016 
privacy office during normal working hours at (Privacy Office name) at (telephone number and 
address). 
VOLUNTARY PARTICIPATION AND DOCUMENTATION OF CONSENT 
Your decision to participate in this study is entirely voluntary.  You may refuse to participate in 
or withdraw from the study at any time without prejudice or loss of benefits to which you are 
otherwise entitled.  A signed copy of this consent form will be given to you for your records and 
a copy will be retained by the investigator for his or her files 
By signing the form below, you acknowledge that you have read the above information about 
this research study, and have had a chance to ask questions to help you understand your 
participation in this study and how your information will be used. 
________________________________________________________ 
 
___________ 
Signature of Subject or Subject’s Authorized Representative 
 
Date 
_________________________________________________________ 
Printed Name of Person Obtaining Informed Consent 
__________________________________________________________  
____________ 
Signature of Person Obtaining Informed Consent 
 
 
Date 
__________________________________________________________ 
Printed Name of Witness* 
_______________________________________________ __________  
___________ 
Signature of Witness* 
 
 
 
 
 
 
Date 
*If the Principal Investigator or Institutional Review Board deems a witness signature is necessary. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 121 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX G: 
SAMPLE PHARMACOGENOMICS AND TUMOR DNA TESTING 
INFORMED CONSENT 
WHAT IS THE PURPOSE OF THIS PART OF THE STUDY? 
The cells of your body contain deoxyribonucleic acid, or DNA for short.  DNA is passed down 
from your parents.  Genes carry the DNA that determine your physical appearance such as the 
color of your eyes and hair.  Differences in our genes help explain why we all look different.  
Differences in our genes may also help explain why some drugs work and are safe in some 
people, but not in others.  Differences in our genes also help explain why some people get certain 
diseases, but others do not. 
The sponsor would like to study the differences in people's DNA to learn more about diseases 
and response to drugs.  This information will be used to try to develop safer and better drugs.  
To do this, the Sponsor would like to do DNA tests related to OMP-21M18 and the diseases for 
which this drug is developed.  The DNA tests are only for research.  The tests are not for your 
medical care.  All volunteers taking part in the main study are also being invited to take part in 
DNA research (where possible). 
WHAT AM I BEING ASKED TO DO? 
You are being asked to give one small blood sample (10 mL, about 2 teaspoons) at Study Day 0.  
Blood will be drawn from a vein using a needle.  DNA will be extracted from your blood sample. 
Your DNA may be tested for specific genes relevant to OMP-21M18 (the study drug), the 
Notch/DLL4 pathways (the targets of the OMP-21M18) and/or other genes related to your 
cancer.  Only DNA research related to OMP-21M18 or to the diseases for which this drug is 
developed will be performed.  No blood sample for DNA research will be taken from you unless 
you sign and date this Informed Consent Form.   
In addition, if a piece of your tumor was previously collected as part of your diagnosis, you are 
being asked to have DNA testing performed on your tumor.  DNA will be extracted to help to 
identify biomarkers that could be used in the future to predict which patients are more likely to 
respond to OMP-21M18 and gemcitabine treatment.  Analysis of candidate genes and/or proteins 
relevant to the Notch pathway may be performed (e.g., Notch1, Hey L, FBW7, etc.). No DNA 
research will be performed on your tumor unless you sign and date this Informed Consent Form.  
The Sponsor will store the samples until there is no DNA left. 
You can also decide not to take part at all in DNA research.  Your decision to give, or not to 
give, a DNA sample will not affect the medical care that you receive from your study doctor or 
his/her staff.  Your participation is voluntary. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 122 of 130 
CONFIDENTIAL 
 
19 December 2016 
HOW WILL MY IDENTITY AND RESULTS BE KEPT CONFIDENTIAL? 
The Sponsor has taken several steps to keep your identity and results confidential.  These are 
described below. 
a)  Coding of your DNA Sample 
Your DNA sample will not have your name or address on it.  Your DNA sample will be coded 
with your Subject number from the main study.  After the study is officially over, the Subject 
number will be removed from your DNA sample.  Your DNA sample and results will be labeled 
with a new number. 
b)  Restricted Access to Your DNA Sample 
The Sponsor will control your DNA sample.  Your DNA sample will be stored in a secure room 
at a facility in Redwood City, CA, or other site designated by the sponsor.  Only authorized staff 
are allowed to enter the room.  Your DNA sample may be transferred to other research partners 
working with the Sponsor.  DNA samples transferred to research partners will not contain your 
Subject number.  Your DNA sample will not be sold, loaned, or given to any other independent 
groups for their own use.  Research partners working with the Sponsor are not allowed to share 
DNA samples with anyone else. 
c)  Restricted Access to Results 
Your DNA results will be stored by the Sponsor both on paper and in computer records.  You will 
not be identified by name in these records.  Your results will only be labeled with a code number.  
This is to protect your privacy.  Your results will be kept as long as necessary.  The following 
people may see your test results: 
· 
The Sponsor 
· 
Research partners working with the Sponsor 
· 
Independent Ethics Committees/Institutional Review Boards 
· 
Regulatory authorities, like the Food and Drug Administration (FDA) or the European 
Medicines Evaluation Agency (EMEA) 
Unless the law requires it, your individual results will not be given to anyone who is not listed 
above.  For example, your results will not be given to employers, insurance companies or family 
members.  Research partners working with the Sponsor may not use or share your results without 
permission from the Sponsor. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 123 of 130 
CONFIDENTIAL 
 
19 December 2016 
DNA results from the study may be published or added to public databases.  They also may be 
presented in public meetings.  No publication or presentation will identify you by your code 
number or name. 
d)  Separate Storage of DNA Forms 
Your study doctor will keep your signed DNA informed consent form, and any other DNA 
forms, separate from your other medical files.  People who have access to your medical files 
(such as insurance companies) would not know that you took part in a DNA research study by 
looking at your medical files.  You will be given a copy of your signed DNA consent form. 
WHAT IF I CHANGE MY MIND LATER? 
If you change your mind and decide later that you no longer want to take part in DNA research, 
you may ask for your DNA sample to be destroyed as long as the study is not officially over.  
You can stay in the main study even if you change your mind about taking part in DNA research. 
WILL I GET MY DNA TEST RESULTS? 
The tests will be performed in a research laboratory.  Results from a research laboratory may not 
always be exact.  They cannot be used to make a diagnosis about your health.  Also, research 
laboratories cannot give advice on health or health risks.  For these reasons, the results of your 
DNA tests will not be given to you or your study doctor (or his/her staff). 
WHAT ARE THE BENEFITS? 
You will not directly benefit from taking part in this DNA research.  This research could provide 
information about OMP-21M18 or the diseases for which this drug is developed.  This 
information could help others in the future. 
WHAT ARE THE RISKS? 
There may be some pain or bruising from the needle stick used to draw the blood.  Some people 
may faint when their blood is drawn.  Very rarely, there may be an infection at the place where 
the needle went into the skin.  Any problem that you have from drawing blood will be handled 
the same way as in the main study.  Your research results cannot be used to make a diagnosis 
about your health. 
WILL I BE PAID FOR TAKING PART OR FOR THE USE OF MY RESULTS? 
You will not be paid for taking part in the DNA research part of the study.  You will not be paid 
for any use of your DNA sample or results or for any inventions that are made from them.  If you 
take part, you are providing your DNA sample for use by the Sponsor.  The Sponsor intends to 
own any use of the results, treatments, or inventions that can be made from the research. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 124 of 130 
CONFIDENTIAL 
 
19 December 2016 
QUESTIONS 
If you have any question about the study and/or its procedure or safety, you may contact Dr. 
(Name of Investigator) at (telephone number).  In the event of any injury, you may contact Dr. 
(name) at (telephone number).  You may also call (Name) at (telephone number) for information 
on experimental subjects’ rights. 
If at any time during this research study you feel that you have not been adequately informed of 
your rights with respect to the privacy of your health information, or you feel that the privacy of 
your health information has not been adequately protected, you may contact or visit (Site’s) 
privacy office during normal working hours at (Privacy Office name) at (telephone number and 
address). 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 125 of 130 
CONFIDENTIAL 
 
19 December 2016 
VOLUNTARY PARTICIPATION AND DOCUMENTATION OF CONSENT 
Your decision to participate in this part of the study is entirely voluntary and. you may choose 
not to participate in this part of the study without prejudice or loss of benefits to which you are 
otherwise entitled in the remainder of the study.  A signed copy of this consent form will be 
given to you for your records and a copy will be retained by the investigator for his or her files. 
By signing the form below, you acknowledge that you have read the above information about 
this research study, and have had a chance to ask questions to help you understand your 
participation in this study and how your information will be used. 
I consent to the provide the Optional Pharmacogenomics Specimen 
 
 Yes 
 
 
 No 
I consent to allow my tumor specimen to be analyzed for DNA 
 
 Yes  
 
 
 No 
_______________________________________________________ 
Printed Name of Subject or Subject’s Authorized Representative 
________________________________________________________ 
 
___________ 
Signature of Subject or Subject’s Authorized Representative  
 
Date 
_________________________________________________________ 
Printed Name of Person Obtaining Informed Consent 
__________________________________________________________  
____________ 
Signature of Person Obtaining Informed Consent 
 
 
 
Date 
__________________________________________________________ 
Printed Name of Witness* 
_________________________________________________________  
___________ 
Signature of Witness*  
 
 
 
 
 
 
Date 
*If the Principal Investigator or Ethics Committee deems a witness signature is necessary. 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 126 of 130 
CONFIDENTIAL 
 
19 December 2016 
APPENDIX H: 
PROTOCOL AMENDMENTS SUMMARY OF CHANGES 
AMENDMENT 1: 
24 NOVEMBER 2014 
RATIONALE 
Study M18-006 has been amended for the following reasons: 
The following changes were made at the request of the FDA.  The inclusion criteria for bilirubin 
was reduced to 1 X ULN, >Grade 2 pulmonary hypertension was added as a treatment 
termination criteria, a section was added regarding the role of the DSMB and clarifying the data 
that they will review and the sample informed consent was revised to clarify that patients will 
receive 6 doses of demcizumab or placebo during each of the two 70 day truncated courses of 
therapy and that patients may receive less intensive gemcitabine/Abraxane therapy than if they 
were not on the study due to demcizumab toxicity. 
In addition, minor changes were made in the protocol to ensure consistency throughout the 
document and/or provide clarity.  
SUMMARY OF CHANGES: 
As a result, all the corresponding sections in the table below have been updated to reflect the 
changes outlined above. Additional minor changes have been made to improve clarity and 
consistency. Substantive new information appears in italics.  
Synopsis 
 
Section 5.0 
OVERALL STUDY DESIGN AND PLAN – DESCRIPTION 
Section 8.1.6 
Treatment Modification and Termination Criteria 
Section 8.4 
Concomitant and Prohibited Therapy 
Section 12.9 
Termination Visit 
Section 12.10 
Follow-up after Termination Visit 
Section 14.1 
Data Safety Monitoring Board 
Section 14.2 
Study Stopping Rules 
Section 14.6.1.3 
BNP Assessment 
Appendix B 
Schedule of Assessments 
Notes to Appendix B 
 
Appendix F 
SAMPLE INFORMED CONSENT 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 127 of 130 
CONFIDENTIAL 
 
19 December 2016 
AMENDMENT 2: 
10 FEBRUARY 2015 
RATIONALE 
Study M18-006 has been amended for the following reasons: 
The requirement for mandatory FFPE (either from archival tissue or from a fresh core biopsy) 
was removed and instead FFPE will only be collected if available; i.e., subjects who do not have 
archival tissue will not undergo a core biopsy to obtain fresh tumor tissue. In addition, the 
requirement for subjects who have two BNP values > 100 pg/mL or one value > 200 pg/mL to be 
referred to a cardiologist has been changed to state that such subjects will be referred to a 
cardiologist if appropriate. Definitions were added to the protocol for “women of child-bearing 
potential” and “adequate contraception”.  Additional serum pregnancy tests were added every 
56 days while on study, at the termination visit and at 56 and 112 days following the termination 
visit for women of child-bearing potential.  Finally, a few minor typos have been corrected.  
SUMMARY OF CHANGES: 
As a result, all the corresponding sections in the table below have been updated to reflect the 
changes outlined above. Additional minor changes have been made to improve clarity and 
consistency. Substantive new information appears in italics.  
Synopsis 
 
Section 5.0 
OVERALL STUDY DESIGN AND PLAN – DESCRIPTION 
Section 6.1 
Inclusion Criteria 
Section 8.1.6 
Treatment Modification and Termination Criteria 
Section 9.2.5 
Pregnancy Testing 
Section 11.0 
EXPLORATORY ASSESSMENTS 
Section 12.1 
Screening 
Section 12.4 
Study Day 56 
Section 12.8 
Study Day 105 
Section 12.9 
Termination Visit 
Section 12.10 
Follow-up after Termination Visit 
Appendix B 
Schedule of Assessments 
Notes to Appendix B 
 
Appendix F 
SAMPLE INFORMED CONSENT 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 128 of 130 
CONFIDENTIAL 
 
19 December 2016 
AMENDMENT 3: 
28 MAY 2015 
RATIONALE 
Study M18-006 has been amended for the following reasons: 
The primary purpose of this amendment was to make the following modifications to the 
Inclusion/Exclusion Criteria.  Inclusion criterion 1 were modified to allow patients with a 
cytologic diagnosis to be eligible.  Exclusion criterion 6 was modified to provide a definition of 
clinically significant ascites.  The previous exclusion criterion 7 was removed so that patients 
with plastic biliary stents are eligible.  The previous exclusion criterion 10 (now exclusion 
criterion 9) was modified to clarify that patients with prior chest wall radiotherapy are excluded 
only if the radiation field involved the heart.  The previous exclusion criterion 16 (now exclusion 
criterion 15) was modified to state that patients on prophylactic doses of heparin, warfarin, factor 
Xa inhibitors or other similar anti-coagulates are eligible. 
In addition, Section 13 was modified to clarify that the BNP measurement must be obtained on 
the Day of the demcizumab dosing and the result reviewed prior to dosing and the Sample 
Informed Consent was modified to clarify the objectives of the study.  In addition, modifications 
were made to clarify the appropriate radiologic assessments to obtain. Finally, minor typos were 
corrected throughout the protocol and other minor changes were made for clarification purposes. 
Finally, a few minor typos have been corrected.  
SUMMARY OF CHANGES: 
As a result, all the corresponding sections in the table below have been updated to reflect the 
changes outlined above. Additional minor changes have been made to improve clarity and 
consistency. Substantive new information appears in italics.  
Synopsis 
 
Section 6.1 
Inclusion Criteria 
Section 6.2 
Exclusion Criteria 
Section 8.2.1.1 
Administration 
Section 8.2.2.1 
Administration 
Section 9.2.3 
BNP Assessment 
Section 9.4 
Cardiac Studies 
Section 9.6 
Pharmacokinetic Assessments 
Section 10.0 
Efficacy Assessments 
Section 12.0 
STUDY VISIT SCHEDULE AND ASSESSMENTS 
Section 12.1 
Screening 
Section 12.2 
Study Day 0 
Section 12.3 
Study Days 7, 14, 21, 28, 35, 42, and 49 
Section 12.4 
Study Days 56 
Section 12.5 
Study Days 63, 70 
Section 12.7 
Study Days 84, 91, 98 
Section 12.9 
Termination Visit 
NOTES TO APPENDIX B 
 
Appendix F 
SAMPLE INFORMED CONSENT 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 129 of 130 
CONFIDENTIAL 
 
19 December 2016 
AMENDMENT 4: 
31 MARCH 2016 
RATIONALE 
The primary purpose of this amendment is to change the method for analyzing the primary 
endpoint of progression-free survival.  The previous approach for the primary endpoint analysis 
involved comparing Arm 1 to Arm 2 and Arm 1 to Arm 3, seperately.  This approach required 
that 80% of patient achieve the PFS endpoint (i.e., either progress or died).  However, a blinded 
review of the data to date suggests that only about 69% of the patients are having a progression-
free survival event.  Thus, it appears that there may not be an adequate number of events at the 
end of the study to conduct the PFS analysis initially described in the protocol.  Thus, the method 
for this analysis has been modified to compare Arm 1 to a pooled dataset of Arms 2 and 3 which 
requires lower percentage of pateints to achieve a PFS endpont. 
In addition, the wording of the study objectives and endpoints were modified to account for this 
modification.  A statement that standard of tests performed prior to the informed consent date 
may be used for screening purposes if they were done within 28 days of Day 0.  Also, wording 
was added to allow the BNP to be drawn the day prior to dosing at a site if approved by the 
Sponsor.  Other minor changes were made for consistency purposes and the typographical errors 
were fixed. 
SUMMARY OF CHANGES: 
As a result, all the corresponding sections in the table below have been updated to reflect the 
changes outlined above. Additional minor changes have been made to improve clarity and 
consistency. Substantive new information appears in italics.  
Synopsis 
 
Section 4.1 
Study Objectives 
Section 9.2.3 
BNP Assessment 
Section 11.0 
EXPLORATORY ASSESSMENTS 
Section 12.0 
STUDY VISIT SCHEDULE AND ASSESSMENTS 
Section 14.0 
STATISTICAL PLAN 
Section 14.2 
Study Stopping Rules 
Section 14.3 
Subject Populations for Analysis 
Section 14.6.4.1 
Best Overall Response 
Section 14.6.4.2 
Clinical Benefit Rate 
Section 14.6.4.3 
Progression-Free Survival and Duration of Response 
Section 14.6.5 
Continuous Variable Assessment of Tumor Length 
Section 14.6.6 
Duration of Response 
Section 14.6.6.1 
Sites of Progression 
Section 14.6.7 
Overall Survival 
Section 14.6.8 
Landmark Survival 
Notes to Appendix B 
 
Appendix F 
SAMPLE INFORMED CONSENT 
 
 


OncoMed Pharmaceuticals, Inc. 
 
Demcizumab 
Protocol M18-006, Amendment 5 
 
Page 130 of 130 
CONFIDENTIAL 
 
19 December 2016 
AMENDMENT 5: 
19 DECEMBER 2016 
RATIONALE 
The primary purpose of this amendment is to add two additional analyses of overall survival to 
be conducted on all deaths through June 1, 2017 and November 1, 2017, respectively.  In 
addition, the protocol was modified to state that subjects in long-term follow-up would have their 
survival status updated every 3 months or sooner at the request of the Sponsor.  In addition, 
changes were made to the Abraxane/gemcitabine dosage modification section to 1) delete the 
statement that subjects having their gemcitabine/Abraxane therapy held for 21 days due to drug 
related toxicity should have their gemcitabine and Abraxane stopped and 2) to add a statement 
that subjects who had undergone two dose reductions of gemcitabine/Abraxane and still were 
unable to tolerate that treatment could receive gemcitabine/Abraxane on Days 1 and 15 
(i.e., omit Day 8) of each 28 day cycle. 
SUMMARY OF CHANGES: 
As a result, all the corresponding sections in the table below have been updated to reflect the 
changes outlined above.  Additional minor changes have been made to improve clarity and 
consistency.  Substantive new information appears in italics.  
Section 8.2.3 
Gemcitabine and Abraxane® Dose Modification Guidelines 
Section 12.10 
Follow-up After Termination Visit 
Section 14.0 
STATISTICAL PLAN 
Section 14.6.7 
Overall Survival